Lectomedin materials and methods

Abstract

Disclosed are novel seven transmembrane receptor polypeptides having characteristic extracellular structure including lectin-binding, olfactomedin-like and mucin-like domains.

Description

BACKGROUND OF THE INVENTION

G-protein coupled receptors (GPCRs) are proteins that interact with G-proteins to transmit an intracellular signal. Upon ligand binding, GPCRs trigger the hydrolysis of GTP to GDP by G-protein subunits; GTP hydrolysis is accompanied by a switch from activity to inactivity. It is estimated that there are roughly 1,000 GPCRs [Clapham, Nature 379:297-299 (1996)] and all characterized to date include a seven transmembrane domain that anchors the receptor to the cell. GPCRs include receptors for opiates, adrenaline, histamine, polypeptide hormones, and photons, among other ligands. These receptors are coupled to a wide variety of cellular second messenger pathways including, for example, pathways that alter intracellular calcium concentrations and cAMP levels.

Among the various GPCRs identified, CD97 appears to be representative of a sub-family of proteins which effect cellular adhesion [McKnight, et al., Immunol Today 17:283-287(1996)]. CD97 and related receptors are unique in that their structure includes a transmembrane domain that directly links a cytoplasmic domain that participates in GTP hydrolysis with extracellular protein binding domains that specifically participate in cell-cell adhesion. The extracellular, amino terminal region of CD97 includes numerous cell-cell adhesive motifs, including multiple epidermal growth factor-like (EGF-like) repeats and an integrin binding site [Hamann J, et al., Immunol 155:1942—1950 (1996); Gray, et al., J. Immunol 157:5438-5447 (1996)]. Proteins that contain EGF-like repeats have been shown to be involved in cell adhesion events [Campbell, et al., Curr. Opin. Struct. Biol. 3:385-392 (1993); Rao,etal., Cell 82:131-141 (1995)], and consistent with this observation, heterologous expression of CD97 in COS cells elicits homotypic cell aggregation that can be blocked in the presence of anti-CD97 monoclonal antibodies [Hamann, et al., J. Exp. Med. 184:1185-1189 (1996)]. CD97 and related proteins have been referred to as the EGF-7TM subfamily of seven transmembrane receptors [McKNight and Gordon, Immunol. Today 17:283-2887 (1996)]. Ligands identified for CD97 include members of the integrin family of cell surface adhesion receptors. Various integlins recognize and interact with their cognate ligands through a trimeric amino acid sequence of arginine-glycine-aspartic acid (denoted RGD in the single letter amino acid code) [D'Souza, etal., Trends Biochem. Sci., 16:246-250 (1991)] and this sequence has been identified in the extracellular region of CD97, between the EGF-like repeats and the transmembrane domain.

CD97 has been shown to undergo post-translational proteolytic processing which results in an extracellular (and potentially soluble) alpha subunit and a smaller, integral membrane beta subunit [Gray, et al., J. Immunol. 157:5438-5447 (1996)]. The two subunits are associated in a non-covalent manner and the alpha subunit is held at the cell surface through its interaction with the beta subunit. The role of proteolysis is unclear, but it may be a mechanism for receptor down-regulation which is common among proteins, such as selectins and intercellular adhesion molecules (ICAMs), that participate in cell adhesion.

Other members of the CD97 sub-family of GPCRs have been identified by amino acid sequence and structural homology and include human EMR1, HE6, BAI1, the calcium-independent receptor of latrotoxin (CIRL), latrophilin, and proteins encoded by the Caenorhabditis elegans open reading frames designated B0457.1 and B0286.2 [Baud V, et al., Genomics 26:334-344 (1995); McKnight, et al., J. Biol. Chem. 271:486-489 (1996); Krasnoperov, et al., Neuron 18:925-937 (1997); Lelianova, et al., J. Biol. Chem. 272:21504-21508 (1997); Davletov, et al., J. Biol. Chem. 271:23239-23245 (1996); Nishimori, et al., Oncogene 15:2145-2150 (1997)]. EMR1, and its murine homolog F4/80, are macrophage-specific in expression and structurally related to CD97 in that they contain multiple extracellular EGF-like repeats, a rod-like stalk region, and the characteristic transmembrane domain of GPCRs [Baud V, et al., Genomics 26:334-344 (1995); McKnight, et al., J. Biol. Chem. 271:486-489 (1996)]. No ligands have been identified for EMR-1 and it is uncertain if the protein undergoes post-translational proteolytic processing.

CIRL [Krasnoperov, et al., Neuron 18:925-937 (1997); Lelianova, et al., J. Biol. Chem. 272:21504-21508 (1997); Davletov, etal., J. Biol. Chem. 271:23239-23245 (1996)] is believed to be expressed specifically in the central nervous system at neuronal presynaptic terminals and, like CD97, undergoes proteolytic cleavage resulting in an extracellular alpha subunit in non-covalent association with an integral membrane seven-transmembrane beta subunit. Cleavage of latrophilin is believed to occur at a Ser-His-Leu/Thr-Asn-Phe site that is conserved in CD97 [Krasnoperov, et al., Neuron 18:925-937 (1997)]. CIRL has been shown to bind latrotoxin, a component of black widow spider venom, in the 0.5 to 1.0 nM range, and binding of the ligand to CIRL expressed in bovine chromaffin cells has been shown to result in exocytosis, a hallmark of toxin binding [Krasnoperov, et al., Neuron 18:925-937 (1997)]. Alpha latrotoxin binding has also been demonstrated at neuromuscular motor endplates, and this interaction elicits explosive secretory granule release of acetylcholine from presynaptic granules, resulting in muscle paralysis characteristic of the spider's bite [Petrenko, et al., F.E.B.S. Letts. 325:81-85 (1993)]. It is unclear, however, if the peripheral toxin effects result from binding to CIRL or some other related protein.

Thus there exists a need in the art to identify and characterize other members of the CD97-like family of GPCRs, in particular human receptors which participate in cellular adhesion and those that participate in cytoplasmic metabolic pathways modulated by extracellular signals. Identification of CD97-like receptors can permit identification and diagnosis of disease states which arise from aberrant signaling by the receptor, as well as disease states that arise from aberrant expression of the receptor itself.

SUMMARY OF THE INVENTION

The present invention provides purified and isolated human seven transmembrane receptor lectomedin polypeptides or fragments thereof, said polypeptides comprising extracellular lectin-binding, olfactomedin-like, and mucin-like domains. Mature lectomedin polypeptides are also provided wherein signal or leader sequences are cleaved. Preferred polypeptides of the invention comprise the amino acid sequence set out in SEQ ID NO: 2 or a fragment thereof, the amino acid sequence set out in SEQ ID NO: 4 or fragment thereof the amino acid sequence set out in SEQ ID NO: 6 or fragment thereof, and the amino acid sequence set out in SEQ ID NO: 58 or fragment thereof.

The invention also provides polynucleotides encoding polypeptides of the invention. Preferred polynucleotides comprising the sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 57. The invention also provides polynucleotides a) encoding a human lectomedin polypeptide selected from the group consisting of the polynucleotide set out in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 57; b) a DNA which hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (a); and c) a DNA which would hybridize to the non-coding strand of the polynucleotide of (a) but for the redundancy of the genetic code. Preferred polynucleotides of the invention are DNA molecules. Preferred DNA molecules are cDNA molecules and genomic DNA molecules. The invention also provides DNA which is a wholly or partially chemically synthesized. Anti-sense polynucleotide which specifically hybridizes with a polynucleotide of the invention are also comprehended.

The invention also proved expression construct comprising the a polynucleotide of the invention, as well as host cells transformed or transfected with a polynucleotide or expression construct of the invention.

The invention also provides polynucleotide of the invention operably linked to a heterologous promoter, and host cells polynucleotides operably linked to a heterologous promoter.

In another aspect, the invention provides methods for producing a human lectomedin polypeptide comprising the steps of: a) growing the host cell of the invention under conditions appropriate for expression of the lectomedin polypeptide and b) isolating the lectomedin polypeptide from the host cell or the medium of its growth.

The invention also proved antibodies specifically immunoreactive with a polypeptide of the invention. Preferably, antibodies of the invention are monoclonal antibodies. The invention also provides cells, e.g. hybridomas, that produce antibodies of the invention. Anti-idiotype antibodies specifically immunoreactive with an antibody of the invention are also comprehended.

The invention also provides methods to identify a specific binding partner compound of a lectomedin polypeptide comprising the steps of: a) contacting the lectomedin polypeptide with a compound under conditions which permit binding between the compound and the lectomedin polypeptide; b) detecting binding of the compound to the lectomedin polypeptide; and c) identifying the compound as a specific binding partner of the lectomedin polypeptide. Methods of the invention embrace specific binding partner that modulate activity of the lectomedin polypeptide. In one aspect, the compound inhibits activity of the lectomedin polypeptide, and in another aspect, the compound enhances activity of the lectomedin polypeptide.

The invention also provides methods to identify a specific binding partner compound of a lectomedin polynucleotide comprising the steps of: a) contacting the lectomedin polynucleotide with a compound under conditions which permit binding between the compound and the lectomedin polynucleotide; b) detecting binding of the compound to the lectomedin polynucleotide; and c) identifying the compound as a specific binding partner of the lectomedin polynucleotide. Methods of the invention embrace specific binding partner that modulates expression of a lectomedin polypeptide encoded by the lectomedin polynucleotide. In one aspect, the compound inhibits expression of the lectomedin polypeptide, and in another aspect, the compound enhances expression of the lectomedin polypeptide. The invention also provides compounds identified by a method of the invention.

In another aspect, the invention comprehends composition comprising the compound identified by a method of the invention and a pharmaceutically acceptable carrier. The invention also provides use of a compound identified by a method of the invention for the preparation of a medicament to treat lectomedin related pathologies.

The invention also provides for use of a lectomedin polypeptide in the preparation of a medicament for the treatment of a lectomedin related disorder.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides purified and isolated polypeptides and underlying polynucleotides for a novel family of transmembrane proteins designated lectomedins. The invention includes both naturally occurring and non-naturally occurring lectomedin polynucleotides and polypeptide products thereof. Naturally occurring lectomedin products include distinct gene and polypeptide species within the lectomedin family, including, for example, allelic variants, which are expressed within cells of the same animal, as well as corresponding species homologs expressed in cells of other animals. The invention further provides splice variants encoded by the same polynucleotide but which arise from distinct mRNA transcripts. Non-naturally occurring lectomedin products include variants of the naturally occurring products such as analogs, fragments, fusion (or chimeric) proteins, and lectomedin products having covalent modifications. The lectomedin family of proteins is distinguished from previously known seven transmembrane families of proteins in that the lectomedin proteins include at least one extracellular lectin binding-like domain and at least one extracellular olfactomedin domain. Unlike many other seven transmembrane proteins, the structure of proteins in the lectomedin family of proteins does not include EGF-like binding domains which effect cell/cell interactions. In a preferred embodiment, the invention provides polynucleotides comprising the sequences set forth in SEQ ID NOs: 1, 3, 5 and 57. The invention also embraces polynucleotides encoding the amino acid sequences set out in SEQ ID NOs: 2, 4, 6, and 58. Presently preferred polypeptides of the invention comprises the amino acid sequences set out in SEQ ID NOs: 2, 4, 6, and 58.

The invention also provides expression constructs (or vectors) comprising polynucleotides of the invention, as well as host cells transformed, transfected, or electroporated to include a polynucleotide or expression construct of the invention. Methods to produce a polypeptide of the invention are also comprehended. The invention further provides antibodies, preferably monoclonal antibodies, specifically immunoreactive with a polypeptide of the invention, as well as cell lines, e.g., hybridomas, that secrete the antibodies.

The present invention provides novel purified and isolated human polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, including splice variants thereof) encoding the human lectomedins. DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences. Genomic DNA of the invention comprises the protein coding region for a polypeptide of the invention and includes allelic variants of the preferred polynucleotides of the invention. Genomic DNA of the invention is distinguishable from genomic DNAs encoding polypeptides other than lectomedin in that it includes the lectomedin coding region found in lectomedin cDNA of the invention. Genomic DNA of the invention can be transcribed into RNA, and the resulting RNA transcript may undergo one or more splicing events wherein one or more introns (i.e., non-coding regions) of the transcript are removed, or “spliced out.” RNA transcripts that can be spliced by alternative mechanisms, and therefore be subjected to removal of different non-coding RNA sequences but still encode a lectomedin polypeptide, are referred to in the art as splice variants, which are embraced by the invention. Splice variants comprehended by the invention, therefore, are encoded by the same DNA sequences but arise from distinct mRNA transcripts. Allelic variants are known in the art to be modified forms of a wild type (predominant) gene sequence, the modification resulting from recombination during chromosomal segregation or exposure to conditions which give rise to genetic mutation. Allelic variants, like wild type genes, are inherently naturally occurring sequences (as opposed to non-naturally occurring variants which arise from in vitro manipulation).

The invention also comprehends cDNA that is obtained through reverse transcription of an RNA polynucleotide encoding lectomedin, followed by second strand synthesis of a complementary strand to provide a double stranded DNA. “Chemically synthesized” as used herein and understood in the art, refers to polynucleotides produced by purely chemical, as opposed to enzymatic, methods. “Wholly” synthesized DNA sequences are therefore produced entirely by chemical means, and “partially” synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means.

Preferred DNA sequences encoding human lectomedin polypeptides are set out in SEQ ID NOs: 1, 3, 5, and 57. The worker of skill in the art will readily appreciate that preferred DNAs of the invention comprise double stranded molecules, for example, the molecule having the sequence set forth in either SEQ ID NOs: 1, 3, 5, or 57, along with the complementary molecule (the “non-coding strand” or “complement”) having a sequence deducible from the sequence of SEQ ID NO: 1 according to Watson-Crick base pairing rules for DNA. Also preferred are polynucleotides encoding the lectomedin polypeptides of SEQ ID NOs: 2, 4, 6, and 58.

The invention further embraces species, preferably mammalian, homologs of the human lectomedin DNA. Species homologs, in general, share at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homology with human DNA of the invention. Percent sequence “homology” with respect to polynucleotides of the invention is defined herein as the percentage of nucleotide bases in the candidate sequence that are identical to nucleotides in the lectomedin coding sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.

The polynucleotide sequence information provided by the invention makes possible large scale expression of the encoded polypeptide by techniques well known and routinely practiced in the art. Polynucleotides also permit identification and isolation of polynucleotides encoding related lectomedin polypeptides by well known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR), ligase chain reaction, as well as other amplification techniques. Examples of related polynucleotides include human and non-human genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptides homologous to lectomedins and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of lectomedin.

The disclosure of full length polynucleotides encoding lectomedin polypeptides makes readily available to the worker of ordinary skill in the art every possible fragment of the full length polynucleotides. The invention therefore provides fragments of lectomedin coding polynucleotides. Such fragments comprise at least 10 to 20, and preferably at least 15, consecutive nucleotides of the polynucleotide. The invention comprehends, however, fragments of various lengths. Preferably, fragment polynucleotides of the invention comprise sequences unique to the lectomedin coding polynucleotide sequence, and therefore hybridize under highly stringent or moderately stringent conditions only (i.e., “specifically”) to polynucleotides encoding lectomedin, or lectomedin fragments thereof containing the unique sequence. Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be identified through use of alignment programs routinely utilized in the art, e.g., those made available in public sequence databases.

The invention also provides fragment polynucleotides that are conserved in one or more polynucleotides encoding members of the lectomedin family of polypeptides. Such fragments include sequences characteristic of the family of lectomedin polynucleotides, and are also referred to as “signature sequences.” The conserved signature sequences are readily discernable following simple sequence comparison of polynucleotides encoding members of the lectomedin family. Fragments of the invention can be labeled in a manner that permits their detection, including radioactive and non-radioactive labeling.

Fragment polynucleotides are particularly useful as probes for detection of full length or other fragment lectomedin coding polynucleotides. One or more fragment polynucleotides can be included in kits that are used to detect the presence of a polynucleotide encoding lectomedin, or used to detect variations in a polynucleotide sequence encoding lectomedin.

The invention also embraces DNA sequences encoding lectomedin species which hybridize under moderately or highly stringent conditions to the non-coding strand, or complement, of the polynucleotide in SEQ ID NOs: 1, 3, 5, or 57. DNA sequences encoding lectomedin polypeptides which would hybridize thereto but for the redundancy of the genetic code are further comprehended by the invention. Exemplary highly stringent conditions are include hybridization at 45° C. in 5×SSPE and 45% formamide, and a final wash at 65° C. in 0.1×SSC. Exemplary moderately stringent condition include a final wash at 55° C. in 1×SSC. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausubel, et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp.6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y. (1989), pp. 9.47 to 9.5 1.

Autonomously replicating recombinant expression constructs such as plasmid and viral DNA vectors incorporating lectomedin coding sequences are also provided. Expression constructs wherein lectomedin-encoding polynucleotides are operably linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator are also provided. Expression control DNA sequences include promoters, enhancers, and operator, and are generally selected based on the expression systems in which the expression construct is to be utilized. Preferred promoter and enhancer sequences are generally selected for the ability to increase gene expression, while operator sequences are generally selected for the ability to regulate gene expression. Expression constructs of the invention may also include sequences encoding one or more selectable markers that permit identification of host cells bearing the construct. Expression constructs may also include sequences that facilitate, and preferably promote, homologous recombination in a host cell. Preferred constructs of the invention also include sequences necessary for replication in a host cell. Expression constructs are preferably utilized for production of an encoded lectomedin protein, but may also be utilized to amplify the construct itself.

According to another aspect of the invention, host cells are provided, including prokaryotic and eukaryotic cells, comprising a polynucleotide of the invention in a manner which permits expression of the encoded lectomedin polypeptide. Polynucleotides of the invention may be introduced into the host cell as part of a circular plasmid, or as linear DNA comprising an isolated protein coding region or a viral vector. Methods for introducing DNA into the host cell well known and routinely practiced in the art include transformation, transfection, electroporation, nuclear injection, or fusion with carriers such as liposomes, micelles, ghost cells, and protoplasts. Expression systems of the invention include bacterial, yeast, fungal, plant, insect, invertebrate, and mammalian cells systems. Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with lectomedin. Host cells of the invention are also useful in methods for large scale production of lectomedin polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown by purification methods known in the art, e.g., conventional chromatographic methods including immunoaffinity chromatography, receptor affinity chromatography, hydrophobic interaction chromatography, lectin affinity chromatography, size exclusion filtration, cation or anion exchange chromatography, high pressure liquid chromatography (HPLC), reverse phase HPLC and the like. Still other methods of purification include those wherein the desired protein is expressed and purified as a fusion protein having a specific tag, label, or chelating moiety that is recognized by a specific binding partner or agent. The purified protein can be cleaved to yield the desired protein, or be left as an intact fusion protein. Cleavage of the fusion component may produce a form of the desired protein having additional amino acid residues as a result of the cleavage process.

Knowledge of lectomedin coding DNA sequences allows for modification of cells to permit, or increase, expression of endogenous lectomedin. Cells can be modified (e.g., by homologous recombination) to provide increased lectomedin expression by replacing, in whole or in part, the naturally occurring lectomedin promoter with all or part of a heterologous promoter so that the cells express lectomedin at higher levels. The heterologous promoter is inserted in such a manner that it is operably linked to lectomedin-encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the lectomedin coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the lectomedin coding sequences in the cells.

The DNA sequence information provided by the present invention also makes possible the development through, e.g. homologous recombination or “knock-out” strategies [Capecchi, Science 244:1288-1292 (1989)], of animals that fail to express functional lectomedin or that express a variant of lectomedin. Such animals are useful as models for studying the in vivo activities of lectomedin and modulators of lectomedin.

The invention also provides purified and isolated mammalian lectomedin polypeptides encoded by a polynucleotide of the invention. Presently preferred are lectomedin polypeptides comprising the amino acid sequence set out in SEQ ID NO: 2, 4, 6, or 58. The invention also embraces lectomedin polypeptides encoded by a DNA selected from the group consisting of: a) the DNA sequence set out in SEQ ID NO: 1, 3, 5 or 57; b) a DNA molecule which hybridizes under high stringent conditions to the noncoding strand of the protein coding portion of (a); and c) a DNA molecule that would hybridize to the DNA of (a) but for the degeneracy of the genetic code.

The invention also embraces variant (or analog) lectomedin polypeptides. In one example, insertion variants are provided wherein one or more amino acid residues supplement a lectomedin amino acid sequence. Insertions may be located at either or both termini of the protein, or may be positioned within internal regions of the lectomedin amino acid sequence. Insertional variants with additional residues at either or both termini can include for example, fusion proteins and proteins including amino acid tags or labels.

In another aspect, the invention provides deletion variants wherein one or more amino acid residues in a lectomedin polypeptide are removed. Deletions can be effected at one or both termini of the lectomedin polypeptide, or with removal of one or more residues within the lectomedin amino acid sequence. Deletion variants, therefore, include all fragments of a lectomedin polypeptide.

In still another aspect, the invention provides substitution variants of lectomedin polypeptides. Substitution variants include those polypeptides wherein one or more amino acid residues of a lectomedin polypeptide are removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature, however, the invention embraces substitutions that are also non-conservative. Conservative substitutions for this purpose may be defined as set out in Tables A, B, or C below.

The invention also provides derivatives of lectomedin polypeptides. Derivatives include lectomedin polypeptides bearing modifications other than insertion, deletion, or substitution of amino acid residues. Preferably, the modifications are covalent in nature, and include, for example, chemical bonding with polymers, lipids, non-naturally occurring amino acids, other organic, and inorganic moieties. Derivatives of the invention may be prepared to increase circulating half-life of a lectomedin polypeptide, or may be designed to improve targeting capacity for the polypeptide to desired cells, tissues, or organs.

The invention also embraces polypeptides have at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% identity and/or homology to the preferred polypeptide of the invention. Percent amino acid sequence “identity” with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the lectomedin sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence “homology” with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the lectomedin sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity.

In one aspect, percent homology is calculated as the percentage of amino acid residues in the smaller of two sequences which align with identical amino acid residue in the sequence being compared, when four gaps in a length of 100 amino acids may be introduced to maximize alignment [Dayhoff, in Altas of Protein Sequence and Structure , Vol. 5, p. 124, National Biochemical Research Foundation, Washington, D.C. (1972), incorporated herein by reference].

Polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Glycosylated and non-glycosylated form of lectomedin polypeptides are embraced.

Insertion variants include lectomedin polypeptides wherein one or more amino acid residues are added to a lectomedin acid sequence, or fragment thereof. Variant products of the invention also include mature lectomedin products, i.e., lectomedin products wherein leader or signal sequences are removed, with additional amino terminal residues. The additional amino terminal residues may be derived from another protein, or may include one or more residues that are not identifiable as being derived from a specific proteins. Lectomedin products with an additional methionine residue at position −1 (Met −1 -lectomedin) are contemplated, as are lectomedin products with additional methionine and lysine residues at positions −2 and −1 (Met −2 -Lys −1 -lectomedin). Variants of lectomedin with multiple, additional Met, Met-Lys, Lys residues are particularly useful for enhanced recombinant protein production in bacterial host cell.

The invention also embraces lectomedin variants having additional amino acid residues which result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide as part of glutathione-S-transferase (GST) fusion product provides the desired polypeptide having an additional glycine residue at position −1 after cleavage of the GST component from the desired polypeptide. Variants which result from expression in other vector systems are also contemplated.

Insertional variants also include fusion proteins wherein the amino and/or carboxy termini of the lectomedin polypeptide is fused to another polypeptide. Examples of such fusion proteins are immunogenic polypeptides, proteins with long circulating half life, such as immunoglobulin constant regions, marker proteins (e.g., fluorescent) and proteins or polypeptide that facilitate purification of the desired lectomedin polypeptide, e.g. FLAG® tags or polyhistidine sequences.

Deletion variants include lectomedin polypeptides wherein one or more amino acid residues are deleted from the lectomedin amino acid sequence. Deletion variants of the invention embrace polypeptide fragments of the sequence set out in SEQ ID NO: 2, 4, 6, or 58 wherein the fragments maintain biological or immunological properties of a lectomedin polypeptide. Fragments comprising at least 5, 10, 15, 20, 25, 30, 35, or 40 consecutive amino acids of SEQ ID NO: 2, 4, 6, or 58 are comprehended by the invention. Preferred polypeptide fragments display antigenic properties unique to or specific for the lectomedin family of polypeptides. Fragments of the invention having the desired biological and immunological properties can be prepared by any of the methods well known and routinely practiced in the art.

Substitution variants of the invention include lectomedin polypeptides, or fragments thereof wherein one or more amino acid residues in the lectomedin amino acid sequence are deleted and replaced with another amino acid residue. Variant polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Amino acids can be classified according to physical properties and contribution to secondary and tertiary protein structure. A conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative substitutions are set out in Table A (from WO 97/09433, page 10, published Mar. 13, 1997 (PCT/GB96/02197, filed Sep. 6, 1996), immediately below.

TABLE A
Conservative Substitutions I
SIDE CHAIN CHARACTERISTIC	AMINO ACID
Aliphatic	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
Aromatic		H F W Y
Other		N Q D E

Alternatively, conservative amino acids can be grouped as described in Lehninger, [ Biochemistry, Second Edition; Worth Publishers, Inc. NY:N.Y. (1975), pp.71-77] as set out in Table B, immediately below.

TABLE B
Conservative Substitutions II
SIDE CHAIN
CHARACTERISTIC               AMINO ACID
Non-polar (hydrophobic)
A. Aliphatic:                A L I V P
B. Aromatic:                 F W
C. Sulfur-containing:        M
D. Borderline:               G
Uncharged-polar
A. Hydroxyl:                 S T Y
B. Amides:                   N Q
C. Sulfhydryl:               C
D. Borderline:               G
Positively Charged (Basic):  K R H
Negatively Charged (Acidic): D E

As still an another alternative, exemplary conservative substitutions are set out in Table C, below.

The invention further embraces lectomedin products, or fragments thereof, covalently modified or derivatized, e.g., to include one or more water soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. Particularly preferred are lectomedin products covalently modified with polyethylene glycol (PEG) subunits. Water soluble polymers may be bonded at specific positions, for example at the amino terminus of the lectomedin products, or randomly attached to one or more side chains of the polypeptide. Additional derivatives include lectomedin species immobilized on a solid support, pin microparticle, or chromatographic resin, as well as lectomedin polypeptides modified to include one or more non-protein labels, tags, or chelating agents.

TABLE C
Conservative Substitutions III
Original Residue Exemplary Substitution
Ala (A)          Val, Leu, Ile
Arg (R)          Lys, Gln, Asn
Asn (N)          Gln, His, Lys, Arg
Asp (D)          Glu
Cys (C)          Ser
Gln (Q)          Asn
Glu (E)          Asp
His (H)          Asn, Gln, Lys, Arg
Ile (I)          Leu, Val, Met, Ala, Phe,
Leu (L)          Ile, Val, Met, Ala, Phe
Lys (K)          Arg, Gln, Asn
Met (M)          Leu, Phe, Ile
Phe (F)          Leu, Val, Ile, Ala
Pro (P)          Gly
Ser (S)          Thr
Thr (T)          Ser
Trp (W)          Tyr
Tyr (Y)          Trp, Phe, Thr, Ser
Val (V)          Ile, Leu, Met, Phe, Ala

Also comprehended by the present invention are antibodies (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and CDR-grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the invention) and other binding proteins specific for lectomedin products or fragments thereof. Preferred antibodies of the invention are human antibodies which are produced and identified according to methods described in WO93/11236, published Jun. 20, 1993, which is incorporated herein by reference in its entirety. Antibody fragments, including Fab, Fab′, F(ab′) 2 , and F v , are also provided by the invention. The term “specific for” indicates that the variable regions of the antibodies of the invention recognize and bind lectomedin polypeptides exclusively (i.e., able to distinguish single lectomedin polypeptides from the family of lectomedin polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), Antibodies: A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, N.Y. (1988), Chapter 6. Antibodies that recognize and bind fragments of the lectomedin polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, lectomedin polypeptides. As with antibodies that are specific for full length lectomedin polypeptides, antibodies of the invention that recognize lectomedin fragments are those which can distinguish single and distinct lectomedin polypeptides from the family of lectomedin polypeptides despite inherent sequence identity, homology, or similarity found in the family of proteins. Antibodies of the invention can be produced using any method well known and routinely practiced in the art.

Non-human antibodies may be humanized by any methods known in the art. In one method, the non-human complementarity determining regions (CDRs) are inserted into a human antibody or consensus antibody framework sequence. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.

Antibodies of the invention are useful for, for example, therapeutic purposes (by modulating activity of lectomedin), diagnostic purposes to detect or quantitate lectomedin, as well as purification of lectomedin. Antibodies are particularly useful for detecting and/or quantitating lectomedin expression in cells, tissues, organs and lysates and extracts thereof, as well as fluids, including serum, plasma, cerebrospinal fluind, urine, sputum, peritoneal fluid, pleural fluid, or pulmonary lavage. Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended. In general, a kit of the invention also includes a control antigen for which the antibody is immunospecific.

Specific binding proteins can be identified or developed using isolated or recombinant lectomedin products, lectomedin variants, or cells expressing such products. Binding proteins are useful for purifying lectomedin products and detection or quantification of lectomedin products in fluid and tissue samples using known immunological procedures. Binding proteins are also manifestly useful in modulating (i.e., blocking, inhibiting or stimulating) biological activities of lectomedin, especially those activities involved in signal transduction.

The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of lectomedins. DNA and amino acid sequence information for lectomedin also permits identification of binding partner compounds with which a lectomedin polypeptide or polynucleotide will interact. Agents that modulate (i.e., increase, decrease, or block) lectomedin activity or expression may be identified by incubating a putative modulator with a lectomedin polypeptide or polynucleotide and determining the effect of the putative modulator on lectomedin activity or expression. The selectivity of a compound that modulates the activity of the lectomedin can be evaluated by comparing its binding activity to one particular lectomedin to its activity to other lectomedin polypeptides. Cell based methods, such as di-hybrid assays to identify DNAs encoding binding compounds and split hybrid assays to identify inhibitors of lectomedin polypeptide interaction with a known binding polypeptide, as well as in vitro methods, including assays wherein a lectomedin polypeptide, lectomedin polynucleotide, or a binding partner are immobilized, and solution assays are contemplated by the invention.

Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to a lectomedin polypeptide or a lectomedin-encoding nucleic acid, oligonucleotides which specifically bind to a lectomedin polypeptide or a lectomedin gene sequence, and other non-peptide compounds (e.g., isolated or synthetic organic and inorganic molecules) which specifically react with a lectomedin polypeptide or its underlying nucleic acid. Mutant lectomedin polypeptides which affect the enzymatic activity or cellular localization of the wild-type lectomedin polypeptides are also contemplated by the invention. Presently preferred targets for the development of selective modulators include, for example: (1) regions of the lectomedin polypeptide which contact other proteins, (2) regions that localize the lectomedin polypeptide within a cell, (3) regions of the lectomedin polypeptide which bind substrate, (4) allosteric regulatory binding site(s) of the lectomedin polypeptide, (5) site(s) of the lectomedin polypeptide wherein covalent modification regulates biological activity and (6) regions of the lectomedin polypeptide which are involved in multimerization of lectomedin subunits. Still other selective modulators include those that recognize specific lectomedin encoding and regulatory polynucleotide sequences. Modulators of lectomedin activity may be therapeutically useful in treatment of a wide range of diseases and physiological conditions in which lectomedin activity is known or suspected to be involved.

Lectomedin polypeptides of the invention are amenable to numerous cell based high throughput screening (HTS) assays known in the art, including melanophore assay to investigate receptor-ligand interaction, yeast based assay systems, and mammalian cell expression systems. For a review, see Jayawickreme and Kost, Curr. Opin. Biotechnol. 8:629-634 (1997). Automated and miniaturized HTS assays are also comprehended as described, for example, in Houston and Banks, Curr. Opin. Biotechnol. 8:734-740 (1997).

There are a number of different libraries used for the identification of small molecule modulators, including, (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random or designed peptides, oligonucleotides or organic molecules.

Chemical libraries consist of structural analogs of known compounds or compounds that are identified as “hits” or “leads” via natural product screening. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) variants thereof. For a review, see Science 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds as a mixture. They are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opin. Biotechnol. 8:701-707 (1997).

Identification of modulators through use of the various libraries described herein permits modification of the candidate “hit” (or “lead”) to optimize the capacity of the “hit” to modulate activity.

The scientific value of the information contributed through the disclosures of DNA and amino acid sequences of the present invention is manifest. As one series of examples, knowledge of the sequence of a cDNA for lectomedin makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding lectomedin and lectomedin expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. DNA/DNA hybridization procedures carried out with DNA sequences of the invention under moderately to highly stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of lectomedin; allelic variants are known in the art to include structurally related proteins sharing one or more of the biochemical and/or immunological properties specific to lectomedin. Similarly, non-human species genes encoding proteins homologous to human lectomedin can also be identified by Southern and/or PCR analysis; species homologs of the invention are particularly useful in animal models for the study of lectomedin-related disorders. As an alternative, complementation studies can be useful for identifying other human lectomedin products as well as non-human proteins, and DNAs encoding the proteins, sharing one or more biological properties of lectomedin.

Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express lectomedin. Polynucleotides of the invention may also be the basis for diagnostic methods useful for identifying a genetic alteration(s) in a lectomedin locus that underlies a disease state or states.

Also made available by the invention are anti-sense polynucleotides which recognize and hybridize to polynucleotides encoding lectomedin. Full length and fragment anti-sense polynucleotides are provided. The worker of ordinary skill will appreciate that fragment antisense molecules of the invention include (i) those which specifically recognize and hybridize to lectomedin RNA (as determined by sequence comparison of DNA encoding lectomedin to DNA encoding other known molecules) as well as (ii) those which recognize and hybridize to RNA encoding variants of the lectomedin family of proteins. Antisense polynucleotides that hybridize to RNA encoding other members of the lectomedin family of proteins are also identifiable through sequence comparison to identify characteristic, or signature, sequences for the family of molecules. Anti-sense polynucleotides are particularly relevant to regulating expression of lectomedin by those cells expressing lectomedin mRNA.

Antisense nucleic acids (preferably 10 to 20 base pair oligonucleotides) capable of specifically binding to lectomedin expression control sequences or lectomedin RNA are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the lectomedin target nucleotide sequence in the cell and prevents transcription or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention. The antisense oligonucleotides may be further modified by poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5′ end.

The invention further contemplates methods to modulate lectomedin expression through use of ribozymes. For a review, see Gibson and Shillitoe, Mol. Biotech. 7:125-137 (1997). Ribozyme technology can be utilized to inhibit translation of lectomedin mRNA in a sequence specific manner through (i) the hybridization of a complementary RNA to a target mRNA and (ii) cleavage of the hybridized mRNA through nuclease activity inherent to the complementary strand. Ribozymes can identified by empirical methods but more preferably are specifically designed based on accessible sites on the target mRNA (Bramlage, et al., Trends in Biotech 16:434-438 (1998). Delivery of ribozymes to target cells can be accomplished using either exogenous or endogenous delivery techniques well known and routinely practiced in the art. Exogenous delivery methods can include use of targeting liposomes or direct local injection. Endogenous methods include use of viral vectors and non-viral plasmids.

Ribozymes can specifically modulate expression of lectomedin when designed to be complementary to regions unique to a polynucleotide encoding lectomedin. “Specifically modulate” therefore is intended to mean that ribozymes of the invention recognizes only a polynucleotide encoding lectomedin. Similarly, ribozymes can be designed to modulate expression of all or some of the lectomedin family of proteins. Ribozymes of this type are designed to recognize polynucleotide sequences conserved in all or some of the polynucleotides which encode the family of proteins.

The invention further embraces methods to modulate transcription of lectomedin through use of oligonucleotide-directed triplet helix formation. For a review, see Lavrovsky, et al., Biochem. Mol. Med. 62:11-22 (1997). Triplet helix formation is accomplished using sequence specific oligonucleotides which hybridize to double stranded DNA in the major groove as defined in the Watson-Crick model. Hybridization of a sequence specific oligonucleotide can thereafter modulate activity of DNA-binding proteins, including, for example, transcription factors and polymerases. Preferred target sequences for hybridization include promoter and enhancer regions to permit transcriptional regulation of lectomedin expression.

Oligonucleotides which are capable of triplet helix formation are also useful for site-specific covalent modification of target DNA sequences. Oligonucleotides useful for covalent modification are coupled to various DNA damaging agents as described in Lavrovsky, et al. [supra].

Mutations in a lectomedin gene that results in loss of normal function of the lectomedin gene product may underlie lectomedin-related human disease states. The invention comprehends gene therapy to restore lectomedin activity would thus be indicated in treating those disease states (for example, various forms of cancer described herein). Delivery of a functional lectomedin gene to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp.25 (1998). For additional reviews of gene therapy technology see Friedmann, Science, 244: 1275-1281 (1989); Verma, Scientific American: 68-84 (1990); and Miller, Nature, 357: 455-460 (1992). Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of lectomedin will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of lectomedin.

The invention further embraces pharmaceutical compositions comprising a lectomedin polypeptide of the invention, generally in combination with a pharmaceutically acceptable carrier. The pharmaceutical compositions optionally may include pharmaceutically acceptable (i.e., sterile and non-toxic) liquid, semisolid, or solid diluents that serve as pharmaceutical vehicles, excipients, or media. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma.

The pharmaceutical compositions can be packaged in forms convenient for delivery. The compositions can be enclosed within a capsule, sachet, cachet, gelatin, paper, or other container. These delivery forms are preferred when compatible with entry of the immunogenic composition into the recipient organism and, particularly, when the immunogenic composition is being delivered in unit dose form. The dosage units can be packaged, e.g., in tablets, capsules, suppositories or cachets.

The pharmaceutical compositions may be introduced into the subject to be treated by any conventional method including, e.g., by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, intrathecal, intraocular, retrobulbar, intrapulmonary (e.g., aerosolized drug solutions) or subcutaneous injection (including depot administration for long term release); by oral, sublingual, nasal, anal, vaginal, or transdermal delivery; or by surgical implantation, e.g., embedded under the splenic capsule, brain, or in the cornea. The treatment may consist of a single dose or a plurality of doses over a period of time.

When given parenterally, lectomedin product compositions are generally injected in doses ranging from 1 μg/kg to 100 mg/kg per day, preferably at doses ranging from 0.1 mg/kg to 50 mg/kg per day, and more preferably at doses ranging from 1 to 20 mg/kg/day. The lectomedin product composition may be administered by an initial bolus followed by a continuous infusion to maintain therapeutic circulating levels of drug product. Those of ordinary skill in the art will readily optimize effective dosages and administration regimens as determined by good medical practice and the clinical condition of the individual patient. The frequency of dosing will depend on the pharmacokinetic parameters of the agents and the route of administration. The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon the route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agents. Depending on the route of administration, a suitable dose may be calculated according to body weight, body surface area or organ size. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein, as well as the pharmacokinetic data observed in the human clinical trials discussed above. Appropriate dosages may be ascertained through use of established assays for determining blood levels dosages in conjunction with appropriate dose-response data. The final dosage regimen will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the drug's specific activity, the severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.

It will be appreciated that the pharmaceutical compositions and treatment methods of the invention may be useful in the fields of human medicine and veterinary medicine. Thus, the subject to be treated may be a mammal, preferably human, or other animals. For veterinary purposes, subjects include, for example, farm animals including cows, sheep, pigs, horses, and goats, companion animals such as dogs and cats; exotic and/or zoo animals; laboratory animals including mice, rats, rabbits, guinea pigs, and hamsters; and poultry such as chickens, turkeys, ducks and geese.

The present invention is illustrated by the following examples. Example 1 describes identification and characterization of cDNA encoding lectomedin polypeptides. Example 2 relates to expression of recombinant lectomedin. Example 3 described characterization of recombinant lectomedin. Ligand affinity chromatography with immobilized lectomedin is described in Example 4. Example 5 describes Northern analysis of lectomedin expression. Example 5 provides an assessment of tissue distribution of lectomedin in mammalian cell types, while Example 6 describes results from in situ hybridization. The chromosome localization of lectomedin is disclosed in Example 7. Example 8 provides production of polyclonal and monoclonal antibodies specific for lectomedin. Example 9 addresses lectomedin expression.

EXAMPLE 1

Isolation and Characterization of Human Lectomedin

Identification of Lectomedin-1α

In an attempt to identify genes encoding novel seven transmembrane receptor proteins related to CD97, a TBLASTN search of the National Center for Biotechnology Information (NCBI, Bethesda, Md.) Expressed Sequence Tag (EST) database was carried out with an amino acid query sequence for full length CD97 (SEQ ID NO: 12). This database contains DNA sequences representing one or both ends of cDNAs collected from a variety of tissue sources. The TBLASTN program was used to determine homology between the protein sequence of CD97 and the six different amino acid sequences encoded by each EST. In the search, ESTs are translated in six reading frames and the amino acid sequences generated are compared to the query CD97 amino acid sequence. Sequences identified as homologous at the amino acid level were examined and any ESTs positively identified as corresponding to a known protein were discarded.

Among the CD97-related sequences identified as corresponding to known proteins were ESTs representing CD97, human EMR1, and murine F4/80. In addition, several ESTs showed statistically significant values for relatedness in the transmembrane region of CD97, but they were not CD97, EMR1, or F4/80. One of the identified ESTs, designated GenBank® Accession No: T47902 (SEQ ID NO: 13), was chosen to attempt identification of a full length cDNA. The basis for choosing T47902 was disclosure in GenBank® that the EST was derived from a human fetal spleen library.

A library probe was first generated by PCR based on the Genbank sequence of T47902. Primers used to amplify a T47902 sequence are set out in SEQ ID NOs: 14 and 15 below.

5′ TGGAGTTTCAGCTGCTATTG SEQ ID NO: 14
5′ TGCCCATCCACAATAGTCTC SEQ ID NO: 15

Mixed human adult spleen cDNA was prepared by standard methods and ligated into vector pcDNA1.amp (Invitrogen) [Van der Vieren, M. et al. Immunity 3:683-690 (1995)]. The resulting plasmid mixture was transformed into E. coli and the bacteria were plated onto LB bacterial plates containing carbenicillin (100 ug/nl). Surviving colonies were collected by scraping and plasmid DNA was prepared by the alkaline lysis method. The cDNA mixture was used as a template for PCR in a reaction mixture including 350 ng cDNA, 100 ng each primer (SEQ ID NO. 14 and NO. 15), 200 μM each deoxynucleotide triphosphate (adenosine, thymidine, cytidine and guanosine), 10 mM Tris-HCl, pH 8.3 (at 25° C.), 50 mM KCl, 1.5 mM MgCl 2 , and 5 units Taq polymerase (Perkin Elmer Corp., Foster City, Calif.). PCR was carried out with an initial denaturation step of seven minutes at 95° C. followed by 30 cycles of denaturation for one minute at 95° C., hybridization for one minute at 55° C., and extension two minutes at 74° C. After PCR, 10 μl of the reaction was separated on a 1.5% agarose gel and an amplification product of 306 bp was detected following ethidium bromide staining. The 306 bp product was eluted from the gel using GeneClean® (BIO101 Inc., Vista Calif.) according to the manufacturer's suggested protocol and ligated into vector pCR2.1 (TA Cloning kit, Invitrogen, Carlsbad, Calif.). The resulting plasmid preparation was transformed into E. coli and the cells plated as described above. Several colonies were selected for DNA minipreps and the cDNA inserts were sequenced.

The 306 bp insert was excised from the pCR2.1® TA Cloning® vector by digestion with EcoRI. Following digestion, DNA fragments were fractionated on an agarose gel. A band of approximately 306 bp was eluted from the gel and labeled by random priming according to standard procedures. The labeled probe was used to screen the human spleen adult cDNA pcDNA1 library (described above) immobilized on nylon membranes following colony lifts from cells spread on LB/carbenicillin plates.

Two cDNA clones, designated 3.3 and 15.3.1, were obtained and purified. Clone 3.3 included an insert of approximately 4200 bp and clone 15.3.1 contained an insert of approximately 2750 bp. Both clones were sequenced by standard automated methods. The nucleotide sequence for clone 3.3 is set out in SEQ ID NO: 9 and the predicted amino acid encoded is set out in SEQ ID NO: 10. The nucleotide sequence for clone 15.3.1 is set out in SEQ ID NO: 16. It was initially presumed that the two clones represented a single cDNA sequence and, relying predominantly on the larger 3.3 insert, a contiguous cDNA was predicted. Neither insert, however, encoded a complete open reading frame, as evidenced by the fact that an in frame ATG translation start site preceded by a Kozak translation initiator sequence and an in-frame stop codon were not found.

In an attempt to isolate the 5′ end of the complete cDNA, RACE PCR was carried out using a human spleen cDNA library (Marathon™ cDNA, Clontech, La Jolla, Calif.). Nested primers (SEQ ID NOs: 17 and 18) utilized in the PCR were designed based on the library vector and clone 3.3 sequences.

5′ GTGATCCAGCTACAGTTGTGCTCAT SEQ ID NO: 17
5′ CTAATGCTTCACAGAATCTCTCTGGC SEQ ID NO: 18

Five microliters of cDNA prepared from human spleen RNA or peripheral blood leukocyte RNA was added to separate reactions with 100 ng downstream nested gene specific primer, adapter primer API (Marathon™ cDNA kit; Clontech Inc., Palo Alto Calif.), 200 μM each deoxynucleotide triphosphate (adenosine, thymidine, cytidine, and guanosine), 10 mM Tris-HCl, pH 8.3 (at 25° C.), 50 mM KCl, 1.5 mM MgCl2, 5 units Taq polymerase. PCR was carried out with an initial denaturation step for two minutes at 94° C., followed by (i) five cycles of 0.05 minutes at 94° C. and seven minutes at 74° C., (ii) five cycles of 0.05 minutes at 94° C. and seven minutes at 72° C., and (iii) 25 cycles of 0.05 minutes at 94° C. and seven minutes at 70° C. Following amplification, the reaction mixture was diluted 1:50, and 5 μl was used in a second amplification reaction including 100 ng upstream internal gene specific primer and adapter primer AP2 (Marathon™ cDNA kit, Clontech) with the same cycling conditions as in the first amplification. Amplification products from the second reaction were separated on a 0.9% agarose gel and a band of approximately 2 kb in the gel was eluted for subcloning into vector pCR2.1® as above. The isolated fragment was designated RACE3.3. The nucleotide and predicted amino acid sequences for the fragment are set out in SEQ ID NOs: 7 and 8, respectively.

When the RACE3.3 sequence was correlated with the sequence for the spleen clone 3.3 to account for overlap, an open reading frame (SEQ ID NO: 33) was deduced encoding a polypeptide of 1114 amino acids (SEQ ID NO: 34) and a predicted molecular weight of approximately 125 kD. Even thought the EST used to screen the spleen library was selected based on sequence similarity to CD97, the polypeptide encoded by the overlapping clones was presumed to represent a unique family of human proteins, related to, but distinct from, any previously identified in GenBank®. The putative extracellular domain in the predicted amino acid sequence did not include EGF domains characteristic of the CD97-like protein family and the amino acid sequence of the transmembrane domain in the predicted protein was only about 45-60% identical to the transmembrane domains of CD97. In addition, the predicted amino acid sequence deduced from the combined RACE3.3 and clone 3.3 open reading frame included potential lectin-binding, olfactomedin-ike, and mucin-like extracellular domains not found in CD97. Based on the presence of the extracellular lectin binding-like and olfactomedin-like domains, the polypeptide encoded by the RACE3.3 and clone 3.3 sequences was designated lectomedin-1α.

A later BLAST search of the GenBank® database using the lectomedin-1α sequence indicated that lectomedin-1α was related to the rat receptor for α-latrotoxin designated latrophilin [Lenianova, et al., J. Biol. Chem. 272:21504-21508 (1997)], and the calcium-independent receptor of α-latrotoxin (CIRL) [Krasnoperov, supra]. Both human lectomedin-1α and rat latrophilin have extracellular lectin binding-like and olfactomedin-like domains, in addition to a seven transmembrane region and a cytoplasmic domain also found in CD97. Lectomedin-1α also includes a sequence at amino acid residues 809 to 814 (in SEQ ID NO: 2) which is similar to a proposed cleavage site conserved in both CD97 and latrophilin. It is possible that these three proteins are processed by an endoprotease (or related proteases) with similar primary sequence specificity. In view of these similarities, lectomedin-1α may be related to a human homolog of the rat latrophilin and may participate in stimulation/secretion coupling in presynaptic termini and/or secretory granule release. Expression of lectomedin in cell and tissue types outside the central nervous system (discussed below), however, indicates that lectomedin is functionally distinct from latrophilin.

The overall amino acid sequence of lectomedin-1α was found to be approximately 80% identical to that of latrophilin, but the amino acid sequence of the latrophilin cytoplasmic domain was unrelated to the predicted cytoplasmic domain of lectomedin-1α. In addition, the location of the initiating methionine in latrophilin differed from that in the predicted open reading frame of lectomedin-1α. After further analysis of the lectomedin-1α polynucleotide sequence, however, a methionine codon in a different reading frame was identified upstream from the originally predicted open reading frame. The location of the upstream methionine codon (with respect to the transmembrane region) more closely corresponded to the position of the latrophilin initiating methionine and the first few amino acids in reading frame with the upstream methionine codon also corresponded to the sequence in latrophilin.

In view of the potential similarity to latrophilin, the polynucleotide sequence encoding the 1114 amino acid lectomedin-1α open reading frame was again compared to the raw data obtained during automated sequencing of the RACE3.3 cDNA. Further inspection showed that a guanosine nucleotide at position 454 had been entered in SEQ ID NO: 33, but was not present in the raw sequence data. The corrected nucleotide sequence for RACE3.3 (i.e., having the extraneous guanosine nucleotide deleted) together with the sequence of clone 3.3 (SEQ ID NO: 9) showed an open reading frame encoding 1177 amino acids. The corrected open reading frame began with the newly identified initiating methionine and included the previously identified lectin binding-like, olfactomedin-like, mucin-like, transmembrane and cytoplasmic domains of lectomedin-1α (SEQ ID NO: 1).

Based on sequence homology with known proteins, domains in various regions of the lectomedin-1α protein were identified. An extracellular region of approximately 831 amino acids showed homology to a previously reported D-galactoside binding lectin binding-like domain [Ozeki, et al., Biochemistry 30:2391-2394 (1991)] (lectomedin-1α amino acids 36 to 131 of SEQ ID NO: 2) and an olfactomedin-like domain [Yokoe and Anholt, Proc. Natl. Acad. Sci. ( USA ) 90:4655-4659 (1993)] (lectomedin-1α amino acids 135 to 327 of SEQ ID NO: 2). Three extracellular and three intracellular domains were separated by seven transmembrane domains (amino acids 832 to 1075 of SEQ ID NO: 2) characteristic of G-protein coupled receptors (GPCR) [Kobilka, etal., Science 238:650-656 (1987)]. A cytoplasmic region of 102 amino acids was adjacent the transmembrane region. Based on the observation that lectomedin-1α contained a region from amino acids 354 to 563 (SEQ ID NO: 2) with many serine and threonine residues (which may be O-glycosylated), as well as many proline residues (which break up alpha helices resulting in an extended structure with many beta turns), a mucin-like domain was identified.

Identification of Additional Lectomedin-1 Species

The sequence for lectomedin-1α was based on the sequences determined for clone 3.3 and the fragment RACE3.3. A second lectomedin cDNA could also be deduced based on the sequence of the second spleen clone 15.3.1. In comparing the sequences for clones 3.3 and 15.3.1, it was first noted that the clones were substantially identical throughout both 5′ regions, except that an adenosine required at position 1620 of clone 3.3 (SEQ ID NO: 7) was apparently not present in clone 15.3.1. As a result, the reading frame of clone 15.3.1 was shifted in comparison to the reading frame of clone 3.3, and thus, clone 15.3.1 did not encode a protein having the characteristic seven transmembrane domain found in lectomedin-1α. When the variant adenosine was inserted into the sequence for clone 15.3.1, the predicted protein sequence was consistent with the lectomedin-1α amino acid sequence up to the first amino acid residue in the cytoplasmic domain. This sequence suggested an alternative splice site in the cytoplasmic region of clone 15.3.1 that produced a shorter cDNA comprising a cytoplasmic domain of approximately forty-eight amino acids (as compared to 107 amino acids in the cytoplasmic domain of the lectomedin-1α cDNA derived solely from clone 3.3 sequences). The lectomedin-1α cDNA deduced from clone 3.3 also terminated at an alternative poly(A + ) site 210 nucleotides upstream from the corresponding poly(A + ) site identified in clone 15.3.1. The differences suggested that clone 15.3.1 represents a second member of the lectomedin family, which was designated lectomedin-1β. A deduced polynucleotide sequence for lectomedin-1β was therefore generated using the overlapping sequence from clone 3.3 (which extended the 5′ region of clone 15.3.1) and the RACE3.3 sequence (to provide an appropriate 5′ end); the complete predicted cDNA and deduced amino acid sequences for lectomedin-1β are set out in SEQ ID NOs: 3 and 4, respectively.

Characterization of the predicted amino acid sequence for lectomedin-1β provides various domains similar (in both sequence and position) to those identified for lectomedin-1α. An extracellular region of approximately 831 amino acids is predicted, including a D-galactoside-binding lectin-like domain (amino acids 36 to 131 of SEQ ID NO: 4), an olfactomedin-like domain (amino acids 135 to 327 of SEQ ID NO: 4), and a mucin-like domain (amino acids 354 to 563 of SEQ ID NO: 4). A seven transmembrane domain (amino acids 832 to 1075 of SEQ ID NO: 4) was located adjacent the extracellular domain, and a cytoplasmic region of 48 amino acids (residues 1076 to 1123 of SEQ ID NO: 4) was located adjacent the transmembrane region.

The originally identified EST designated T49702 (SEQ ID NO: 13) was described in GenBank® to represent the 5′ end of a cDNA clone designated 71509 (SEQ ID NO: 21), and when GenBank® was further searched for a DNA sequence representing the 3′ end of clone 71509, a second EST designated T47903 (SEQ ID NO: 30) was identified. Clone 71509 (SEQ ID NO: 21) was purchased, sequenced, and compared to the corresponding regions in lectomedin-1α and lectomedin-1β. The sequence of clone 71509 was identical to portions of the lectomedin-1α and 1β sequences, but, like the alternative splicing apparent from comparing lectomedin-1α and lectomedin-1β, yet another alternative splicing event was found based on the sequence of clone 71509. Specifically, the sequence of clone 71509 was found to lack a 106 bp sequence found in clone 3.3. Clone 15.3.1 also lacked the same 106 bp and an additional 97 bp of 5′ upstream DNA. Clone 15.3.1 therefore lacked 203 bp of sequence found in the lectomedin-1α clone. The 106 bp deletion resulted in a frame shift in the region encoding the cytoplasmic domain, providing a third lectomedin protein. This third alternative lectomedin polynucleotide and predicted amino acid sequence (SEQ ID NO: 5 and 6, respectively) was designated lectomedin-1γ.

As with the other lectomedin polypeptides, lectomedin-1γ is predicted to include (i) an extracellular region of approximately 831 amino acids with a D-galactoside binding lectin-like domain (amino acids 36 to 131 of SEQ ID NO: 6), an olfactomedin-like domain (amino acids 135 to 327 of SEQ ID NO: 6) and a mucin-like domain (amino acids 354 to 563 of SEQ ID NO: 6), (ii) a seven transmembrane region (amino acids 832 to 1075 of SEQ ID NO: 6), and (iii) a cytoplasmic region of 328 amino acids (amino acids 1076 to 1403 of SEQ ID NO: 6).

The sequences at which the three clones diverged showed hallmarks of the canonical 3 exon sequence with the presence of an AG dinucleotide. However, these regions differed from the accepted intron junction sequences which have been found to include highly conserved GT dinucleotides [ GENES IV, B. Lewin, Cell Press, Cambridge Mass. (1992), p. 597]. The identification of these sequences indicated that the clones were derived from alternatively spliced RNAs rather than from incomplete RNA splicing wherein the canonical exon/intron junction sequence (AG/GT) would be expected.

Identification of Lectomedin-2 and Lectomedin-3 Species

Lectomedin 1α and rat latrophilin (SEQ ID NO: 19) were used as query sequences in a subsequent BLAST search in an attempt to identify any additional ESTs with sequence homology. Two human ESTs designated AA683020 (SEQ ID NO: 22) and M79057 (SEQ ID NO: 23) were identified as being closely related to both lectomedin-1α and rat latrophilin. The sequence for EST AA683020 corresponds to the region from nucleotide 3275 to 3643 in the lectomedin-1α sequence (SEQ ID NO: 22) and the sequence for EST M79057 corresponds to nucleotides 2561 to 2842 in lectomedin-1α.

The BLAST search results indicated that both ESTs were more closely related to the sequence encoding rat latrophilin than to the nucleotide sequence encoding lectomedin-1α, further distinguishing lectomedin-1α from the rat protein and suggesting that the human ESTs may be more closely related to a putative human homolog of rat latrophilin. In view of the apparent relatedness between the human EST sequences and human lectomedin-1α, however, the AA683020 and M79057 ESTs were determined to represent unique lectomedin-2 and lectomedin-3 species.

In an effort to isolate cDNAs encoding full length lectomedin-2 and lectomedin-3 proteins, primers were designed based on the EST sequences for both lectomedin-2 and lectomedin-3 to amplify probes for library screening. Primers for amplifying a lectomedin-2 sequence were NHlect2.5 (SEQ ID NO: 35) and NHlect2.3 (SEQ ID NO: 36), and primers for the lectomedin-3 sequence were Nhlct.5 (SEQ ID NO: 37) and NHlct.3 (SEQ ID NO: 38).

NHlect2.5 GGGCCTCACCTGGGCTTTCGGCCTCCTC SEQ ID NO:35
NHlect2.3 GGACTGGTGCCCCCACGCGTGTCAGCAC SEQ ID NO:36
Nhlct.5   CCAACAAGACCCATACCAGCTGTG SEQ ID NO:37
Nhlct 3   CTGAGTCTTGTCGATCCCGACC SEQ ID NO:38

PCR was carried out using a Clontech human brain Marathon-Ready™ cDNA library as template. Reaction conditions included an initial incubation at 94° C. for five minutes, followed by 25 cycles at 94° C. for 30 seconds, 55° C. for 30 seconds, and 72° C. for 30 seconds, followed by a final extension step of 72° C. for 7 minutes and cooling to 4° C. in a Perkin-Elmer GeneAmp™ PCR System 9700. The resulting PCR products were gel purified using low melting point agarose (Gibco/BRL) and a QIAGEN® gel extraction kit according to the manufacturer's suggested protocol. The purified amplification products were separately cloned into vector pCRII® with a TA Cloning kit (Invitrogen), and sequencing was carried out to identify errors associated with PCR.

Probes for cDNA library screening were prepared by purifying EcoRI fragments from the pCRII® clones. The lectomedin-2 digestion products provided two fragments, 274 and 158 bp, and the 274 bp fragment was purified. The lectomedin-3 digestion resulted in a 297 bp EcoRI fragment.

A human fetal brain cDNA library in the LAMBDA ZAP® II vector was purchased from Stratagene (La Jolla, Calif.). Approximately 50,000 pfu were plated on twenty 150 mm LBM agar plates with LE392 E. coli. Plates were inverted and incubated at 37° C. overnight. The next day, the plates were chilled at 4° C. for two hours before preparing filter replicas. Amersham Hybond®N + nylon transfer membrane filters, with a diameter of 132 mm and a removal rating of 0.45 μm, were used to prepare two replicas of each plate. Filters were soaked in denaturing solution for two minutes, soaked in neutralizing solution for two minutes, and UV crosslinked in a Stratagene UV Stratalinker 2400. Filters were prehybridized overnight at 65° C. with 20 filters in 80 ml of prehybridization solution.

Hybridization probes were prepared by labeling the EcoRI fragments with 32 P-dCTP and 32 P-dTTP (800 Ci/mmol each, NEN Life Sciences Products) using a random priming kit (Boehringer Mannheim GmbH, Germany). The labeled probes were added to 20 ml hybridization solution per 20 filters and hybridization was carried out at 65° C. overnight. The filters were washed the next day and air dried before autoradiography at −70° C. for one to three days. Once films were developed, positive plaques were picked and removed to 500 μl of phage diluent buffer including one drop of chloroform. Dilutions of the positive plaques were prepared and plated on 100 mm LBM agar plates.

The plates were screened a second time as described above using 82 mm Amersham Hybond® N + filters, except that only one set of replica filters was prepared. Positive plaques from the second screening were screened for a third time to ensure that only positive plaques were picked for the phage rescue.

Positive plaques were prepared using an Exassist®/SOLR phage rescue system (Stratagene, La Jolla, Calif.) according to the manufacturer's suggested protocol. The rescue procedure produced E. coli colonies containing the DNA of interest cloned into a pBluescript® SK vector with flanking EcoRI restriction sites. Plasmid DNA was purified using the Wizard® Plus Miniprep Kit (Promega, Madison, Wis.) and digested with EcoRI to determine relative size.

The resulting purified clones were analyzed by DNA sequencing at both the 5′ and 3′ ends. Of the positive clones identified by the probe derived from EST M79057, several of the longest isolates were chosen for complete DNA sequence analysis. Two clones (designated 2.1 and 2.4) were found to comprise overlapping DNA sequences totaling 5611 bp including a complete open reading fame encoding 1470 amino acids. Of the clones identified with the AA683020 probe, all comprised sequences identical to clones derived from EST M79057. These results indicated that the AA683020 and M79057 ESTs represented non-overlapping regions from a single mRNA species. The two clones therefore were derived from the same lectomedin-2 gene. The polynucleotide encoding lectomedin-2 is set out in SEQ ID NO: 57, and its amino acid sequence is set out in SEQ ID NO: 58.

The organization of various domains in the predicted polypeptide sequence of lectomedin-2 was related to that in lectomedin-1. The approximately 851 amino acid extracellular domain of lectomedin-2 included a region with homology to the D-galactoside binding lectin-like domain (amino acids 36 to 131 of SEQ ID NO.: 57), an olfactomedin-like domain (amino acids 135 to 325 of SEQ ID NO: 57), three extracellular and three intracellular domains separated by seven transmembrane domains (approximately amino acids 852 to 1095 of SEQ ID NO: 57) and a cytoplasmic region (approximately amino acids 1096 to 1470 of SEQ ID NO: 57). The cytoplasmic region of lectomedin-2 was most similar in length and sequence identity to lectomedin-1γ. Comparison of the overall polypeptide sequences of lectomedin-1γ and lectomedin-2 showed 62.5% amino acid identity. Comparison of the overall polypeptide sequences of lectomedin-2 and CIRL showed 97.6% amino acid identity. These comparisons indicated that lectomedin-2 is more closely related by sequence to CIRL than lectomedin-1γ.

A strategy was designed to assemble the overlapping clones 2-1 and 2-4 in the mammalian expression vector pcDNA3 to produce full length lectomedin-2 open reading frame. Two primers (SEQ ID NOs: 61 and 62) were used to amplify a region of cDNA clone 2-1.

JD#1   ATATAAGCTTGCTGCCACCATGGCCCGC SEQ ID NO:61
Lecto- ATGACCCACAGCCCGTTCTC SEQ ID NO:62
3#31

Primer JD#1 (SEQ ID NO: 61) incorporated a HindIII site to facilitate cloning. The resulting 843 bp amplified product was digested with HindIII and BamHI and a 535 bp DNA fragment was isolated. The 535 bp fragment from clone 2-1 was ligated with a 1912 bp BamHI/SalI fragment from clone 2-1, a 2904 bp SalI/EcoRV DNA fragment from clone 2-4, and pcDNA3 (Invitrogen) previously digested with HindlIl and EcoRV.

Identification of Additional Lectomedin Species

A BLAST search of the GenBank EST database with lectomedin-1α or lectomedin-2 as query sequences identified EST sequences identical to lectomedin-1, EST sequences identical to lectomedin-2 and ESTs that were significantly related to but distinct from both known lectomedins. See Table 1. One of these unique lectomedin ESTs (GenBank Acc# R50822) was derived from clone #37438. Clone #37438 was purchased and its DNA sequence completely determined. The polynucleotide sequence for clone #37438 is set out in SEQ ID NO: 59, and the encoded amino acid sequence is set out in SEQ ID NO: 60. The 3′ sequence of clone #37438 is comprised of an untranslated region preceded by a predicted coding sequence for a protein with significant amino acid homology to the cytoplasmic domains of lectomedin-lγ and lectomedin-2. The 5′ end of the sequence of clone #37438 was unrelated to the lectomedins, but was identical to the nucleotide sequence for a tRNA synthetase. This clone may represent a partially spliced mRNA or it might be a cloning artifact.

The cDNA clone #37438 was used to generate a labeled probe to screen approximately one million clones from a human fetal brain cDNA library by techniques standard in the art. Hybridization was carried out at 43° C. in the presence of 45% formamide and filters were washed in 0.1×SSC at 68° C. for 90 minutes. Positive clones identified were isolated to homogeneity and partial sequence analysis was carried out with eleven of the clones. The DNA sequence of one clone (#11) was determined to have 3′ sequences identical to clone #37438 and 5′ sequences within the upstream coding sequences similar to, but distinct from, lectomedin-1 and lectomedin-2.

TABLE 1
Additional Lectomedin Species
	Lectomedin-4	T10363	(SEQ ID NO: 39),
		R19057	(SEQ ID NO: 40),
	Lectomedin-5	R50822	(SEQ ID NO: 41)
	Lectomedin-6	W03697	(SEQ ID NO: 42)
	Lectomedin-7	H18951	(SEQ ID NO: 43)
	Lectomedin-8	AA769730	(SEQ ID NO: 44)
	Lectomedin-9	C17798	(SEQ ID NO: 45)
	Lectomedin-10	Z44961	(SEQ ID NO: 46)
	Lectomedin-11	AA369669	(SEQ ID NO: 47)
	Lectomedin-12	AB011122	(SEQ ID NO: 48)

EXAMPLE 2

Recombinant Expression of Lectomedin

Lectomedin-1α

A. Expression vectors encoding lectomedin isoforms were constructed by combining DNA fragments from clone 3.3 and RACE3.3 described above.

In one approach, both clone 3.3 and RACE3.3 polynucleotides are first modified in the overlapping regions by insertion of a silent mutation to introduce a SacI restriction site. PCR is employed using primers (SEQ ID NOs: 25 and 26) to amplify a 5′ sequence from the RACE3.3 cDNA template that changes G to C at position 1455 to create the desired restriction site. In amplification of the RACE3.3 fragment, the 5′ primer (SEQ ID NO: 26) is designed based on sequences at the ATG start codon; the primer introduces a BamHI restriction site to facilitate cloning and a Kozak consensus start sequence.

5′-TCTTCAGCTGAGCTCTTCAAAACC SEQ ID NO:24
5′-GGTTTTGAAGAGCTCAGCTGAAGA SEQ ID NO:25
5′-CAGCAGGGATCCACCATGGTGTCTT- SEQ ID NO:26
CTGGTTGCAGAATGCGAAGTCTGTGG
5′-GACGATGACGCGGCCGCCTATTAAAGAC- SEQ ID NO:27
TTGTAACCAGCTGCATTTGTCCTTCTC

In amplification of the clone 3.3 DNA with primers set out in SEQ ID NOs: 24 and 27, the 3′ primer is based on sequences at the stop site of translation and is designed to introduce a NotI restriction site.

The resulting amplification products, a RACE3.3 fragment with a 5′ BamHI site and a 3′ SacI site, and a clone 3.3 DNA with a 5′ SacI site and a 3′ NotI site, are digested with appropriate enzymes, ligated together, and cloned into the mammalian expression vector pcDNA+3, (Invitrogen, Carlsbad, Calif.) previously digested with BamHI and NotI.

B. As an alternative approach, a lectomedin-1α-encoding DNA is generated using PCR with the 5′ primer used to amplify RACE3.3 described above and the 3′ primer used to amplify the clone 3.3 DNA also described above.

In the PCR, both RACE3.3 and clone 3.3 DNA are combined with the two primers. After an initial denaturing step, the RACE3.3 and clone 3.3 DNA will anneal across the overlapping regions and the double stranded region will serve as primers in the first extension that produces a complete double stranded lectomedin-1α DNA. Subsequent amplifications will result from extension from the 5′ and 3′ primers. The amplification product is then purified, digested with BamHI and NotI, and inserted into the pcDNA vector previously digested with the same enzymes.

C. In another approach, an expression vector encoding lectomedin-1α was constructed in a two step procedure. First, PCR was carried out using a XbaI fragments of clone 3.3 and primers 3.3.24 (SEQ ID NO: 52) and Lecto 3′ express (SEQ ID NO: 27) along with Taq polymerase.

CCTACCACAGCTGTGACAATAACTTCTTCAGCTGAGC SEQ ID NO:52

A second PCR was carried out using an EcoRI fragment of RACE 3.3 as template DNA and primers Lecto 5′ express (SEQ ID NO: 26) and Lecto6 (SEQ ID NO: 25) with Vent® polymerase (New England Biolabs, Beverly, Mass.). The two amplification products were purified, denatured, and annealed. Because the two fragments overlap in a region of approximately 100 nucleotides, annealing results in a partially double stranded molecule spanning the entire lectomedin-1α coding region. Extension with Taq polymerase first produces a double stranded lectomedin-1α coding region. The double stranded molecule was then amplified using primers in SEQ ID NOs: 26 and 27. The SEQ ID NO: 26 primer was designed to introduce a BamHI restriction site, followed by a Kozak consensus start site. The resulting amplification product was digested with NotI and BamHI, and the lectomedin-1α fragment was gel purified. The fragment was ligated into pcDNA3 (Invitrogen, Carlsbad, Calif.) previously digested with BamHI and NotI. Sequence analysis of the resulting plasmid, designated pcDNA3 Lectomedin-1α#2, indicated that several errors were introduced in the amplification process. The correct lectomedin-1α coding sequence was constructed from regions of pcDNA3 Lectomedin-1α#2 without errors ligated to fragments of RACE3.3 and clone 3.3 as follows.

A 166 bp HindIII/BglII fragment from pcDNA3 Lectomedin-1α#2, a 628 bp BglII/BstXI fragment from RACE3.3, and a 775 bp BstXI/ApaI fragment from pcDNA3 Lectomedin-1α#2 were ligated in the presence of pBluescript® KS+ (pBSKS) (Stratagene) previously digested with BstXI and ApaI. The resulting plasmid was designated pBSKSlectoHindIII/ApaI#14.

In a another reaction, a 306 bp ApaI/EcoRI fragment from clone 3.3 and a 2486 bp EcoRI/EcoRI fragment from clone 3.3 were ligated in the presence of pB SKS previously digested with Apal and EcoRI. The resulting plasmid was designated pBSKSlecto I alphaEcoRI/ApaI#6.

Plasmids pNEF6 and pDEF2 encode promoter regions and a 5′ intron from the gene encoding Chinese hamster ovary elongation factor 1, in addition to neomycin (G418) resistance for selection. Construction of pNEF6 and pDEF2 was carried out as follows.

Plasmid pEF1/XN was generated by ligation of an 11 kb NotI/XbaI fragment from pSK/EF1.12 (WO 98/49289, published Nov. 5, 1998, incorporated herein by reference), having the XbaI site blunt ended with Klenow polymerase, with a 2.22 NotI/SmaI fragment from pDC31 (WO 98/49289).

Plasmid pNEF3 was generated by ligation of a 4.19 kb SalI/NsiI fragment (the NsiI site blunt ended with Klenow polymerase) from pSKEF1.7 (WO 98/49289) with a 7.96 kb SalI/PmeI fragment from pNEF1 (WO 98/49289).

Plasmid pNEF5 was constructed with a 9.2 kb AscI/NotI fragment from pNEF3 and an 11 kb AscI/NotI fragment from pEX1/XN.

Plasmid pNEF6 was constructed by ligation of a 19.7 kb XbaI/Asp718 fragment fom pNEF5 with a 0.844 kb XbaI/Asp718 fragment from pRc/CMv (Invitrogen).

A 736 bp NotI/HindIII fragment (including the intron sequence) was isolated from pDEF2 and combined with a 1571 HindIII/ApaI fragment (including the Kozak sequence, translation start site, and coding region for amino acids 1 to 515) from pBSKSlectoHindIII/ApaI#14, a 3714 bp ApaI/XbaI fragment (encoding amino acids 516 to 1177 of lectomedin-1α and including a stop codon and untranslated sequences) from pBSKSlectolalphaEcoRI/Apa#6, and pNEF6 previously digested with XbaI and NotI. The resulting plasmid was designated pNEF6Lectomedin1A#3.1.

Lectomedin-1β and Lectomedin-1γ

Clone 15.3.1 and clone 71509 were separately amplified with primers lecto3.3.10 and 3.3.19.

TCAGACACTCATACTGCTGTG SEQ ID NO:49
CACAGTCCACAACTTGCAC SEQ ID NO:50

The resulting amplification products were digested with StuI and NcoI, and a 113 bp fragment from 15.3.1 (lectomedin-1β) and a 210 bp fragment from 71509 (lectomedin-1γ) were purified. Each fragment was separately ligated into pBSKSlecto1alphaEcoRI/ApaI#6 previously digested with StuI and NcoI. The resulting plasmids were designated pBSKSlecto1betaEcoRI/ApaI#7 and pBSKSlecto1gammaEcoRI/ApaI#6.

To create a lectomedin-1β expression plasmid, the reaction described above for construction of the lectomedin-1α expression plasmid was repeated except that a 2586 bp ApaI/XbaI fragment from pBSKSlecto1betaEcoRI/ApaI#7 was substituted for the 3714 bp ApaI/XbaI from pBSKSlecto1alphaEcoRI/ApaI#6 to provide plasmid pNEF6Lectomedin1B#4.2.

To create a lectomedin-1γ expression plasmid, the same lectomedin-1α reaction above was carried out except that a 2683 bp ApaI/XbaI fragment from pBSKSlecto1gammaEcoRI/ApaI#6 was substituted for the 3714 bp ApaI/XbaI from pBSKSlectol1alphaEcoRI/Apal#6 to provide plasmid pNEF6Lectomedin1G.

Expression of a Soluble Lectomedin-1 Ig Fusion Protein

An expression construct was also prepared in parental vector pDC37 encoding a soluble, truncated form of lectomedin-1 as a fusion protein with human immunoglobulin G1 hinge and constant heavy chain regions 2 and 3 [hinge CH2-CH3] sequence [Sadhu, et al., Cell Adhesion and Commun. 2:429-440 (1994)]. Plasmid pDC37, encoding human VCAM-1 with human IgG1 hinge-CH2 coding sequences, is a derivative of pDC31 generated by digestion with SalI, filled in with Klenow polymerase, and blunt end ligated to eliminate the SalI site.

Plasmid pDC37/VCAM1.Ig1.2c was digested with HindIII and SalI and a fragment lacking the VACM-1 coding region was isolated. The isolated HindIII/SalI fragment was ligated with a 1571 bp HindIII/ApaI fragment from pcDNA3Lectomedin-1a#2 and an amplification product from clone 3.3 prepared using primers lecto Sal Ig (SEQ ID NO: 51) and 3.3.24 (SEQ ID NO: 52).

lecto SaL Ig          SEQ ID NO:51
GACGCTGGTCGACTAGGTGGCTGCATGCACACGTTGTTCG
3.3.24          SEQ ID NO:52
CCTACCACAGCTGTGACAATAACTTCTTCAGCTGAGC

Primer lecto Sal Ig generated a unique SalI site in the amplification product (after codon 811 of lectomedin-1) to permit in-frame ligation to IgG1 coding sequences. The resulting plasmid was designated pDC37Lecto.Ig#7.

A 736 bp NotI/HindIII fragment from pDEF2 was ligated with a 1571 bp HindIII/ApaIII fragment (encoding the Kozak sequence, start site, and amino acids 1 to 515 from lectomedin-1α) from pcDNA3 Lectomedin-1a#2, a 1788 bp ApaI/XbaI fragment (encoding amino acids 516 to 811 from lectomedin-1 fused to IgG sequences) from pDC37Lecto.Ig#7, and pDEF14 previously digested with NotI and XbaI. The resulting plasmid was designated pDEF14Lecto.Ig#2.

Plasmid pDEF14Lecto.Ig#2 was transfected into DHFR − DG44 CHO cells and stably transfected cells were selected.

EXAMPLE 3

Characterization of Recombinant Lectomedin

Characterization of the protein expression level in recombinant cells is carried out using polyclonal antisera (produced as described in Example 8), and functional analysis, with respect to latrotoxin binding (discussed below) and/or release of secretory granule contents, is performed as previously described.

In initial characterization, Chinese hamster ovary (CHO) cells were transfected by standard methods (i.e., calcium phosphate or cationic lipids) with lectomedin-1α expression construct. After 48 hours incubation, the cells were lysed in PBS containing 1% Triton® X-100 and protease inhibitors, and proteins in the detergent soluble fraction were separated by SDS-PAGE. After transfer to nitrocellulose membrane, the blot was incubated with rabbit antiserum immunospecific for lectomedin-1α (generated against amino acids 432-852 as immunogen). Immunoreactivity was detected using a goat anti-rabbit IgG (conjugated with horseradish peroxidase) followed by chemiluminescence detection and exposure to X-ray film (using a Renaissance® detection kit, NEN Life Sciences, Boston, Mass.).

For functional characterization, secretory cells of the endocrine system are employed which readily accept DNA constructs by transfection. Cell lines useful in functional characterization include, for example, mouse anterior pituitary corticotroph continuous cells (AtT20; ATCC CCL 89), rat pancreatic islet insulinoma continuous cells (RinM5F), or human pituitary somatotroph continuous cells (GH3; ATCC CCL 82.1). After an appropriate amount of time to allow protein synthesis, incubation of the transfected cells with alpha-latrotoxin, or another ligand, is followed by detection of stimulated secretion of proteins using enzyme-linked immunosorbant assay or radioimmunoassay (RIA). For example, increased secretion from the exemplified cells lines is accomplished through detection of adrenocorticotrophic hormone (ACTH) release from AtT20 cells, insulin release from RinM5F cells, or growth hormone release from GH3 cells.

In addition, since lectomedin-1 is a G-protein coupled receptor, ligand binding would be expected to trigger intracellular second messenger effector pathway activity changes such as, for example, increased production of cyclic AMP (cAMP) or changes in intracellular calcium concentration. Changes of these types are measured by standard techniques, for example, RIA detection of cAMP or fluorescence detection of calcium binding indicators (i.e., Fura 2).

An exemplary alpha-latrotoxin binding assay has been previously described [Meldolesi, J. Neurochem. 38:1559-1569 (1982), Petrenko, et al., EMBO J, 9:2023-2027 (1990)]. Cells are transfected with either vector DNA alone (control cells) or a lectomedin 1-encoding expression plasmid (assay cells). Both assay and control cells are homogenized in buffer (120 mM NaCl, 4.7 mM KCl, 1.2 mM each MgSO 4 , K 2 HPO 4 , and CaCl 2 , 20 mM Na 2 HPO 4 —HCl, pH 7.4, and 10 mM glucose) and protein concentrations are determined by standard methods. Known amounts of protein from control or transfected assay cell membranes are spotted on nitrocellulose paper and placed in separate wells of a 24 well dish. The paper is rinsed once with buffer containing 100 mM KCl, 2 mM CaCl 2 , and 20 mM Tris, pH 7.7, and incubated for one hour in the same buffer supplemented to 1.5% (w/v) with bovine serum albumin (BSA) (blocking buffer). Solutions of blocking buffer containing from 0.1 to 1.2 nM of 125 I-labeled alpha-latrotoxin, labeled to a specific activity of 1500 to 2000 Ci/mmol, without or with a large excess (100 nM) of unlabeled toxin are incubated for thirty minutes with the immobilized protein. The paper is rinsed three times with 1 ml of blocking buffer over a 20 minute time period and counts per minute remaining are determined with a gamma counter. Nonspecific binding is determined to be the value of radioactive counts remaining after incubation of labeled toxin in the presence of a large excess of unlabeled toxin. Specific counts are converted to nanomoles of toxin bound per milligram of protein spotted and the data is plotted as nanomoles bound toxin versus nanomoles free toxin. The data are converted to bound toxin divided by free toxin versus bound toxin to derive a Scatchard plot for number of binding sites (a linear plot being the expected result for a single toxin binding site on the receptor).

In additional characterizations, the lectomedin fusion protein Lecto-1Ig (Example 2) was purified using protein A Sepharose® (Amersham Pharmacia Biotech, Piscataway, N.J.) affinity chromatography and conditioned growth media derived from one of two clones designated G10 and E10. Media was loaded onto the column which was then washed extensively with 50 mM Tris, pH 7.5, 50 mM NaCl. Protein was eluted in buffer containing 50 mM citric acid, pH 4.0, and 50 mM citric acid, pH 3.0. The majority of the protein eluted in the pH 3.0 buffer. Protein fractions were pooled, neutralized with 1 M Tris, pH 8.0, and dialyzed against PBS. Purified protein was filtered, aliquoted, flash frozen and stored at −70° C.

Amino terminal sequencing indicated that the mature amino terminus of the protein was identified as a phenylalanine residue at position 26. This observation indicated that the recombinant protein was recognized and cleaved by a signal peptidase in the CHO cells and that the amino terminus was not blocked.

Size exclusion chromatography suggested a protein with a molecular weight of approximately 650 kDal as compared to the molecular weight determined on SDS PAGE of approximately 170 kDal. The gel filtration result suggested that four monomers combined to produce the 650 kDal protein.

Treatment of the protein with N-glycosidase F, O-glycosidase, and/or neurominidase (Boehringer Mannheim) in 10 mM Na 2 HPO 4 (pH 6.8), 5 mM EDTA, 0.25% Triton® X-100, 0.5% SDS, and 0.5% β-mercaptoethanol (BME), at 37° C., resulted in reduction of protein molecular weight. After treatment with N-glycosidase F alone, monomeric protein molecular weight was approximately 130 kDal. After treatment with N-glycosidase F, O-glycosidase, and neuraminidase, monomeric protein molecular weight was approximately 125 kDal. These observations suggest that the observed SDS PAGE molecular weight may be attributable to approximately 40 kDal N-linked carbohydrate and approximately 5 kDal O-linked carbohydrate.

EXAMPLE 4

Ligand Affinity Chromatography

In an attempt to isolate a ligand for lectomedin-1, an affinity column was generated with immobilized lectomedin-1. In short, 10 mg of purified sLecto-1Ig was coupled to CNBr-activated Sepharose 4B resin (AmershamPharmacia) according to the manufacturer's suggested protocol. Greater than 96% of the lectomedin protein was coupled to the resin.

A detergent extract was prepared from human spleen (3.48 g wet weight). Tissue was homogenized in 15 ml buffer containing 1% Triton® X-100, 25 mM Tris, pH 8, 150 mM NaCl, 5 mM iodoacetamide, 5 mM EDTA, 1 mM phenylnethylsulfonyl fluoride (PMSF), and 1 μg/ml pepstatin and aprotinin using a Waring blender. Homogenization was carried out at low speed. The resulting homogenate was cooled on ice for one hour and centrifuged at 100,000×g for 60 min. The supernatant (approximately 120 mg total protein) was mixed with the sLecto-1Ig-coupled resin with rotation overnight at 4° C. The resin was drained and washed extensively with 10 mM Tris (pH 8), 150 mM NaCl, and 10 mM Tris (pH 8), 1 M NaCl. Protein was eluted with five bed volumes of 100 mM D-lactose, 10 mM Tris, pH 8.0, 150 mM NaCl. Five equal fractions were collected. The resin was further eluted with four bed volumes of 100 mM glycine, pH 2.0, and four equal fractions were collected and neutralized with 1 M Tris, pH 8.0. The resin was then neutralized in 10 mM Tris, pH 8.0/150 mM NaCl. Fractions from the resin were analyzed by SDS-PAGE and bands of approximately 95, 71, 55 and 30 kDal were detected.

Fractions with the highest protein yields were spin concentrated (Ultrafree® 10, Millipore, New Bedford, Mass.) and proteins were separated with 12% SDS-PAGE. Coomassie staining revealed four prominent bands in the lactose eluate of approximately 30-32, 55, 70, and 80-95 kDal. Bands were excised from the gel, rinsed twice in 50:50 acetonitrile:water, and stored at −70° C. until sequence analyses were performed. Sequence results indicated that the 30-32 kDal protein was Mac-2 (also called galectin-3, GenBank® Accession No: g106937), the 55 kDal protein was fibrinogen γ A chain (GenBank® Accession No: g71827) and the 80-95 kDal protein was immunoglobulin mu chain constant region.

Mac-2 (galectin-3) is synthesized by numerous immune cell populations and epithelia, and is a major non-integrin laminin binding protein [Perillo, et al., J. Mol. Med. 76:402-412 (1998)]. Recent observations indicated that Mac-2 was expressed in vessels in early atherosclerotic lesions in association with infiltrating monocytes. Expression was not detected in normal vessels. Expression was also detected in aortic smooth muscle cells in culture, as well as in animals following a hypercholesterolemic feeding regimen and post balloon angioplasty [Arar, et al., FEBS Letts.430:307-311 (1998), Nachtigal, et al., Am.J.Pathol. 152:1199-1208 (1998)]. Mac-2 stimulates normal fibroblast proliferation, neural cell adhesion, and neurite outgrowth [Inohjara, et la., Exp. Cell. Res. 245:294-302 (1998); Pesheva, et al., J. Neurosci. Res. 54:639-654 (1998)].

The binding results from lectomedin affinity chromatography, in view of the art, suggest that secretion of Mac-2 by infiltrating macrophages during atherogenesis and binding to lectomedin-1 expressed on smooth muscle cells of vascular tunica media may be required for smooth muscle proliferation in atherosclerosis. [Ross, Nature 362:801-809 (1993)].

Previous work has indicated that circulating components of the thrombolytic pathway, including firinogen, are associated with chronic vascular disease (i.e. , hypertension, atherosclerosis). Studied showed that circulating fibrinogen levels may be elevated in hypertensive patient populations. These observations suggest a role for lectomedin in various vascular disease states.

EXAMPLE 5

Northern Analysis

In an attempt to assess human lectomedin-1α expression, Northern blot analysis was performed using a commercial multi-tissue blot (Clontech, Palo Alto, Calif.) with RNA derived from various human tissue sources. The probe used was a 531 bp BstM fragment derived from the extracellular region of clone 3.3 (bases 1860 to 2350 in SEQ ID NO: 7). Hybridization was carried out in Express-Hyb™ Solution (Clontech) at 68° C. for two hours; the final wash was carried out at 68° C. in 0.1×SSC for one hour.

Results indicated expression of two predominant transcripts of 6.6 and 7 kb. The highest levels of expression were detected in spleen, prostate, and lung. Lower signals were in duodenum, placenta, thymus, testis, colonic mucosa, heart, and liver. Lowest levels were found in skeletal muscle, kidney, pancreas, and brain. No signal was observed in ovary and peripheral blood leukocytes.

EXAMPLE 6

In situ Hybridization

In order to verify results from Northern analysis, in situ hybridization was carried out using various human tissue sections.

Probes for in situ hybridization analysis were prepared as follows. Clone 3.3 was engineered by PCR to include a SacI site near the 5′ end of the cDNA by changing a G nucleotide to C at position 1459 of the composite sequence. A 626 bp SacI/EcoRI fragment was prepared and subcloned into pBSSK (Stratagene, La Jolla, Calif.). The resulting plasmid was linearized with either EcoRI or SacI. The ends of the SacI linearized DNA were made blunt by standard procedures using T4 DNA polymerase. Linear DNAs were used to generate 35 S-labeled sense or antisense strand probes for in situ hybridization with tissue sections from spleen, lung, prostate, heart, thymus, duodenum.

The results obtained from hybridization experiments were inconclusive due to high background with sense strand control probe.

In another approach to localizing the lectomedin-1 mRNA, two other fragments of the lectomedin-1 cDNA were subcloned into the pBluescript vector. A 1238 bp BamHI/SacI fragment of lectomedin-1α (SEQ ID NO: 1) was subcloned. A representative clone including this fragment was designated as probe BS. A 2855 bp BamHI/XbaI fragment of lectomedin-1 α (SEQ ID NO: 1) was subcloned and a representative clone was isolated and designated as probe BX. 35 S-labeled sense and antisense probes from both BS and BX were prepared by methods standard in the art and hybridized with tissue sections from human brain occipital cortex, cerebellum and thalamus; interventricular septum, sino-atrial node and atrium of the heart; small intestine, spleen, lung, prostate, adrenal gland and pancreas.

Specific signals were observed with the antisense BS probe in cardiac myocytes (heart), endocrine secretory cells of the adrenal cortex, occipital cortex neurons and cerebellar purkinje neurons, granule layer neurons and some molecular layer neurons. The antisense BX probe produced similar patterns except for the presence of specific signals in a subset of secretory cells of the prostate.

EXAMPLE 7

Human Lectomedin Chromosomal Localization

The contiguous lectomedin-1α cDNA deduced from combining clone 3.3 and RACE3.3 sequences was used as a query to search the NCBI Sequence-Tagged Sites (STS) database in an attempt to map the chromosomal location of a gene encoding lectomedin-1α.

Two STSs were identified, designate SHGC-36772 and WI-1 1936, which were mapped to chromosome 1 by radiation hybrid mapping techniques. The STS WI-11936 mapping has been further refined to chromosome locus 1p31.

In an effort to identify the chromosomal localization of the gene for lectomedin-2, the full length nucleotide sequence was used to query the GenBank® high throughput genomic sequences nucleotide database using the BLAST algorithm. Results indicated that a portion of chromosome 17 had identity with a portion of the lectomedin-2 DNA sequence. Query of the human Genemap '98 at NCBI for the localization of this region of chromosome 17, showed that the lectomedin-2 gene mapped to chromosome 17p11.1-q12.

To identify the chromosomal localization of the gene for lectomedin-3, an accession number query (using EST R50822) of the Unigene database at the National Center for Biotechnology Information (NCBI) was carried out. The results identified a cluster of ESTs, including R50822 that mapped to human chromosome 4. Refinement of the localization was carried by searching the human GeneMap '98 out at NCBI, which showed that EST the cluster containing R80522 was assigned to 4q12-13.3.

EXAMPLE 8

Preparation of Antibodies to Lectomedin

Generation of Polyclonal Anti-sera with Extracellular Lectomedin-1 Fragments

An E. coli expression vector was constructed encoding the extracellular region of lectomedin-1α (residues 432 to 852 of SEQ ID NO: 1) as a fusion protein with a biotinylated tag at the amino terminus. The plasmid, designed “Biolecto 1st ECD” was constructed as follows.

PCR primers “lecto-1” and “lecto-2” (SEQ ID NOs: 31 and 32, respectively) were used to amplify a 1283 bp fragment of clone 3.3 (nucleotides 1508-2772 in SEQ ID NO: 9 which encodes the amino acid sequence from residue 432 to residue 852 of SEQ ID NO: 10). This region of the lectomedin-1 polypeptide is approximately 69% identical with latrophilin.

primer lecto-1                 SEQ ID NO:31
5′-TACAA                                                                        CCATGG                                                                    GCACAACTGTAGCTGG
primer lecto-2                 SEQ ID NO:32
5′-TACA                                                                        AGATCT                                                                    AGCAGATAGCCAGGCAAACAAGGG

Primer lecto-1 introduced an NcoI restriction site (underlined above) in the amplification product and primer lecto-2 introduced a BglII restriction site (underlined above) and a translational termination site. The amplified fragment was subcloned into plasmid arabio1b previously digested with NcoI and BglII to form plasmid Biolecto1stECD. The plasmid arabio1b contains the Salmonella typhimurium arabinose promoter and araC gene, as well as the biotin transferase gene [Kashishian, et al., J. Bio. Chem. 273:27412-27419 (1998)]. The expression product of the final construct provides a fusion protein of approximately 55 kDa with the biotin tag at the N-terminus, and the lectomedin-1 amino acids 432 to 852 at the C-terminus.

The plasmid Biolecto1stECD was transformed into E. coli using standard procedures and single colonies were isolated and grown for plasmid preparation. A culture including the desired plasmid was grown at 30° C. in LB/carbenicillin supplemented with biotin (4 μM) and induced in the presence of arabinose (0.5%) for 16 hours. Bacteria were collected by centrifugation and lysed with hen egg lysozyme (10 μg/ml) in TEN buffer (50 mM Tris-HCl, pH 7.5 at 25° C., 0.5 mM EDTA, 0.3 M NaCl) on ice for 15 minutes. After incubation on ice, NP-40 detergent was added to 0.2% final concentration and the resulting mixture sonicated briefly on ice. Insoluble material was removed by centrifugation at 15,000×g for ten minutes, after which the pellet washed five times with the additional of TEN buffer followed by sonication and centrifugation. The final pellet was solubilized in 2× sample loading buffer for preparative SDS-PAGE separation.

A major band of 55 kDa was detected after treating the gel for 30 minutes in 0.4 M KCl. The 55 kDa band was excised from the gel and the fusion protein eluted in dialysis tubing using 0.5% SDS-PAGE running buffer. The collected protein was concentrated, spin-dialyzed (30,000 MW cutoff Ultrafree® Centrifugal Filter Device; Millipore Corp. Bedford, Mass.), and stored.

The purified protein was used to immunize two rabbits to generate antisera according to well known procedures. Briefly, two New Zealand white rabbits (designated #7234 and #7278) were prebled to obtain preimmune serum and then immunized with 250 μg of purified BiolectolstECD fusion protein emulsified with complete Freund's adjuvant. The rabbits were boosted repeatedly with 250 μg of purified fusion protein in incomplete Fruend's adjuvant. The first three boosts were given at one month intervals, the third and fourth boosts following a three month interval, and the fourth and fifth boost following an additional one month interval. Blood was drawn by ear vein puncture two weeks after the second, third, fourth, and fifth boosts to determine antibody titers.

Immunoprecipitation was carried out with the resulting polyclonal sera using extracts from tissues/cell lines, including brain cortex, lung, spleen, liver, skeletal muscle, hippocampus, and prostate carcinoma cell line PC-3 (ATCC, CRL 1435). Protein species having molecular weights of 200, 180, 170, and 70 kDa were detected which may have represented full length proteins, proteolytic fragments, or isoforms of lectomedin including the α, β, and γ proteins.

Serum obtained from rabbit #7234 after the fifth boost was subjected to antigen-specific affinity chromatography by methods standard in the art. Briefly, 10 ml of 0.45 or 0.8 microfiltered serum (100×g supernatant) adjusted to 10 mM Tris, pH 7.5, was incubated with sLecto-1Ig agarose beads for 16 hours at 4° C. with rotation. The beads were drained and washed with 20 bed volumes of 0.5 M NaCl, 10 mM Tris, pH 7.5, until absorbance OD 280 reached 0.03. Bound antibody was eluted with five bed volumes of 100 mM glycine, pH 2.5. The eluates were collected as 0.5 ml fractions and neutralized with 1 M Tris, pH 8. The sLecto-1Ig agarose beads were neutralized with 50 mM Tris, pH 7.5/150 mM NaCl and stored at 4° C. in the same buffer supplemented with 0.1% timerool. Fractions were analyzed by SDS-PAGE for the presence of immunoglobulin heavy and light chains. The peak fractions were pooled, the buffer was exchanged with PBS, and the volume reduced by 90%. The final product was mixed with an equal volume of sterile glycerol, aliquoted, flash frozen, and stored at −70° C. until use.

Generation of Polyclonal Antisera with Synthetic Lectomedin-1 Cytoplasmic Peptides

Peptides specific to the carboxy terminal cytoplasmic regions of α, β, and γ isoforms of lectomedin- 1 were synthesized as immunogens for producing polyclonal antisera in New Zealand White rabbits. The peptides were designed from the DNA sequence in the cytoplasmic region of lectomedin 1α (SEQ ID NO: 53), lectomedin 1β (SEQ ID NO: 54), and lectomedin 1γ (SEQ ID NO: 55).

Cys-Leu-Gln-Asp-Leu-Tyr-His-Leu-Glu-Leu-Leu-Leu-Gly-Gln-Ile-Ala SEQ ID NO:53
Cys-Thr-Arg-Thr-Ser-Ala-Arg-Tyr-Ser-Ser-Gyl-Thr-Gln-Asp-Ile-His SEQ ID NO:54
Cys-Glu-Gly-Asp-Val-Arg-Glu-Gly-Gln-Met-Gln-Leu-Val-Thr-Ser-Leu SEQ ID NO:55

Peptides comprising the carboxy terminal regions of the related lectomedin-2 (SEQ ID NO: 63) and lectomedin-3 (SEQ ID NO: 64) proteins were also synthesized.

Cys-Pro-Gly-Pro-Asp-Gly-Asp-Gly-Asp-Gly-Gln-Met-Gln-Leu-Val-Thr-Ser-Leu SEQ ID NO:63
Cys-Pro-Glu-Gly-Ser-Ser-Lys-Gly-Pro-Ala-His-Leu-Val-Thr-Ser-Leu SEQ ID NO:64

The synthesized peptides were individually conjugated to Keyhole Limpet Hemocyanin (KLH) (Imject, Pierce) according to the manufacturer's suggested protocol. Rabbits were prebled, and 100 μg of conjugated peptide in complete Freund's adjuvant was injected per rabbit, two rabbits per isoform. At three week intervals, the rabbits were boosted with the same dose of antigen in incomplete Freud's adjuvant. Animals were bled 10 days after the third injection and serum titer determined by ELISA.

Briefly, Immulon® 4 (Dynax Technologies, Chantilly, Va.) plates were coated with unconjugated peptide at 2 μg/ml. Plates were blocked with 0.5% fish skin gelatin and washed. Serial dilutions of the pre-immune serum and test bleeds from each rabbit were incubated on the peptide-coated plates. After washing, goat anti-rabbit-horseradish peroxidase (HRP) conjugated secondary antibody was added. The plates were washed and signal detected by tetramethyl benzidine (TMB) (Sigma) reagent.

Serum from rabbits #6484 and #6453 immunized with the lectomedin-1β peptide showed reactivity three-fold greater than pre-immune serum at a 3000-fold dilution. Serum from rabbits #6868 and #6307 immunized with lectomedin-1γ showed three-fold greater reactivity over pre-immune serum at a 3000-fold dilution. Serum from rabbits #7347 and #6490 immunized with lectomedin-1α, showed three-fold greater reactivity at a 200-fold dilution.

In view of these results, a second lectomedin-1α peptide (SEQ ID NO: 56) was synthesized and the immunization protocol described above was repeated with two additional rabbits. Serum from these rabbits is assayed for specific reactivity as described above.

Cys-Ser-Arg-Ile-Arg-Arg-Met-Trp-Asn-Asp-Thr-Val-Arg-Lys-Gln-Ser SEQ ID NO:56

Monoclonal Antibody Production

In an attempt to produce monoclonal antibodies immunospecific for lectomedin polypeptides, the following procedure was carried out.

Five 6 to 12 week old BALB/c mice were prebled on day 0 and immunized by subcutaneous injection with 20 μg of the lectomedin-1α, lectomedin-1β, or lectomedin-1γ peptides (SEQ ID NOs: 53, 54, and 55) described above (60 μg total) in complete Freund's adjuvant. On Days 21, 41, and 62, each mouse was boosted with 10 μg of each peptide (30 μg total) in incomplete Freund's adjuvant. Test bleeds were drawn on day 72 and reactivity determined by ELISA against individual peptides as described in generation of polyclonal antisera, with the exception that specific mouse antibody was detected with a goat anti-mouse-HRP.

Immune serum from all five mice showed reactivity to lectomedin-1β and lectomedin-1γ peptides greater than pre-immune serum at a 12800-fold dilution. Serum from all of the mice showed modest reactivity to lectomedin-1α peptide.

Additional peptides comprising the carboxyl termini of lectomedin-2 and lectomedin-3 (SEQ ID NOs: 58 and ) were synthesized to screen for cross reactive antibodies recognizing similar epitopes found in termini of lectomedin-1γ, lectomedin-2 and lectomedin-3.

In an another approach to generate an immune response to lectomedin-1α, five additional mice were immunized with the second lectomedin-1α peptide (SEQ ID NO: 56) described above. Immune serum from each of the mice is tested for lectomedin-1α reactivity by ELISA (described above) prior to fusion and hybridoma cloning.

The spleen of the immunized animal is removed aseptically and a single-cell suspension is formed by grinding the spleen between the frosted ends of two glass microscope slides submerged in serum free RPMI 1640 (Gibco, Canada) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 μg/ml streptomycin. The cell suspension is filtered with a sterile 70-mesh Nitex cell strainer (Becton Dickinson, Parsippany, N.J.), and washed twice by centrifuging at 200×g for five minutes and resuspending the pellet in 20 ml serum free RPMI. Thymocytes taken from naive Balb/c mice are prepared in the same manner.

Approximately 2×10 8 spleen cells are combined with 4×10 7 NS-1 cells (kept in log phase in RPMI with 11% fetal bovine serum [FBS] for three days prior to fusion). The cells are collectedy centrifugation and the supernatant is aspirated. The cell pellet is dislodged and 2 ml of 37° C. PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer Mannheim) is added while stirring over the course of one minute, followed by the addition of 14 ml of serum free RPMI over seven minutes. Additional RPMI can be added and the cells are centrifuged at 200×g for 10 minutes. After discarding the supernatant, the pellet is resuspended in 200 ml RPMI containing 15% FBS, 100 mM sodium hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim), and 1.5×10 6 thymocytes/mil. The suspension is dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 μl/well. Cells are fed on days 2, 4, and 6 days post-fusion by aspirating 100 μl from each well and adding 100 μl/well plating medium containing 10 U/ml IL-6 and lacking thymocytes.

When cell growth reaches 60-80% confluence (day 8 to 10), culture supernatants are taken from each well and screened for reactivity to lectomedin by ELISA. ELISAs are performed as follows. Immulon 4 plates (Dynatech, Cambridge, Mass.) are coated at 4° C. with 50 μl/well with 100 ng/well of inmmunogen in 50 mM carbonate buffer, pH 9.6. Plates are washed with PBS with 0.05%, Tween® 20 (PBST) and blocked 30 minutes at 37° C. with 0.5% fish skin gelatin. Plates are washed as described above and 50 μl culture supernatant is added. After incubation at 37° C. for 30 minutes, plates were washed as above, then 50 μl of horseradish peroxidase conjugated goat anti-mouse IgG(fc) (Jackson ImmunoResearch, West Grove, Pa.) [diluted 1:10,000 in PBST] is added. Plates are incubated at 37° C. for 30 minutes, washed with PBST and 100 μl of substrate, consisting of 1 mg/ml TMB (Sigma) and 0.15 ml/ml 30% H 2 O 2 in 100 mM citrate, pH 4.5, is added. The color reaction is stopped with the addition of 50 μl of 15% H 2 SO 4 . Absorbance at 450 nm is read on a plate reader (Dynatech).

EXAMPLE 9

Immunocytochemistry for Expression of Lectomedin

Polyclonal antisera generated in rabbit #7234 (and affinity purified) as described above was used to determine lectomedin expression patterns in human and rat tissues. Human tissues were obtained from the National Disease Research Interchange (NDRI, Philadelphia, Pa.), including human brain (cortex and cerebellum), heart (septum and atrium), prostate, lung, liver, spleen, small intestines, adrenal gland, and artery (renal, pulmonary and subclavian). Aorta was obtained from the Pathological Determinants of Atherosclerosis in Youth (PDAY) Study, Louisiana State University Medical Center. Rat tissue was prepared using procedures well known and routinely practiced in the art.

Frozen tissues were embedded in OCT (Tissue-Tek), sectioned at 6 micron thickness, mounted onto Superfrost Plus (VWR Scientific) slides, and stored at −20° C. until the assay was performed. Paraffin-embedded, formalin-fixed tissues were stored at room temperature until the assay was performed. Prior to assay, frozen tissue was fixed in acetone for two minutes at 4° C., except for brain tissue which was fixed in ether for five minutes at room temperature. Formalin-fixed tissue was deparaffinized with two three-minute washes in each of xylene, 100% ethanol, 95% ethanol, and 70% ethanol. Endogenous peroxidase activity was quenched by incubating the fixed cryosections in buffer containing 0.1% sodium azide and 0.33% hydrogen peroxide in phosphate buffered saline (PBS) during a 15 minute incubation. All incubations were carried out at room temperature unless otherwise indicated. Slides were rinsed in TBST (20 mM Trizma® base [Sigma], 150 mM NaCl, 0.05% Tween®, pH 7.2) and blocked in a solution containing 30% normal human serum albumin (Boston Biomedica), 5% normal goat serum (Harlan), and 2% bovine serum albumin (Sigma) in TBST for 30 minutes. Nonspecific binding was blocked using sequential 15 minute incubations with avidin and biotin blocking solution (SP-2001, Vector Labs, Burlingame Calif.). Slides were rinsed in TSBT after each incubation. Primary antibody at concentrations ranging from 1 μg/ml to 5 μg/ml was applied to each section for one hour, after which sides were washed in TSBT three times. Biotinylated goat anti-rabbit antibody conjugated to peroxidase (Vector Labs) was diluted 1:200 in blocking solution and applied to the slides for 30 minutes. Slides were washed for five minutes and incubated for 30 minutes with ABC Elite reagent (avidin-biotin-peroxidase kit PK-6100, Vector Labs). Slides were washed twice for five minutes per wash in TSBT. Substrate solution (DAB substrate kit for peroxidase, Vector Labs) was applied to the slides and the desired color intensity was allowed to develop over approximately five minutes. The reaction was stopped with deionized water, and the slides were counterstained with Gill's hematoxylin (Sigma) solution, rinsed in water, dehydrated in ethanol, and mounted with Cytoseal mounting medium (Stephens Scientific) for light microscopic evaluation.

In human brain cortex, labeling with 7234 sera was detected in a subset of neurons (including large and small pyrimidal neurons), granule cells, and smooth muscle cells of the vasculature. Human cerebellum staining with 7234 sera was localized to purkinje neurons and neurons of the granular cell layer. Human heart (septal and atrial sections) showed cardiomyocyte immunoreactivity, most prominently at cardial myocyte cell junctions transverse to the plane of the contractile apparatus called intercalated dicks.

In double label experiments using a commercially available connexin antibody (Zymed, San Francisco, Calif.), which stains connexin found at the intercalated disks, the previous results were confirmed as results indicated that connexin antibody and 7234 antisera staining co-localized on the intercalated disks.

Sections of human prostate showed weak stromal cell labeling and cytoplasmic skeletal muscle staining. Lung staining was found in cartilage and some bronchial smooth muscle cells, with certain cells staining more strongly than others. The medulla of the adrenal gland showed strong positive staining.

Human liver, spleen, and small intestines exhibited a non-specific pattern of immunoreactivity. Human aorta showed immunoreactivity with 7234 sera in the vessel wall that was primarily located in the tunica intima (lumenal muscle layer) and tunica media (intermediate muscle layer). Thoracic aorta, pulmonary artery, and renal antery each showed similar staining patterns. When compared with staining with an antibody to smooth muscle α-actin (an accepted marker for smooth muscle cells), lectomedin-1 immunoreactivity was found primarily in the same cells (i.e., smooth muscle cells).

Staining in rat tissues with 7234 sera demonstrated similar patterns as observed in human tissues. In brain, some neuronal populations and the smooth muscle of the vasculature were stained. In the heart, disks, cardiomyocytes, and vascular smooth muscle all showed immunoreactivity.

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

64 1 5597 DNA Homo sapiens CDS (217)..(3747) 1cggcgaacag acgttctttc tcctccatgc agttacacaa aaggagggct acggaaacta 60aaagtttcgg ggcctctggc tcggtgtgtg gagaaaagag aaaacctgga gacgggatat 120gaagatcaat gatgcagact gatggtcttg atgaagctgg gcatttataa ctagattcat 180taaggaatac aaagaaaata cttaaaggga tcaata atg gtg tct tct ggt tgc 234 Met Val Ser Ser Gly Cys 1 5aga atg cga agt ctg tgg ttt atc att gta atc agc ttc tta cca aat 282Arg Met Arg Ser Leu Trp Phe Ile Ile Val Ile Ser Phe Leu Pro Asn 10 15 20aca gaa ggt ttc agc aga gca gct tta cca ttt ggg ctg gtg agg cga 330Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro Phe Gly Leu Val Arg Arg 25 30 35gaa tta tcc tgt gaa ggt tat tct ata gat ctg cga tgc ccg ggc agt 378Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp Leu Arg Cys Pro Gly Ser 40 45 50gat gtc atc atg att gag agc gct aac tat ggt cgg acg gat gac aag 426Asp Val Ile Met Ile Glu Ser Ala Asn Tyr Gly Arg Thr Asp Asp Lys 55 60 65 70att tgt gat gct gac cca ttt cag atg gag aat aca gac tgc tac ctc 474Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn Thr Asp Cys Tyr Leu 75 80 85ccc gat gcc ttc aaa att atg act caa agg tgc aac aat cga aca cag 522Pro Asp Ala Phe Lys Ile Met Thr Gln Arg Cys Asn Asn Arg Thr Gln 90 95 100tgt ata gta gtt act ggg tca gat gtg ttt cct gat cca tgt cct gga 570Cys Ile Val Val Thr Gly Ser Asp Val Phe Pro Asp Pro Cys Pro Gly 105 110 115aca tac aaa tac ctt gaa gtc caa tat gaa tgt gtc cct tac att ttt 618Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu Cys Val Pro Tyr Ile Phe 120 125 130gtg tgt cct ggg acc ttg aaa gca att gtg gac tca cca tgt ata tat 666Val Cys Pro Gly Thr Leu Lys Ala Ile Val Asp Ser Pro Cys Ile Tyr135 140 145 150gaa gct gaa caa aag gcg ggt gct tgg tgc aag gac cct ctt cag gct 714Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala 155 160 165gca gat aaa att tat ttc atg ccc tgg act ccc tat cgt acc gat act 762Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr Pro Tyr Arg Thr Asp Thr 170 175 180tta ata gaa tat gct tct tta gaa gat ttc caa aat agt cgc caa aca 810Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe Gln Asn Ser Arg Gln Thr 185 190 195aca aca tat aaa ctt cca aat cga gta gat ggt act gga ttt gtg gtg 858Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp Gly Thr Gly Phe Val Val 200 205 210tat gat ggt gct gtc ttc ttt aac aaa gaa aga acg agg aat att gtg 906Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu Arg Thr Arg Asn Ile Val215 220 225 230aaa ttt gac ttg agg act aga att aag agt ggc gag gcc ata att aac 954Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Ala Ile Ile Asn 235 240 245tat gcc aac tac cat gat acc tca cca tac aga tgg gga gga aag act 1002Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp Gly Gly Lys Thr 250 255 260gat atc gac cta gca gtt gat gaa aat ggt tta tgg gtc att tac gcc 1050Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala 265 270 275act gaa cag aac aat gga atg ata gtt att agc cag ctg aat cca tac 1098Thr Glu Gln Asn Asn Gly Met Ile Val Ile Ser Gln Leu Asn Pro Tyr 280 285 290act ctt cga ttt gaa gca acg tgg gag act gta tac gac aaa cgt gcc 1146Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr Val Tyr Asp Lys Arg Ala295 300 305 310gca tca aat gct ttt atg ata tgc gga gtc ctc tat gtg gtt agg tca 1194Ala Ser Asn Ala Phe Met Ile Cys Gly Val Leu Tyr Val Val Arg Ser 315 320 325gtt tat caa gac aat gaa agt gaa aca ggc aag aac tca att gat tac 1242Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly Lys Asn Ser Ile Asp Tyr 330 335 340att tat aat acc cga tta aac cga gga gaa tat gta gac gtt ccc ttc 1290Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu Tyr Val Asp Val Pro Phe 345 350 355ccc aac cag tat cag tat att gct gca gtg gat tac aat cca aga gat 1338Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val Asp Tyr Asn Pro Arg Asp 360 365 370aac caa ctt tac gtg tgg aac aat aac ttc att tta cga tat tct ctg 1386Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe Ile Leu Arg Tyr Ser Leu375 380 385 390gag ttt ggt cca cct gat cct gcc caa gtg cct acc aca gct gtg aca 1434Glu Phe Gly Pro Pro Asp Pro Ala Gln Val Pro Thr Thr Ala Val Thr 395 400 405ata act tct tca gct gag ctg ttc aaa acc ata ata tca acc aca agc 1482Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr Ile Ile Ser Thr Thr Ser 410 415 420act act tca cag aaa ggc ccc atg agc aca act gta gct gga tca cag 1530Thr Thr Ser Gln Lys Gly Pro Met Ser Thr Thr Val Ala Gly Ser Gln 425 430 435gaa gga agc aaa ggg aca aaa cca cct cca gca gtt tct aca acc aaa 1578Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro Ala Val Ser Thr Thr Lys 440 445 450att cca cct ata aca aat att ttt ccc ctg cca gag aga ttc tgt gaa 1626Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu Pro Glu Arg Phe Cys Glu455 460 465 470gca tta gac tcc aag ggg ata aag tgg cct cag aca caa agg gga atg 1674Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro Gln Thr Gln Arg Gly Met 475 480 485atg gtt gaa cga cca tgc cct aag gga aca aga gga act gcc tca tat 1722Met Val Glu Arg Pro Cys Pro Lys Gly Thr Arg Gly Thr Ala Ser Tyr 490 495 500ctc tgc atg att tcc act gga aca tgg aac cct aag ggc ccc gat ctt 1770Leu Cys Met Ile Ser Thr Gly Thr Trp Asn Pro Lys Gly Pro Asp Leu 505 510 515agc aac tgt acc tca cac tgg gtg aat cag ctg gct cag aag atc aga 1818Ser Asn Cys Thr Ser His Trp Val Asn Gln Leu Ala Gln Lys Ile Arg 520 525 530agc gga gaa aat gct gct agt ctt gcc aat gaa ctg gct aaa cat acc 1866Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn Glu Leu Ala Lys His Thr535 540 545 550aaa ggg cca gtg ttt gct ggg gat gta agt tct tca gtg aga ttg atg 1914Lys Gly Pro Val Phe Ala Gly Asp Val Ser Ser Ser Val Arg Leu Met 555 560 565gag cag ttg gtg gac atc ctt gat gca cag ctg cag gaa ctg aaa cct 1962Glu Gln Leu Val Asp Ile Leu Asp Ala Gln Leu Gln Glu Leu Lys Pro 570 575 580agt gaa aaa gat tca gct gga cgg agt tat aac aag gca att gtt gac 2010Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr Asn Lys Ala Ile Val Asp 585 590 595aca gtg gac aac ctt ctg aga cct gaa gct ttg gaa tca tgg aaa cat 2058Thr Val Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu Ser Trp Lys His 600 605 610atg aat tct tct gaa caa gca cat act gca aca atg tta ctc gat aca 2106Met Asn Ser Ser Glu Gln Ala His Thr Ala Thr Met Leu Leu Asp Thr615 620 625 630ttg gaa gaa gga gct ttt gtc cta gct gac aat ctt tta gaa cca aca 2154Leu Glu Glu Gly Ala Phe Val Leu Ala Asp Asn Leu Leu Glu Pro Thr 635 640 645agg gtc tca atg ccc aca gaa aat att gtc ctg gaa gtt gcc gta ctc 2202Arg Val Ser Met Pro Thr Glu Asn Ile Val Leu Glu Val Ala Val Leu 650 655 660agt aca gaa gga cag atc caa gac ttt aaa ttt cct ctg ggc atc aaa 2250Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys Phe Pro Leu Gly Ile Lys 665 670 675gga gca ggc agc tca atc caa ctg tcc gca aat acc gtc aaa cag aac 2298Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala Asn Thr Val Lys Gln Asn 680 685 690agc agg aat ggg ctt gca aag ttg gtg ttc atc att tac cgg agc ctg 2346Ser Arg Asn Gly Leu Ala Lys Leu Val Phe Ile Ile Tyr Arg Ser Leu695 700 705 710gga cag ttc ctt agt aca gaa aat gca acc att aaa ctg ggt gct gat 2394Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr Ile Lys Leu Gly Ala Asp 715 720 725ttt att ggt cgt aat agc acc att gca gtg aac tct cac gtc att tca 2442Phe Ile Gly Arg Asn Ser Thr Ile Ala Val Asn Ser His Val Ile Ser 730 735 740gtt tca atc aat aaa gag tcc agc cga gta tac ctg act gat cct gtg 2490Val Ser Ile Asn Lys Glu Ser Ser Arg Val Tyr Leu Thr Asp Pro Val 745 750 755ctt ttt acc ctg cca cac att gat cct gac aat tat ttc aat gca aac 2538Leu Phe Thr Leu Pro His Ile Asp Pro Asp Asn Tyr Phe Asn Ala Asn 760 765 770tgc tcc ttc tgg aac tac tca gag aga act atg atg gga tat tgg tct 2586Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr Met Met Gly Tyr Trp Ser775 780 785 790acc cag ggc tgc aag ctg gtt gac act aat aaa act cga aca acg tgt 2634Thr Gln Gly Cys Lys Leu Val Asp Thr Asn Lys Thr Arg Thr Thr Cys 795 800 805gca tgc agc cac cta acc aat ttt gca att ctc atg gcc cac agg gaa 2682Ala Cys Ser His Leu Thr Asn Phe Ala Ile Leu Met Ala His Arg Glu 810 815 820att gca tat aaa gat ggc gtt cat gaa tta ctt ctt aca gtc atc acc 2730Ile Ala Tyr Lys Asp Gly Val His Glu Leu Leu Leu Thr Val Ile Thr 825 830 835tgg gtg gga att gtc att tcc ctt gtt tgc ctg gct atc tgc atc ttc 2778Trp Val Gly Ile Val Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Phe 840 845 850acc ttc tgc ttt ttc cgt ggc cta cag agt gac cga aat act att cac 2826Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp Arg Asn Thr Ile His855 860 865 870aag aac ctt tgt atc aac ctt ttc att gct gaa ttt att ttc cta ata 2874Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala Glu Phe Ile Phe Leu Ile 875 880 885ggc att gat aag aca aaa tat gcg att gca tgc cca ata ttt gca gga 2922Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala Cys Pro Ile Phe Ala Gly 890 895 900ctt cta cac ttt ttc ttt ttg gca gct ttt gct tgg atg tgc cta gaa 2970Leu Leu His Phe Phe Phe Leu Ala Ala Phe Ala Trp Met Cys Leu Glu 905 910 915ggt gtg cag ctc tac cta atg tta gtt gaa gtt ttt gaa agt gaa tat 3018Gly Val Gln Leu Tyr Leu Met Leu Val Glu Val Phe Glu Ser Glu Tyr 920 925 930tca agg aaa aaa tat tac tat gtt gct ggt tac ttg ttt cct gcc aca 3066Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly Tyr Leu Phe Pro Ala Thr935 940 945 950gtg gtt gga gtt tca gct gct att gac tat aag agc tat gga aca gaa 3114Val Val Gly Val Ser Ala Ala Ile Asp Tyr Lys Ser Tyr Gly Thr Glu 955 960 965aaa gct tgc tgg ctt cat gtt gat aac tac ttt ata tgg agc ttc att 3162Lys Ala Cys Trp Leu His Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile 970 975 980gga cct gtt acc ttc att att ctg cta aat att atc ttc ttg gtg atc 3210Gly Pro Val Thr Phe Ile Ile Leu Leu Asn Ile Ile Phe Leu Val Ile 985 990 995aca ttg tgc aaa atg gtg aag cat tca aac act ttg aaa cca gat tct 3258Thr Leu Cys Lys Met Val Lys His Ser Asn Thr Leu Lys Pro Asp Ser 1000 1005 1010agc agg ttg gaa aac att aag tct tgg gtg ctt ggc gct ttc gct ctt 3306Ser Arg Leu Glu Asn Ile Lys Ser Trp Val Leu Gly Ala Phe Ala Leu1015 1020 1025 1030ctg tgt ctt ctt ggc ctc acc tgg tcc ttt ggg ttg ctt ttt att aat 3354Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe Gly Leu Leu Phe Ile Asn 1035 1040 1045gag gag act att gtg atg gca tat ctc ttc act ata ttt aat gct ttc 3402Glu Glu Thr Ile Val Met Ala Tyr Leu Phe Thr Ile Phe Asn Ala Phe 1050 1055 1060cag gga gtg ttc att ttc atc ttt cac tgt gct ctc caa aag aaa gta 3450Gln Gly Val Phe Ile Phe Ile Phe His Cys Ala Leu Gln Lys Lys Val 1065 1070 1075cga aaa gaa tat ggc aag tgc ttc aga cac tca tac tgc tgt gga ggc 3498Arg Lys Glu Tyr Gly Lys Cys Phe Arg His Ser Tyr Cys Cys Gly Gly 1080 1085 1090ctc cca act gag agt ccc cac agt tca gtg aag gca tca acc acc aga 3546Leu Pro Thr Glu Ser Pro His Ser Ser Val Lys Ala Ser Thr Thr Arg1095 1100 1105 1110acc agt gct cgc tat tcc tct ggc aca cag agt cgt ata aga aga atg 3594Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln Ser Arg Ile Arg Arg Met 1115 1120 1125tgg aat gat act gtg aga aaa caa tca gaa tct tct ttt atc tca ggt 3642Trp Asn Asp Thr Val Arg Lys Gln Ser Glu Ser Ser Phe Ile Ser Gly 1130 1135 1140gac atc aat agc act tca aca ctt aat caa gga ctg aca tca cat ggt 3690Asp Ile Asn Ser Thr Ser Thr Leu Asn Gln Gly Leu Thr Ser His Gly 1145 1150 1155ctg aga gcc cat ctt caa gat tta tat cat tta gag cta ctc tta ggc 3738Leu Arg Ala His Leu Gln Asp Leu Tyr His Leu Glu Leu Leu Leu Gly 1160 1165 1170cag ata gcc tgagcagaca gacatgatgt gagttgtcca aagacattca 3787Gln Ile Ala1175ctgaacaatg ccagggatac aagtgccatg gatactctac cgctaaatgg taattttaac 3847aacagctact cgctgcacaa gggtgactat aatgacagcg tgcaagttgt ggactgtgga 3907ctaagtctga atgatactgc ttttgagaaa atgatcattt cagaattagt gcacaacaac 3967ttacggggca gcagcaagac tcacaacctc gagctcacgc taccagtcaa acctgtgatt 4027ggaggtagca gcagtgaaga tgatgctatt gtggcagatg cttcatcttt aatgcacagc 4087gacaacccag ggctggagct ccatcacaaa gaactcgagg caccacttat tcctcagcgg 4147actcactccc ttctgtacca accccagaag aaagtgaagt ccgagggaac tgacagctat 4207gtctcccaac tgacagcaga ggctgaagat cacctacagt cccccaacag agactctctt 4267tatacaagca tgcccaatct tagagactct ccctatccgg agagcagccc tgacatggaa 4327gaagacctct ctccctccag gaggagtgag aatgaggaca tttactataa aagcatgcca 4387aatcttggag ctggccatca gcttcagatg tgctaccaga tcagcagggg caatagtgat 4447ggttatataa tccccattaa caaagaaggg tgtattccag aaggagatgt tagagaagga 4507caaatgcagc tggttacaag tctttaatca tacagctaag gaattccaag ggccacatgc 4567gagtattaat aaataaagac accattggcc tgacgcagct ccctcaaact ctgcttgaag 4627agatgactct tgacctgtgg ttctctggtg taaaaaagat gactgaacct tgcagttctg 4687tgaattttta taaaacatac aaaaactttg tatatacaca gagtatacta aagtgaatta 4747tttgttacaa agaaaagaga tgccagccag gtattttaag attctgctgc tgtttagaga 4807aattgtgaaa caagcaaaac aaaactttcc agccatttta ctgcagcagt ctgtgaacta 4867aatttgtaaa tatggctgca ccatttttgt aggcctgcat tgtattatat acaagacgta 4927ggctttaaaa tcctgtggga caaatttact gtaccttact attcctgaca agacttggaa 4987aagcaggaga gatattctgc atcagtttgc agttcactgc aaatctttta cattaaggca 5047aagattgaaa acatgcttaa ccactagcaa tcaagccaca ggccttattt catatgtttc 5107ctcaactgta caatgaacta ttctcatgaa aaatggctaa agaaattata ttttgttcta 5167ttgctagggt aaaataaata catttgtgtc caactgaaat ataattgtca ttaaaataat 5227tttaaagagt gaagaaaata ttgtgaaaag ctcttggttg cacatgttat gaaatgtttt 5287ttcttacact ttgtcatggt aagttctact cattttcact tcttttccac tgtatacagt 5347gttctgcttt gacaaagtta gtctttatta cttacattta aatttcttat tgccaaaaga 5407acgtgtttta tggggagaaa caaactcttt gaagccagtt atgtcatgcc ttgcacaaaa 5467gtgatgaaat ctagaaaaga ttgtgtgtca cccctgttta ttcttgaaca gagggcaaag 5527agggcactgg gcacttctca caaactttct agtgaacaaa aggtgcctat tcttttttaa 5587aaaaaaaaaa 5597 2 1177 PRT Homo sapiens 2Met Val Ser Ser Gly Cys Arg Met Arg Ser Leu Trp Phe Ile Ile Val 1 5 10 15Ile Ser Phe Leu Pro Asn Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro 20 25 30Phe Gly Leu Val Arg Arg Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp 35 40 45Leu Arg Cys Pro Gly Ser Asp Val Ile Met Ile Glu Ser Ala Asn Tyr 50 55 60Gly Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu 65 70 75 80Asn Thr Asp Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Thr Gln Arg 85 90 95Cys Asn Asn Arg Thr Gln Cys Ile Val Val Thr Gly Ser Asp Val Phe 100 105 110Pro Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu 115 120 125Cys Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Lys Ala Ile Val 130 135 140Asp Ser Pro Cys Ile Tyr Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys145 150 155 160Lys Asp Pro Leu Gln Ala Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr 165 170 175Pro Tyr Arg Thr Asp Thr Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe 180 185 190Gln Asn Ser Arg Gln Thr Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp 195 200 205Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu 210 215 220Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser225 230 235 240Gly Glu Ala Ile Ile Asn Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr 245 250 255Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly 260 265 270Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Met Ile Val Ile 275 280 285Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr 290 295 300Val Tyr Asp Lys Arg Ala Ala Ser Asn Ala Phe Met Ile Cys Gly Val305 310 315 320Leu Tyr Val Val Arg Ser Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly 325 330 335Lys Asn Ser Ile Asp Tyr Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu 340 345 350Tyr Val Asp Val Pro Phe Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val 355 360 365Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe 370 375 380Ile Leu Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ala Gln Val385 390 395 400Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr 405 410 415Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro Met Ser Thr 420 425 430Thr Val Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro 435 440 445Ala Val Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu 450 455 460Pro Glu Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro465 470 475 480Gln Thr Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro Lys Gly Thr 485 490 495Arg Gly Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly Thr Trp Asn 500 505 510Pro Lys Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp Val Asn Gln 515 520 525Leu Ala Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn 530 535 540Glu Leu Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly Asp Val Ser545 550 555 560Ser Ser Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu Asp Ala Gln 565 570 575Leu Gln Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr 580 585 590Asn Lys Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg Pro Glu Ala 595 600 605Leu Glu Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala His Thr Ala 610 615 620Thr Met Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val Leu Ala Asp625 630 635 640Asn Leu Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu Asn Ile Val 645 650 655Leu Glu Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys 660 665 670Phe Pro Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala 675 680 685Asn Thr Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys Leu Val Phe 690 695 700Ile Ile Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr705 710 715 720Ile Lys Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr Ile Ala Val 725 730 735Asn Ser His Val Ile Ser Val Ser Ile Asn Lys Glu Ser Ser Arg Val 740 745 750Tyr Leu Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile Asp Pro Asp 755 760 765Asn Tyr Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr 770 775 780Met Met Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val Asp Thr Asn785 790 795 800Lys Thr Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn Phe Ala Ile 805 810 815Leu Met Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val His Glu Leu 820 825 830Leu Leu Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser Leu Val Cys 835 840 845Leu Ala Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser 850 855 860Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala865 870 875 880Glu Phe Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala 885 890 895Cys Pro Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu Ala Ala Phe 900 905 910Ala Trp Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met Leu Val Glu 915 920 925Val Phe Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly 930 935 940Tyr Leu Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala Ile Asp Tyr945 950 955 960Lys Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val Asp Asn Tyr 965 970 975Phe Ile Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile Leu Leu Asn 980 985 990Ile Ile Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys His Ser Asn 995 1000 1005Thr Leu Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys Ser Trp Val 1010 1015 1020Leu Gly Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe1025 1030 1035 1040Gly Leu Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala Tyr Leu Phe 1045 1050 1055Thr Ile Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile Phe His Cys 1060 1065 1070Ala Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Phe Arg His 1075 1080 1085Ser Tyr Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His Ser Ser Val 1090 1095 1100Lys Ala Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln1105 1110 1115 1120Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser Glu 1125 1130 1135Ser Ser Phe Ile Ser Gly Asp Ile Asn Ser Thr Ser Thr Leu Asn Gln 1140 1145 1150Gly Leu Thr Ser His Gly Leu Arg Ala His Leu Gln Asp Leu Tyr His 1155 1160 1165Leu Glu Leu Leu Leu Gly Gln Ile Ala 1170 1175 3 5617 DNA Homo sapiens CDS (217)..(3585) 3cggcgaacag acgttctttc tcctccatgc agttacacaa aaggagggct acggaaacta 60aaagtttcgg ggcctctggc tcggtgtgtg gagaaaagag aaaacctgga gacgggatat 120gaagatcaat gatgcagact gatggtcttg atgaagctgg gcatttataa ctagattcat 180taaggaatac aaagaaaata cttaaaggga tcaata atg gtg tct tct ggt tgc 234 Met Val Ser Ser Gly Cys 1 5aga atg cga agt ctg tgg ttt atc att gta atc agc ttc tta cca aat 282Arg Met Arg Ser Leu Trp Phe Ile Ile Val Ile Ser Phe Leu Pro Asn 10 15 20aca gaa ggt ttc agc aga gca gct tta cca ttt ggg ctg gtg agg cga 330Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro Phe Gly Leu Val Arg Arg 25 30 35gaa tta tcc tgt gaa ggt tat tct ata gat ctg cga tgc ccg ggc agt 378Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp Leu Arg Cys Pro Gly Ser 40 45 50gat gtc atc atg att gag agc gct aac tat ggt cgg acg gat gac aag 426Asp Val Ile Met Ile Glu Ser Ala Asn Tyr Gly Arg Thr Asp Asp Lys 55 60 65 70att tgt gat gct gac cca ttt cag atg gag aat aca gac tgc tac ctc 474Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn Thr Asp Cys Tyr Leu 75 80 85ccc gat gcc ttc aaa att atg act caa agg tgc aac aat cga aca cag 522Pro Asp Ala Phe Lys Ile Met Thr Gln Arg Cys Asn Asn Arg Thr Gln 90 95 100tgt ata gta gtt act ggg tca gat gtg ttt cct gat cca tgt cct gga 570Cys Ile Val Val Thr Gly Ser Asp Val Phe Pro Asp Pro Cys Pro Gly 105 110 115aca tac aaa tac ctt gaa gtc caa tat gaa tgt gtc cct tac att ttt 618Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu Cys Val Pro Tyr Ile Phe 120 125 130gtg tgt cct ggg acc ttg aaa gca att gtg gac tca cca tgt ata tat 666Val Cys Pro Gly Thr Leu Lys Ala Ile Val Asp Ser Pro Cys Ile Tyr135 140 145 150gaa gct gaa caa aag gcg ggt gct tgg tgc aag gac cct ctt cag gct 714Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala 155 160 165gca gat aaa att tat ttc atg ccc tgg act ccc tat cgt acc gat act 762Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr Pro Tyr Arg Thr Asp Thr 170 175 180tta ata gaa tat gct tct tta gaa gat ttc caa aat agt cgc caa aca 810Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe Gln Asn Ser Arg Gln Thr 185 190 195aca aca tat aaa ctt cca aat cga gta gat ggt act gga ttt gtg gtg 858Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp Gly Thr Gly Phe Val Val 200 205 210tat gat ggt gct gtc ttc ttt aac aaa gaa aga acg agg aat att gtg 906Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu Arg Thr Arg Asn Ile Val215 220 225 230aaa ttt gac ttg agg act aga att aag agt ggc gag gcc ata att aac 954Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Ala Ile Ile Asn 235 240 245tat gcc aac tac cat gat acc tca cca tac aga tgg gga gga aag act 1002Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp Gly Gly Lys Thr 250 255 260gat atc gac cta gca gtt gat gaa aat ggt tta tgg gtc att tac gcc 1050Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala 265 270 275act gaa cag aac aat gga atg ata gtt att agc cag ctg aat cca tac 1098Thr Glu Gln Asn Asn Gly Met Ile Val Ile Ser Gln Leu Asn Pro Tyr 280 285 290act ctt cga ttt gaa gca acg tgg gag act gta tac gac aaa cgt gcc 1146Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr Val Tyr Asp Lys Arg Ala295 300 305 310gca tca aat gct ttt atg ata tgc gga gtc ctc tat gtg gtt agg tca 1194Ala Ser Asn Ala Phe Met Ile Cys Gly Val Leu Tyr Val Val Arg Ser 315 320 325gtt tat caa gac aat gaa agt gaa aca ggc aag aac tca att gat tac 1242Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly Lys Asn Ser Ile Asp Tyr 330 335 340att tat aat acc cga tta aac cga gga gaa tat gta gac gtt ccc ttc 1290Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu Tyr Val Asp Val Pro Phe 345 350 355ccc aac cag tat cag tat att gct gca gtg gat tac aat cca aga gat 1338Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val Asp Tyr Asn Pro Arg Asp 360 365 370aac caa ctt tac gtg tgg aac aat aac ttc att tta cga tat tct ctg 1386Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe Ile Leu Arg Tyr Ser Leu375 380 385 390gag ttt ggt cca cct gat cct gcc caa gtg cct acc aca gct gtg aca 1434Glu Phe Gly Pro Pro Asp Pro Ala Gln Val Pro Thr Thr Ala Val Thr 395 400 405ata act tct tca gct gag ctg ttc aaa acc ata ata tca acc aca agc 1482Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr Ile Ile Ser Thr Thr Ser 410 415 420act act tca cag aaa ggc ccc atg agc aca act gta gct gga tca cag 1530Thr Thr Ser Gln Lys Gly Pro Met Ser Thr Thr Val Ala Gly Ser Gln 425 430 435gaa gga agc aaa ggg aca aaa cca cct cca gca gtt tct aca acc aaa 1578Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro Ala Val Ser Thr Thr Lys 440 445 450att cca cct ata aca aat att ttt ccc ctg cca gag aga ttc tgt gaa 1626Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu Pro Glu Arg Phe Cys Glu455 460 465 470gca tta gac tcc aag ggg ata aag tgg cct cag aca caa agg gga atg 1674Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro Gln Thr Gln Arg Gly Met 475 480 485atg gtt gaa cga cca tgc cct aag gga aca aga gga act gcc tca tat 1722Met Val Glu Arg Pro Cys Pro Lys Gly Thr Arg Gly Thr Ala Ser Tyr 490 495 500ctc tgc atg att tcc act gga aca tgg aac cct aag ggc ccc gat ctt 1770Leu Cys Met Ile Ser Thr Gly Thr Trp Asn Pro Lys Gly Pro Asp Leu 505 510 515agc aac tgt acc tca cac tgg gtg aat cag ctg gct cag aag atc aga 1818Ser Asn Cys Thr Ser His Trp Val Asn Gln Leu Ala Gln Lys Ile Arg 520 525 530agc gga gaa aat gct gct agt ctt gcc aat gaa ctg gct aaa cat acc 1866Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn Glu Leu Ala Lys His Thr535 540 545 550aaa ggg cca gtg ttt gct ggg gat gta agt tct tca gtg aga ttg atg 1914Lys Gly Pro Val Phe Ala Gly Asp Val Ser Ser Ser Val Arg Leu Met 555 560 565gag cag ttg gtg gac atc ctt gat gca cag ctg cag gaa ctg aaa cct 1962Glu Gln Leu Val Asp Ile Leu Asp Ala Gln Leu Gln Glu Leu Lys Pro 570 575 580agt gaa aaa gat tca gct gga cgg agt tat aac aag gca att gtt gac 2010Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr Asn Lys Ala Ile Val Asp 585 590 595aca gtg gac aac ctt ctg aga cct gaa gct ttg gaa tca tgg aaa cat 2058Thr Val Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu Ser Trp Lys His 600 605 610atg aat tct tct gaa caa gca cat act gca aca atg tta ctc gat aca 2106Met Asn Ser Ser Glu Gln Ala His Thr Ala Thr Met Leu Leu Asp Thr615 620 625 630ttg gaa gaa gga gct ttt gtc cta gct gac aat ctt tta gaa cca aca 2154Leu Glu Glu Gly Ala Phe Val Leu Ala Asp Asn Leu Leu Glu Pro Thr 635 640 645agg gtc tca atg ccc aca gaa aat att gtc ctg gaa gtt gcc gta ctc 2202Arg Val Ser Met Pro Thr Glu Asn Ile Val Leu Glu Val Ala Val Leu 650 655 660agt aca gaa gga cag atc caa gac ttt aaa ttt cct ctg ggc atc aaa 2250Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys Phe Pro Leu Gly Ile Lys 665 670 675gga gca ggc agc tca atc caa ctg tcc gca aat acc gtc aaa cag aac 2298Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala Asn Thr Val Lys Gln Asn 680 685 690agc agg aat ggg ctt gca aag ttg gtg ttc atc att tac cgg agc ctg 2346Ser Arg Asn Gly Leu Ala Lys Leu Val Phe Ile Ile Tyr Arg Ser Leu695 700 705 710gga cag ttc ctt agt aca gaa aat gca acc att aaa ctg ggt gct gat 2394Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr Ile Lys Leu Gly Ala Asp 715 720 725ttt att ggt cgt aat agc acc att gca gtg aac tct cac gtc att tca 2442Phe Ile Gly Arg Asn Ser Thr Ile Ala Val Asn Ser His Val Ile Ser 730 735 740gtt tca atc aag aaa gag tcc agc cga gta tac ctg act gat cct gtg 2490Val Ser Ile Lys Lys Glu Ser Ser Arg Val Tyr Leu Thr Asp Pro Val 745 750 755ctt ttt acc ctg cca cac att gat cct gac aat tat ttc aat gca aac 2538Leu Phe Thr Leu Pro His Ile Asp Pro Asp Asn Tyr Phe Asn Ala Asn 760 765 770tgc tcc ttc tgg aac tac tca gag aga act atg atg gga tat tgg tct 2586Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr Met Met Gly Tyr Trp Ser775 780 785 790acc cag ggc tgc aag ctg gtt gac act aat aaa act cga aca acg tgt 2634Thr Gln Gly Cys Lys Leu Val Asp Thr Asn Lys Thr Arg Thr Thr Cys 795 800 805gca tgc agc cac cta acc aat ttt gca att ctc atg gcc cac agg gaa 2682Ala Cys Ser His Leu Thr Asn Phe Ala Ile Leu Met Ala His Arg Glu 810 815 820att gca tat aaa gat ggc gtt cat gaa tta ctt ctt aca gtc atc acc 2730Ile Ala Tyr Lys Asp Gly Val His Glu Leu Leu Leu Thr Val Ile Thr 825 830 835tgg gtg gga att gtc att tcc ctt gtt tgc ctg gct atc tgc atc ttc 2778Trp Val Gly Ile Val Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Phe 840 845 850acc ttc tgc ttt ttc cgt ggc cta cag agt gac cga aat act att cac 2826Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp Arg Asn Thr Ile His855 860 865 870aag aac ctt tgt atc aac ctt ttc att gct gaa ttt att ttc cta ata 2874Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala Glu Phe Ile Phe Leu Ile 875 880 885ggc att gat aag aca aaa tat gcg att gca tgc cca ata ttt gca gga 2922Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala Cys Pro Ile Phe Ala Gly 890 895 900ctt cta cac ttt ttc ttt ttg gca gct ttt gct tgg atg tgc cta gaa 2970Leu Leu His Phe Phe Phe Leu Ala Ala Phe Ala Trp Met Cys Leu Glu 905 910 915ggt gtg cag ctc tac cta atg tta gtt gaa gtt ttt gaa agt gaa tat 3018Gly Val Gln Leu Tyr Leu Met Leu Val Glu Val Phe Glu Ser Glu Tyr 920 925 930tca agg aaa aaa tat tac tat gtt gct ggt tac ttg ttt cct gcc aca 3066Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly Tyr Leu Phe Pro Ala Thr935 940 945 950gtg gtt gga gtt tca gct gct att gac tat aag agc tat gga aca gaa 3114Val Val Gly Val Ser Ala Ala Ile Asp Tyr Lys Ser Tyr Gly Thr Glu 955 960 965aaa gct tgc tgg ctt cat gtt gat aac tac ttt ata tgg agc ttc att 3162Lys Ala Cys Trp Leu His Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile 970 975 980gga cct gtt acc ttc att att ctg cta aat att atc ttc ttg gtg atc 3210Gly Pro Val Thr Phe Ile Ile Leu Leu Asn Ile Ile Phe Leu Val Ile 985 990 995aca ttg tgc aaa atg gtg aag cat tca aac act ttg aaa cca gat tct 3258Thr Leu Cys Lys Met Val Lys His Ser Asn Thr Leu Lys Pro Asp Ser 1000 1005 1010agc agg ttg gaa aac att aag tct tgg gtg ctt ggc gct ttc gct ctt 3306Ser Arg Leu Glu Asn Ile Lys Ser Trp Val Leu Gly Ala Phe Ala Leu1015 1020 1025 1030ctg tgt ctt ctt ggc ctc acc tgg tcc ttt ggg ttg ctt ttt att aat 3354Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe Gly Leu Leu Phe Ile Asn 1035 1040 1045gag gag act att gtg atg gca tat ctc ttc act ata ttt aat gct ttc 3402Glu Glu Thr Ile Val Met Ala Tyr Leu Phe Thr Ile Phe Asn Ala Phe 1050 1055 1060cag gga gtg ttc att ttc atc ttt cac tgt gct ctc caa aag aaa gta 3450Gln Gly Val Phe Ile Phe Ile Phe His Cys Ala Leu Gln Lys Lys Val 1065 1070 1075cga aaa gaa tat ggc aag tgc ttc aga cac tca tac tgc tgt gga ggc 3498Arg Lys Glu Tyr Gly Lys Cys Phe Arg His Ser Tyr Cys Cys Gly Gly 1080 1085 1090ctc cca act gag agt ccc cac agt tca gtg aag gca tca acc acc aga 3546Leu Pro Thr Glu Ser Pro His Ser Ser Val Lys Ala Ser Thr Thr Arg1095 1100 1105 1110acc agt gct cgc tat tcc tct ggc aca cag gac att cac tgaacaatgc 3595Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln Asp Ile His 1115 1120cagggataca agtgccatgg atactctacc gctaaatggt aattttaaca acagctactc 3655gctgcacaag ggtgactata atgacagcgt gcaagttgtg gactgtggac taagtctgaa 3715tgatactgct tttgagaaaa tgatcatttc agaattagtg cacaacaact tacggggcag 3775cagcaagact cacaacctcg agctcacgct accagtcaaa cctgtgattg gaggtagcag 3835cagtgaagat gatgctattg tggcagatgc ttcatcttta atgcacagcg acaacccagg 3895gctggagctc catcacaaag aactcgaggc accacttatt cctcagcgga ctcactccct 3955tctgtaccaa ccccagaaga aagtgaagtc cgagggaact gacagctatg tctcccaact 4015gacagcagag gctgaagatc acctacagtc ccccaacaga gactctcttt atacaagcat 4075gcccaatctt agagactctc cctatccgga gagcagccct gacatggaag aagacctctc 4135tccctccagg aggagtgaga atgaggacat ttactataaa agcatgccaa atcttggagc 4195tggccatcag cttcagatgt gctaccagat cagcaggggc aatagtgatg gttatataat 4255ccccattaac aaagaagggt gtattccaga aggagatgtt agagaaggac aaatgcagct 4315ggttacaagt ctttaatcat acagctaagg aattccaagg gccacatgcg agtattaata 4375aataaagaca ccattggcct gacgcagctc cctcaaactc tgcttgaaga gatgactctt 4435gacctgtggt tctctggtgt aaaaaagatg actgaacctt gcagttctgt gaatttttat 4495aaaacataca aaaactttgt atatacacag agtatactaa agtgaattat ttgttacaaa 4555gaaaagagat gccagccagg tattttaaga ttctgctgct gtttagagaa attgtgaaac 4615aagcaaaaca aaactttcca gccattttac tgcagcagtc tgtgaactaa atttgtaaat 4675atggctgcac catttttgta ggcctgcatt gtattatata caagacgtag gctttaaaat 4735cctgtgggac aaatttactg taccttacta ttcctgacaa gacttggaaa agcaggagag 4795atattctgca tcagtttgca gttcactgca aatcttttac attaaggcaa agattgaaaa 4855catgcttaac cactagcaat caagccacag gccttatttc atatgtttcc tcaactgtac 4915aatgaactat tctcatgaaa aatggctaaa gaaattatat tttgttctat tgctagggta 4975aaataaatac atttgtgtcc aactgaaata taattgtcat taaaataatt ttaaagagtg 5035aagaaaatat tgtgaaaagc tcttggttgc acatgttatg aaatgttttt tcttacactt 5095tgtcatggta agttctactc attttcactt cttttccact gtatacagtg ttctgctttg 5155acaaagttag tctttattac ttacatttaa atttcttatt gccaaaagaa cgtgttttat 5215ggggagaaac aaactctttg aagccagtta tgtcatgcct tgcacaaaag tgatgaaatc 5275tagaaaagat tgtgtgtcac ccctgtttat tcttgaacag agggcaaaga gggcactggg 5335cacttctcac aaactttcta gtgaacaaaa ggtgcctatt cttttttaaa aaaataaaat 5395aaaacataaa tattactctt ccatattcct tctgcctata tttagtaatt aatttatttt 5455atgataaagt tctaatgaaa tgtaaattgt ttcagcaaaa ttctgctttt ttttcatccc 5515tttgtgtaaa cctgttaata atgagcccat cactaatatc cagtgtaaag tttaacacgg 5575tttgacagta aataaatgtg aattttttca aaaaaaaaaa aa 5617 4 1123 PRT Homo sapiens 4Met Val Ser Ser Gly Cys Arg Met Arg Ser Leu Trp Phe Ile Ile Val 1 5 10 15Ile Ser Phe Leu Pro Asn Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro 20 25 30Phe Gly Leu Val Arg Arg Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp 35 40 45Leu Arg Cys Pro Gly Ser Asp Val Ile Met Ile Glu Ser Ala Asn Tyr 50 55 60Gly Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu 65 70 75 80Asn Thr Asp Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Thr Gln Arg 85 90 95Cys Asn Asn Arg Thr Gln Cys Ile Val Val Thr Gly Ser Asp Val Phe 100 105 110Pro Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu 115 120 125Cys Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Lys Ala Ile Val 130 135 140Asp Ser Pro Cys Ile Tyr Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys145 150 155 160Lys Asp Pro Leu Gln Ala Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr 165 170 175Pro Tyr Arg Thr Asp Thr Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe 180 185 190Gln Asn Ser Arg Gln Thr Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp 195 200 205Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu 210 215 220Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser225 230 235 240Gly Glu Ala Ile Ile Asn Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr 245 250 255Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly 260 265 270Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Met Ile Val Ile 275 280 285Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr 290 295 300Val Tyr Asp Lys Arg Ala Ala Ser Asn Ala Phe Met Ile Cys Gly Val305 310 315 320Leu Tyr Val Val Arg Ser Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly 325 330 335Lys Asn Ser Ile Asp Tyr Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu 340 345 350Tyr Val Asp Val Pro Phe Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val 355 360 365Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe 370 375 380Ile Leu Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ala Gln Val385 390 395 400Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr 405 410 415Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro Met Ser Thr 420 425 430Thr Val Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro 435 440 445Ala Val Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu 450 455 460Pro Glu Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro465 470 475 480Gln Thr Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro Lys Gly Thr 485 490 495Arg Gly Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly Thr Trp Asn 500 505 510Pro Lys Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp Val Asn Gln 515 520 525Leu Ala Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn 530 535 540Glu Leu Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly Asp Val Ser545 550 555 560Ser Ser Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu Asp Ala Gln 565 570 575Leu Gln Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr 580 585 590Asn Lys Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg Pro Glu Ala 595 600 605Leu Glu Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala His Thr Ala 610 615 620Thr Met Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val Leu Ala Asp625 630 635 640Asn Leu Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu Asn Ile Val 645 650 655Leu Glu Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys 660 665 670Phe Pro Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala 675 680 685Asn Thr Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys Leu Val Phe 690 695 700Ile Ile Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr705 710 715 720Ile Lys Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr Ile Ala Val 725 730 735Asn Ser His Val Ile Ser Val Ser Ile Lys Lys Glu Ser Ser Arg Val 740 745 750Tyr Leu Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile Asp Pro Asp 755 760 765Asn Tyr Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr 770 775 780Met Met Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val Asp Thr Asn785 790 795 800Lys Thr Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn Phe Ala Ile 805 810 815Leu Met Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val His Glu Leu 820 825 830Leu Leu Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser Leu Val Cys 835 840 845Leu Ala Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser 850 855 860Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala865 870 875 880Glu Phe Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala 885 890 895Cys Pro Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu Ala Ala Phe 900 905 910Ala Trp Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met Leu Val Glu 915 920 925Val Phe Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly 930 935 940Tyr Leu Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala Ile Asp Tyr945 950 955 960Lys Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val Asp Asn Tyr 965 970 975Phe Ile Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile Leu Leu Asn 980 985 990Ile Ile Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys His Ser Asn 995 1000 1005Thr Leu Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys Ser Trp Val 1010 1015 1020Leu Gly Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe025 1030 1035 1040Gly Leu Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala Tyr Leu Phe 1045 1050 1055Thr Ile Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile Phe His Cys 1060 1065 1070Ala Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Phe Arg His 1075 1080 1085Ser Tyr Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His Ser Ser Val 1090 1095 1100Lys Ala Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln105 1110 1115 1120Asp Ile His 5 5491 DNA Homo sapiens CDS (217)..(4425) 5cggcgaacag acgttctttc tcctccatgc agttacacaa aaggagggct acggaaacta 60aaagtttcgg ggcctctggc tcggtgtgtg gagaaaagag aaaacctgga gacgggatat 120gaagatcaat gatgcagact gatggtcttg atgaagctgg gcatttataa ctagattcat 180taaggaatac aaagaaaata cttaaaggga tcaata atg gtg tct tct ggt tgc 234 Met Val Ser Ser Gly Cys 1 5aga atg cga agt ctg tgg ttt atc att gta atc agc ttc tta cca aat 282Arg Met Arg Ser Leu Trp Phe Ile Ile Val Ile Ser Phe Leu Pro Asn 10 15 20aca gaa ggt ttc agc aga gca gct tta cca ttt ggg ctg gtg agg cga 330Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro Phe Gly Leu Val Arg Arg 25 30 35gaa tta tcc tgt gaa ggt tat tct ata gat ctg cga tgc ccg ggc agt 378Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp Leu Arg Cys Pro Gly Ser 40 45 50gat gtc atc atg att gag agc gct aac tat ggt cgg acg gat gac aag 426Asp Val Ile Met Ile Glu Ser Ala Asn Tyr Gly Arg Thr Asp Asp Lys 55 60 65 70att tgt gat gct gac cca ttt cag atg gag aat aca gac tgc tac ctc 474Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn Thr Asp Cys Tyr Leu 75 80 85ccc gat gcc ttc aaa att atg act caa agg tgc aac aat cga aca cag 522Pro Asp Ala Phe Lys Ile Met Thr Gln Arg Cys Asn Asn Arg Thr Gln 90 95 100tgt ata gta gtt act ggg tca gat gtg ttt cct gat cca tgt cct gga 570Cys Ile Val Val Thr Gly Ser Asp Val Phe Pro Asp Pro Cys Pro Gly 105 110 115aca tac aaa tac ctt gaa gtc caa tat gaa tgt gtc cct tac att ttt 618Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu Cys Val Pro Tyr Ile Phe 120 125 130gtg tgt cct ggg acc ttg aaa gca att gtg gac tca cca tgt ata tat 666Val Cys Pro Gly Thr Leu Lys Ala Ile Val Asp Ser Pro Cys Ile Tyr135 140 145 150gaa gct gaa caa aag gcg ggt gct tgg tgc aag gac cct ctt cag gct 714Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala 155 160 165gca gat aaa att tat ttc atg ccc tgg act ccc tat cgt acc gat act 762Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr Pro Tyr Arg Thr Asp Thr 170 175 180tta ata gaa tat gct tct tta gaa gat ttc caa aat agt cgc caa aca 810Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe Gln Asn Ser Arg Gln Thr 185 190 195aca aca tat aaa ctt cca aat cga gta gat ggt act gga ttt gtg gtg 858Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp Gly Thr Gly Phe Val Val 200 205 210tat gat ggt gct gtc ttc ttt aac aaa gaa aga acg agg aat att gtg 906Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu Arg Thr Arg Asn Ile Val215 220 225 230aaa ttt gac ttg agg act aga att aag agt ggc gag gcc ata att aac 954Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Ala Ile Ile Asn 235 240 245tat gcc aac tac cat gat acc tca cca tac aga tgg gga gga aag act 1002Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp Gly Gly Lys Thr 250 255 260gat atc gac cta gca gtt gat gaa aat ggt tta tgg gtc att tac gcc 1050Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala 265 270 275act gaa cag aac aat gga atg ata gtt att agc cag ctg aat cca tac 1098Thr Glu Gln Asn Asn Gly Met Ile Val Ile Ser Gln Leu Asn Pro Tyr 280 285 290act ctt cga ttt gaa gca acg tgg gag act gta tac gac aaa cgt gcc 1146Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr Val Tyr Asp Lys Arg Ala295 300 305 310gca tca aat gct ttt atg ata tgc gga gtc ctc tat gtg gtt agg tca 1194Ala Ser Asn Ala Phe Met Ile Cys Gly Val Leu Tyr Val Val Arg Ser 315 320 325gtt tat caa gac aat gaa agt gaa aca ggc aag aac tca att gat tac 1242Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly Lys Asn Ser Ile Asp Tyr 330 335 340att tat aat acc cga tta aac cga gga gaa tat gta gac gtt ccc ttc 1290Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu Tyr Val Asp Val Pro Phe 345 350 355ccc aac cag tat cag tat att gct gca gtg gat tac aat cca aga gat 1338Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val Asp Tyr Asn Pro Arg Asp 360 365 370aac caa ctt tac gtg tgg aac aat aac ttc att tta cga tat tct ctg 1386Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe Ile Leu Arg Tyr Ser Leu375 380 385 390gag ttt ggt cca cct gat cct gcc caa gtg cct acc aca gct gtg aca 1434Glu Phe Gly Pro Pro Asp Pro Ala Gln Val Pro Thr Thr Ala Val Thr 395 400 405ata act tct tca gct gag ctg ttc aaa acc ata ata tca acc aca agc 1482Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr Ile Ile Ser Thr Thr Ser 410 415 420act act tca cag aaa ggc ccc atg agc aca act gta gct gga tca cag 1530Thr Thr Ser Gln Lys Gly Pro Met Ser Thr Thr Val Ala Gly Ser Gln 425 430 435gaa gga agc aaa ggg aca aaa cca cct cca gca gtt tct aca acc aaa 1578Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro Ala Val Ser Thr Thr Lys 440 445 450att cca cct ata aca aat att ttt ccc ctg cca gag aga ttc tgt gaa 1626Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu Pro Glu Arg Phe Cys Glu455 460 465 470gca tta gac tcc aag ggg ata aag tgg cct cag aca caa agg gga atg 1674Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro Gln Thr Gln Arg Gly Met 475 480 485atg gtt gaa cga cca tgc cct aag gga aca aga gga act gcc tca tat 1722Met Val Glu Arg Pro Cys Pro Lys Gly Thr Arg Gly Thr Ala Ser Tyr 490 495 500ctc tgc atg att tcc act gga aca tgg aac cct aag ggc ccc gat ctt 1770Leu Cys Met Ile Ser Thr Gly Thr Trp Asn Pro Lys Gly Pro Asp Leu 505 510 515agc aac tgt acc tca cac tgg gtg aat cag ctg gct cag aag atc aga 1818Ser Asn Cys Thr Ser His Trp Val Asn Gln Leu Ala Gln Lys Ile Arg 520 525 530agc gga gaa aat gct gct agt ctt gcc aat gaa ctg gct aaa cat acc 1866Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn Glu Leu Ala Lys His Thr535 540 545 550aaa ggg cca gtg ttt gct ggg gat gta agt tct tca gtg aga ttg atg 1914Lys Gly Pro Val Phe Ala Gly Asp Val Ser Ser Ser Val Arg Leu Met 555 560 565gag cag ttg gtg gac atc ctt gat gca cag ctg cag gaa ctg aaa cct 1962Glu Gln Leu Val Asp Ile Leu Asp Ala Gln Leu Gln Glu Leu Lys Pro 570 575 580agt gaa aaa gat tca gct gga cgg agt tat aac aag gca att gtt gac 2010Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr Asn Lys Ala Ile Val Asp 585 590 595aca gtg gac aac ctt ctg aga cct gaa gct ttg gaa tca tgg aaa cat 2058Thr Val Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu Ser Trp Lys His 600 605 610atg aat tct tct gaa caa gca cat act gca aca atg tta ctc gat aca 2106Met Asn Ser Ser Glu Gln Ala His Thr Ala Thr Met Leu Leu Asp Thr615 620 625 630ttg gaa gaa gga gct ttt gtc cta gct gac aat ctt tta gaa cca aca 2154Leu Glu Glu Gly Ala Phe Val Leu Ala Asp Asn Leu Leu Glu Pro Thr 635 640 645agg gtc tca atg ccc aca gaa aat att gtc ctg gaa gtt gcc gta ctc 2202Arg Val Ser Met Pro Thr Glu Asn Ile Val Leu Glu Val Ala Val Leu 650 655 660agt aca gaa gga cag atc caa gac ttt aaa ttt cct ctg ggc atc aaa 2250Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys Phe Pro Leu Gly Ile Lys 665 670 675gga gca ggc agc tca atc caa ctg tcc gca aat acc gtc aaa cag aac 2298Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala Asn Thr Val Lys Gln Asn 680 685 690agc agg aat ggg ctt gca aag ttg gtg ttc atc att tac cgg agc ctg 2346Ser Arg Asn Gly Leu Ala Lys Leu Val Phe Ile Ile Tyr Arg Ser Leu695 700 705 710gga cag ttc ctt agt aca gaa aat gca acc att aaa ctg ggt gct gat 2394Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr Ile Lys Leu Gly Ala Asp 715 720 725ttt att ggt cgt aat agc acc att gca gtg aac tct cac gtc att tca 2442Phe Ile Gly Arg Asn Ser Thr Ile Ala Val Asn Ser His Val Ile Ser 730 735 740gtt tca atc aat aaa gag tcc agc cga gta tac ctg act gat cct gtg 2490Val Ser Ile Asn Lys Glu Ser Ser Arg Val Tyr Leu Thr Asp Pro Val 745 750 755ctt ttt acc ctg cca cac att gat cct gac aat tat ttc aat gca aac 2538Leu Phe Thr Leu Pro His Ile Asp Pro Asp Asn Tyr Phe Asn Ala Asn 760 765 770tgc tcc ttc tgg aac tac tca gag aga act atg atg gga tat tgg tct 2586Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr Met Met Gly Tyr Trp Ser775 780 785 790acc cag ggc tgc aag ctg gtt gac act aat aaa act cga aca acg tgt 2634Thr Gln Gly Cys Lys Leu Val Asp Thr Asn Lys Thr Arg Thr Thr Cys 795 800 805gca tgc agc cac cta acc aat ttt gca att ctc atg gcc cac agg gaa 2682Ala Cys Ser His Leu Thr Asn Phe Ala Ile Leu Met Ala His Arg Glu 810 815 820att gca tat aaa gat ggc gtt cat gaa tta ctt ctt aca gtc atc acc 2730Ile Ala Tyr Lys Asp Gly Val His Glu Leu Leu Leu Thr Val Ile Thr 825 830 835tgg gtg gga att gtc att tcc ctt gtt tgc ctg gct atc tgc atc ttc 2778Trp Val Gly Ile Val Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Phe 840 845 850acc ttc tgc ttt ttc cgt ggc cta cag agt gac cga aat act att cac 2826Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp Arg Asn Thr Ile His855 860 865 870aag aac ctt tgt atc aac ctt ttc att gct gaa ttt att ttc cta ata 2874Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala Glu Phe Ile Phe Leu Ile 875 880 885ggc att gat aag aca aaa tat gcg att gca tgc cca ata ttt gca gga 2922Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala Cys Pro Ile Phe Ala Gly 890 895 900ctt cta cac ttt ttc ttt ttg gca gct ttt gct tgg atg tgc cta gaa 2970Leu Leu His Phe Phe Phe Leu Ala Ala Phe Ala Trp Met Cys Leu Glu 905 910 915ggt gtg cag ctc tac cta atg tta gtt gaa gtt ttt gaa agt gaa tat 3018Gly Val Gln Leu Tyr Leu Met Leu Val Glu Val Phe Glu Ser Glu Tyr 920 925 930tca agg aaa aaa tat tac tat gtt gct ggt tac ttg ttt cct gcc aca 3066Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly Tyr Leu Phe Pro Ala Thr935 940 945 950gtg gtt gga gtt tca gct gct att gac tat aag agc tat gga aca gaa 3114Val Val Gly Val Ser Ala Ala Ile Asp Tyr Lys Ser Tyr Gly Thr Glu 955 960 965aaa gct tgc tgg ctt cat gtt gat aac tac ttt ata tgg agc ttc att 3162Lys Ala Cys Trp Leu His Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile 970 975 980gga cct gtt acc ttc att att ctg cta aat att atc ttc ttg gtg atc 3210Gly Pro Val Thr Phe Ile Ile Leu Leu Asn Ile Ile Phe Leu Val Ile 985 990 995aca ttg tgc aaa atg gtg aag cat tca aac act ttg aaa cca gat tct 3258Thr Leu Cys Lys Met Val Lys His Ser Asn Thr Leu Lys Pro Asp Ser 1000 1005 1010agc agg ttg gaa aac att aag tct tgg gtg ctt ggc gct ttc gct ctt 3306Ser Arg Leu Glu Asn Ile Lys Ser Trp Val Leu Gly Ala Phe Ala Leu1015 1020 1025 1030ctg tgt ctt ctt ggc ctc acc tgg tcc ttt ggg ttg ctt ttt att aat 3354Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe Gly Leu Leu Phe Ile Asn 1035 1040 1045gag gag act att gtg atg gca tat ctc ttc act ata ttt aat gct ttc 3402Glu Glu Thr Ile Val Met Ala Tyr Leu Phe Thr Ile Phe Asn Ala Phe 1050 1055 1060cag gga gtg ttc att ttc atc ttt cac tgt gct ctc caa aag aaa gta 3450Gln Gly Val Phe Ile Phe Ile Phe His Cys Ala Leu Gln Lys Lys Val 1065 1070 1075cga aaa gaa tat ggc aag tgc ttc aga cac tca tac tgc tgt gga ggc 3498Arg Lys Glu Tyr Gly Lys Cys Phe Arg His Ser Tyr Cys Cys Gly Gly 1080 1085 1090ctc cca act gag agt ccc cac agt tca gtg aag gca tca acc acc aga 3546Leu Pro Thr Glu Ser Pro His Ser Ser Val Lys Ala Ser Thr Thr Arg1095 1100 1105 1110acc agt gct cgc tat tcc tct ggc aca cag agt cgt ata aga aga atg 3594Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln Ser Arg Ile Arg Arg Met 1115 1120 1125tgg aat gat act gtg aga aaa caa tca gaa tct tct ttt atc tca ggt 3642Trp Asn Asp Thr Val Arg Lys Gln Ser Glu Ser Ser Phe Ile Ser Gly 1130 1135 1140gac atc aat agc act tca aca ctt aat caa gga cat tca ctg aac aat 3690Asp Ile Asn Ser Thr Ser Thr Leu Asn Gln Gly His Ser Leu Asn Asn 1145 1150 1155gcc agg gat aca agt gcc atg gat act cta ccg cta aat ggt aat ttt 3738Ala Arg Asp Thr Ser Ala Met Asp Thr Leu Pro Leu Asn Gly Asn Phe 1160 1165 1170aac aac agc tac tcg ctg cac aag ggt gac tat aat gac agc gtg caa 3786Asn Asn Ser Tyr Ser Leu His Lys Gly Asp Tyr Asn Asp Ser Val Gln1175 1180 1185 1190gtt gtg gac tgt gga cta agt ctg aat gat act gct ttt gag aaa atg 3834Val Val Asp Cys Gly Leu Ser Leu Asn Asp Thr Ala Phe Glu Lys Met 1195 1200 1205atc att tca gaa tta gtg cac aac aac tta cgg ggc agc agc aag act 3882Ile Ile Ser Glu Leu Val His Asn Asn Leu Arg Gly Ser Ser Lys Thr 1210 1215 1220cac aac ctc gag ctc acg cta cca gtc aaa cct gtg att gga ggt agc 3930His Asn Leu Glu Leu Thr Leu Pro Val Lys Pro Val Ile Gly Gly Ser 1225 1230 1235agc agt gaa gat gat gct att gtg gca gat gct tca tct tta atg cac 3978Ser Ser Glu Asp Asp Ala Ile Val Ala Asp Ala Ser Ser Leu Met His 1240 1245 1250agc gac aac cca ggg ctg gag ctc cat cac aaa gaa ctc gag gca cca 4026Ser Asp Asn Pro Gly Leu Glu Leu His His Lys Glu Leu Glu Ala Pro1255 1260 1265 1270ctt att cct cag cgg act cac tcc ctt ctg tac caa ccc cag aag aaa 4074Leu Ile Pro Gln Arg Thr His Ser Leu Leu Tyr Gln Pro Gln Lys Lys 1275 1280 1285gtg aag tcc gag gga act gac agc tat gtc tcc caa ctg aca gca gag 4122Val Lys Ser Glu Gly Thr Asp Ser Tyr Val Ser Gln Leu Thr Ala Glu 1290 1295 1300gct gaa gat cac cta cag tcc ccc aac aga gac tct ctt tat aca agc 4170Ala Glu Asp His Leu Gln Ser Pro Asn Arg Asp Ser Leu Tyr Thr Ser 1305 1310 1315atg ccc aat ctt aga gac tct ccc tat ccg gag agc agc cct gac atg 4218Met Pro Asn Leu Arg Asp Ser Pro Tyr Pro Glu Ser Ser Pro Asp Met 1320 1325 1330gaa gaa gac ctc tct ccc tcc agg agg agt gag aat gag gac att tac 4266Glu Glu Asp Leu Ser Pro Ser Arg Arg Ser Glu Asn Glu Asp Ile Tyr1335 1340 1345 1350tat aaa agc atg cca aat ctt gga gct ggc cat cag ctt cag atg tgc 4314Tyr Lys Ser Met Pro Asn Leu Gly Ala Gly His Gln Leu Gln Met Cys 1355 1360 1365tac cag atc agc agg ggc aat agt gat ggt tat ata atc ccc att aac 4362Tyr Gln Ile Ser Arg Gly Asn Ser Asp Gly Tyr Ile Ile Pro Ile Asn 1370 1375 1380aaa gaa ggg tgt att cca gaa gga gat gtt aga gaa gga caa atg cag 4410Lys Glu Gly Cys Ile Pro Glu Gly Asp Val Arg Glu Gly Gln Met Gln 1385 1390 1395ctg gtt aca agt ctt taatcataca gctaaggaat tccaagggcc acatgcgagt 4465Leu Val Thr Ser Leu 1400attaataaat aaagacacca ttggcctgac gcagctccct caaactctgc ttgaagagat 4525gactcttgac ctgtggttct ctggtgtaaa aaagatgact gaaccttgca gttctgtgaa 4585tttttataaa acatacaaaa actttgtata tacacagagt atactaaagt gaattatttg 4645ttacaaagaa aagagatgcc agccaggtat tttaagattc tgctgctgtt tagagaaatt 4705gtgaaacaag caaaacaaaa ctttccagcc attttactgc agcagtctgt gaactaaatt 4765tgtaaatatg gctgcaccat ttttgtaggc ctgcattgta ttatatacaa gacgtaggct 4825ttaaaatcct gtgggacaaa tttactgtac cttactattc ctgacaagac ttggaaaagc 4885aggagagata ttctgcatca gtttgcagtt cactgcaaat cttttacatt aaggcaaaga 4945ttgaaaacat gcttaaccac tagcaatcaa gccacaggcc ttatttcata tgtttcctca 5005actgtacaat gaactattct catgaaaaat ggctaaagaa attatatttt gttctattgc 5065tagggtaaaa taaatacatt tgtgtccaac tgaaatataa ttgtcattaa aataatttta 5125aagagtgaag aaaatattgt gaaaagctct tggttgcaca tgttatgaaa tgttttttct 5185tacactttgt catggtaagt tctactcatt ttcacttctt ttccactgta tacagtgttc 5245tgctttgaca aagttagtct ttattactta catttaaatt tcttattgcc aaaagaacgt 5305gttttatggg gagaaacaaa ctctttgaag ccagttatgt catgccttgc acaaaagtga 5365tgaaatctag aaaagattgt gtgtcacccc tgtttattct tgaacagagg gcaaagaggg 5425cactgggcac ttctcacaaa ctttctagtg aacaaaaggt gcctattctt ttttaaaaaa 5485aaaaaa 5491 6 1403 PRT Homo sapiens 6Met Val Ser Ser Gly Cys Arg Met Arg Ser Leu Trp Phe Ile Ile Val 1 5 10 15Ile Ser Phe Leu Pro Asn Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro 20 25 30Phe Gly Leu Val Arg Arg Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp 35 40 45Leu Arg Cys Pro Gly Ser Asp Val Ile Met Ile Glu Ser Ala Asn Tyr 50 55 60Gly Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu 65 70 75 80Asn Thr Asp Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Thr Gln Arg 85 90 95Cys Asn Asn Arg Thr Gln Cys Ile Val Val Thr Gly Ser Asp Val Phe 100 105 110Pro Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu 115 120 125Cys Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Lys Ala Ile Val 130 135 140Asp Ser Pro Cys Ile Tyr Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys145 150 155 160Lys Asp Pro Leu Gln Ala Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr 165 170 175Pro Tyr Arg Thr Asp Thr Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe 180 185 190Gln Asn Ser Arg Gln Thr Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp 195 200 205Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu 210 215 220Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser225 230 235 240Gly Glu Ala Ile Ile Asn Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr 245 250 255Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly 260 265 270Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Met Ile Val Ile 275 280 285Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr 290 295 300Val Tyr Asp Lys Arg Ala Ala Ser Asn Ala Phe Met Ile Cys Gly Val305 310 315 320Leu Tyr Val Val Arg Ser Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly 325 330 335Lys Asn Ser Ile Asp Tyr Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu 340 345 350Tyr Val Asp Val Pro Phe Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val 355 360 365Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe 370 375 380Ile Leu Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ala Gln Val385 390 395 400Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr 405 410 415Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro Met Ser Thr 420 425 430Thr Val Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro 435 440 445Ala Val Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu 450 455 460Pro Glu Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro465 470 475 480Gln Thr Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro Lys Gly Thr 485 490 495Arg Gly Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly Thr Trp Asn 500 505 510Pro Lys Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp Val Asn Gln 515 520 525Leu Ala Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn 530 535 540Glu Leu Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly Asp Val Ser545 550 555 560Ser Ser Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu Asp Ala Gln 565 570 575Leu Gln Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr 580 585 590Asn Lys Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg Pro Glu Ala 595 600 605Leu Glu Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala His Thr Ala 610 615 620Thr Met Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val Leu Ala Asp625 630 635 640Asn Leu Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu Asn Ile Val 645 650 655Leu Glu Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys 660 665 670Phe Pro Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala 675 680 685Asn Thr Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys Leu Val Phe 690 695 700Ile Ile Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr705 710 715 720Ile Lys Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr Ile Ala Val 725 730 735Asn Ser His Val Ile Ser Val Ser Ile Asn Lys Glu Ser Ser Arg Val 740 745 750Tyr Leu Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile Asp Pro Asp 755 760 765Asn Tyr Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr 770 775 780Met Met Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val Asp Thr Asn785 790 795 800Lys Thr Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn Phe Ala Ile 805 810 815Leu Met Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val His Glu Leu 820 825 830Leu Leu Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser Leu Val Cys 835 840 845Leu Ala Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser 850 855 860Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala865 870 875 880Glu Phe Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala 885 890 895Cys Pro Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu Ala Ala Phe 900 905 910Ala Trp Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met Leu Val Glu 915 920 925Val Phe Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly 930 935 940Tyr Leu Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala Ile Asp Tyr945 950 955 960Lys Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val Asp Asn Tyr 965 970 975Phe Ile Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile Leu Leu Asn 980 985 990Ile Ile Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys His Ser Asn 995 1000 1005Thr Leu Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys Ser Trp Val 1010 1015 1020Leu Gly Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe1025 1030 1035 1040Gly Leu Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala Tyr Leu Phe 1045 1050 1055Thr Ile Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile Phe His Cys 1060 1065 1070Ala Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Phe Arg His 1075 1080 1085Ser Tyr Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His Ser Ser Val 1090 1095 1100Lys Ala Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln1105 1110 1115 1120Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser Glu 1125 1130 1135Ser Ser Phe Ile Ser Gly Asp Ile Asn Ser Thr Ser Thr Leu Asn Gln 1140 1145 1150Gly His Ser Leu Asn Asn Ala Arg Asp Thr Ser Ala Met Asp Thr Leu 1155 1160 1165Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser Leu His Lys Gly Asp 1170 1175 1180Tyr Asn Asp Ser Val Gln Val Val Asp Cys Gly Leu Ser Leu Asn Asp1185 1190 1195 1200Thr Ala Phe Glu Lys Met Ile Ile Ser Glu Leu Val His Asn Asn Leu 1205 1210 1215Arg Gly Ser Ser Lys Thr His Asn Leu Glu Leu Thr Leu Pro Val Lys 1220 1225 1230Pro Val Ile Gly Gly Ser Ser Ser Glu Asp Asp Ala Ile Val Ala Asp 1235 1240 1245Ala Ser Ser Leu Met His Ser Asp Asn Pro Gly Leu Glu Leu His His 1250 1255 1260Lys Glu Leu Glu Ala Pro Leu Ile Pro Gln Arg Thr His Ser Leu Leu1265 1270 1275 1280Tyr Gln Pro Gln Lys Lys Val Lys Ser Glu Gly Thr Asp Ser Tyr Val 1285 1290 1295Ser Gln Leu Thr Ala Glu Ala Glu Asp His Leu Gln Ser Pro Asn Arg 1300 1305 1310Asp Ser Leu Tyr Thr Ser Met Pro Asn Leu Arg Asp Ser Pro Tyr Pro 1315 1320 1325Glu Ser Ser Pro Asp Met Glu Glu Asp Leu Ser Pro Ser Arg Arg Ser 1330 1335 1340Glu Asn Glu Asp Ile Tyr Tyr Lys Ser Met Pro Asn Leu Gly Ala Gly1345 1350 1355 1360His Gln Leu Gln Met Cys Tyr Gln Ile Ser Arg Gly Asn Ser Asp Gly 1365 1370 1375Tyr Ile Ile Pro Ile Asn Lys Glu Gly Cys Ile Pro Glu Gly Asp Val 1380 1385 1390Arg Glu Gly Gln Met Gln Leu Val Thr Ser Leu 1395 1400 7 1527 DNA Homo sapiens CDS (217)..(1527) 7cggcgaacag acgttctttc tcctccatgc agttacacaa aaggagggct acggaaacta 60aaagtttcgg ggcctctggc tcggtgtgtg gagaaaagag aaaacctgga gacgggatat 120gaagatcaat gatgcagact gatggtcttg atgaagctgg gcatttataa ctagattcat 180taaggaatac aaagaaaata cttaaaggga tcaata atg gtg tct tct ggt tgc 234 Met Val Ser Ser Gly Cys 1 5aga atg cga agt ctg tgg ttt atc att gta atc agc ttc tta cca aat 282Arg Met Arg Ser Leu Trp Phe Ile Ile Val Ile Ser Phe Leu Pro Asn 10 15 20aca gaa ggt ttc agc aga gca gct tta cca ttt ggg ctg gtg agg cga 330Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro Phe Gly Leu Val Arg Arg 25 30 35gaa tta tcc tgt gaa ggt tat tct ata gat ctg cga tgc ccg ggc agt 378Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp Leu Arg Cys Pro Gly Ser 40 45 50gat gtc atc atg att gag agc gct aac tat ggt cgg acg gat gac aag 426Asp Val Ile Met Ile Glu Ser Ala Asn Tyr Gly Arg Thr Asp Asp Lys 55 60 65 70att tgt gat gct gac cca ttt cag atg gag aat aca gac tgc tac ctc 474Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn Thr Asp Cys Tyr Leu 75 80 85ccc gat gcc ttc aaa att atg act caa agg tgc aac aat cga aca cag 522Pro Asp Ala Phe Lys Ile Met Thr Gln Arg Cys Asn Asn Arg Thr Gln 90 95 100tgt ata gta gtt act ggg tca gat gtg ttt cct gat cca tgt cct gga 570Cys Ile Val Val Thr Gly Ser Asp Val Phe Pro Asp Pro Cys Pro Gly 105 110 115aca tac aaa tac ctt gaa gtc caa tat gaa tgt gtc cct tac att ttt 618Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu Cys Val Pro Tyr Ile Phe 120 125 130gtg tgt cct ggg acc ttg aaa gca att gtg gac tca cca tgt ata tat 666Val Cys Pro Gly Thr Leu Lys Ala Ile Val Asp Ser Pro Cys Ile Tyr135 140 145 150gaa gct gaa caa aag gcg ggt gct tgg tgc aag gac cct ctt cag gct 714Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala 155 160 165gca gat aaa att tat ttc atg ccc tgg act ccc tat cgt acc gat act 762Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr Pro Tyr Arg Thr Asp Thr 170 175 180tta ata gaa tat gct tct tta gaa gat ttc caa aat agt cgc caa aca 810Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe Gln Asn Ser Arg Gln Thr 185 190 195aca aca tat aaa ctt cca aat cga gta gat ggt act gga ttt gtg gtg 858Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp Gly Thr Gly Phe Val Val 200 205 210tat gat ggt gct gtc ttc ttt aac aaa gaa aga acg agg aat att gtg 906Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu Arg Thr Arg Asn Ile Val215 220 225 230aaa ttt gac ttg agg act aga att aag agt ggc gag gcc ata att aac 954Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Ala Ile Ile Asn 235 240 245tat gcc aac tac cat gat acc tca cca tac aga tgg gga gga aag act 1002Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp Gly Gly Lys Thr 250 255 260gat atc gac cta gca gtt gat gaa aat ggt tta tgg gtc att tac gcc 1050Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala 265 270 275act gaa cag aac aat gga atg ata gtt att agc cag ctg aat cca tac 1098Thr Glu Gln Asn Asn Gly Met Ile Val Ile Ser Gln Leu Asn Pro Tyr 280 285 290act ctt cga ttt gaa gca acg tgg gag act gta tac gac aaa cgt gcc 1146Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr Val Tyr Asp Lys Arg Ala295 300 305 310gca tca aat gct ttt atg ata tgc gga gtc ctc tat gtg gtt agg tca 1194Ala Ser Asn Ala Phe Met Ile Cys Gly Val Leu Tyr Val Val Arg Ser 315 320 325gtt tat caa gac aat gaa agt gaa aca ggc aag aac tca att gat tac 1242Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly Lys Asn Ser Ile Asp Tyr 330 335 340att tat aat acc cga tta aac cga gga gaa tat gta gac gtt ccc ttc 1290Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu Tyr Val Asp Val Pro Phe 345 350 355ccc aac cag tat cag tat att gct gca gtg gat tac aat cca aga gat 1338Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val Asp Tyr Asn Pro Arg Asp 360 365 370aac caa ctt tac gtg tgg aac aat aac ttc att tta cga tat tct ctg 1386Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe Ile Leu Arg Tyr Ser Leu375 380 385 390gag ttt ggt cca cct gat cct gcc caa gtg cct acc aca gct gtg aca 1434Glu Phe Gly Pro Pro Asp Pro Ala Gln Val Pro Thr Thr Ala Val Thr 395 400 405ata act tct tca gct gag ctg ttc aaa acc ata ata tca acc aca agc 1482Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr Ile Ile Ser Thr Thr Ser 410 415 420act act tca cag aaa ggc ccc atg agc aca act gta gct gga tca 1527Thr Thr Ser Gln Lys Gly Pro Met Ser Thr Thr Val Ala Gly Ser 425 430 435 8 437 PRT Homo sapiens 8Met Val Ser Ser Gly Cys Arg Met Arg Ser Leu Trp Phe Ile Ile Val 1 5 10 15Ile Ser Phe Leu Pro Asn Thr Glu Gly Phe Ser Arg Ala Ala Leu Pro 20 25 30Phe Gly Leu Val Arg Arg Glu Leu Ser Cys Glu Gly Tyr Ser Ile Asp 35 40 45Leu Arg Cys Pro Gly Ser Asp Val Ile Met Ile Glu Ser Ala Asn Tyr 50 55 60Gly Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu 65 70 75 80Asn Thr Asp Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Thr Gln Arg 85 90 95Cys Asn Asn Arg Thr Gln Cys Ile Val Val Thr Gly Ser Asp Val Phe 100 105 110Pro Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu 115 120 125Cys Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Lys Ala Ile Val 130 135 140Asp Ser Pro Cys Ile Tyr Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys145 150 155 160Lys Asp Pro Leu Gln Ala Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr 165 170 175Pro Tyr Arg Thr Asp Thr Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe 180 185 190Gln Asn Ser Arg Gln Thr Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp 195 200 205Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu 210 215 220Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser225 230 235 240Gly Glu Ala Ile Ile Asn Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr 245 250 255Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly 260 265 270Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Met Ile Val Ile 275 280 285Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr 290 295 300Val Tyr Asp Lys Arg Ala Ala Ser Asn Ala Phe Met Ile Cys Gly Val305 310 315 320Leu Tyr Val Val Arg Ser Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly 325 330 335Lys Asn Ser Ile Asp Tyr Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu 340 345 350Tyr Val Asp Val Pro Phe Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val 355 360 365Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe 370 375 380Ile Leu Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ala Gln Val385 390 395 400Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr 405 410 415Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro Met Ser Thr 420 425 430Thr Val Ala Gly Ser 435 9 4190 DNA Homo sapiens CDS (1)..(2340) 9gcc caa gtg cct acc aca gct gtg aca ata act tct tca gct gag ctg 48Ala Gln Val Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu 1 5 10 15ttc aaa acc ata ata tca acc aca agc act act tca cag aaa ggc ccc 96Phe Lys Thr Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro 20 25 30atg agc aca act gta gct gga tca cag gaa gga agc aaa ggg aca aaa 144Met Ser Thr Thr Val Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys 35 40 45cca cct cca gca gtt tct aca acc aaa att cca cct ata aca aat att 192Pro Pro Pro Ala Val Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile 50 55 60ttt ccc ctg cca gag aga ttc tgt gaa gca tta gac tcc aag ggg ata 240Phe Pro Leu Pro Glu Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile 65 70 75 80aag tgg cct cag aca caa agg gga atg atg gtt gaa cga cca tgc cct 288Lys Trp Pro Gln Thr Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro 85 90 95aag gga aca aga gga act gcc tca tat ctc tgc atg att tcc act gga 336Lys Gly Thr Arg Gly Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly 100 105 110aca tgg aac cct aag ggc ccc gat ctt agc aac tgt acc tca cac tgg 384Thr Trp Asn Pro Lys Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp 115 120 125gtg aat cag ctg gct cag aag atc aga agc gga gaa aat gct gct agt 432Val Asn Gln Leu Ala Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser 130 135 140ctt gcc aat gaa ctg gct aaa cat acc aaa ggg cca gtg ttt gct ggg 480Leu Ala Asn Glu Leu Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly145 150 155 160gat gta agt tct tca gtg aga ttg atg gag cag ttg gtg gac atc ctt 528Asp Val Ser Ser Ser Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu 165 170 175gat gca cag ctg cag gaa ctg aaa cct agt gaa aaa gat tca gct gga 576Asp Ala Gln Leu Gln Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly 180 185 190cgg agt tat aac aag gca att gtt gac aca gtg gac aac ctt ctg aga 624Arg Ser Tyr Asn Lys Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg 195 200 205cct gaa gct ttg gaa tca tgg aaa cat atg aat tct tct gaa caa gca 672Pro Glu Ala Leu Glu Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala 210 215 220cat act gca aca atg tta ctc gat aca ttg gaa gaa gga gct ttt gtc 720His Thr Ala Thr Met Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val225 230 235 240cta gct gac aat ctt tta gaa cca aca agg gtc tca atg ccc aca gaa 768Leu Ala Asp Asn Leu Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu 245 250 255aat att gtc ctg gaa gtt gcc gta ctc agt aca gaa gga cag atc caa 816Asn Ile Val Leu Glu Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln 260 265 270gac ttt aaa ttt cct ctg ggc atc aaa gga gca ggc agc tca atc caa 864Asp Phe Lys Phe Pro Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln 275 280 285ctg tcc gca aat acc gtc aaa cag aac agc agg aat ggg ctt gca aag 912Leu Ser Ala Asn Thr Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys 290 295 300ttg gtg ttc atc att tac cgg agc ctg gga cag ttc ctt agt aca gaa 960Leu Val Phe Ile Ile Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu305 310 315 320aat gca acc att aaa ctg ggt gct gat ttt att ggt cgt aat agc acc 1008Asn Ala Thr Ile Lys Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr 325 330 335att gca gtg aac tct cac gtc att tca gtt tca atc aat aaa gag tcc 1056Ile Ala Val Asn Ser His Val Ile Ser Val Ser Ile Asn Lys Glu Ser 340 345 350agc cga gta tac ctg act gat cct gtg ctt ttt acc ctg cca cac att 1104Ser Arg Val Tyr Leu Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile 355 360 365gat cct gac aat tat ttc aat gca aac tgc tcc ttc tgg aac tac tca 1152Asp Pro Asp Asn Tyr Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser 370 375 380gag aga act atg atg gga tat tgg tct acc cag ggc tgc aag ctg gtt 1200Glu Arg Thr Met Met Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val385 390 395 400gac act aat aaa act cga aca acg tgt gca tgc agc cac cta acc aat 1248Asp Thr Asn Lys Thr Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn 405 410 415ttt gca att ctc atg gcc cac agg gaa att gca tat aaa gat ggc gtt 1296Phe Ala Ile Leu Met Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val 420 425 430cat gaa tta ctt ctt aca gtc atc acc tgg gtg gga att gtc att tcc 1344His Glu Leu Leu Leu Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser 435 440 445ctt gtt tgc ctg gct atc tgc atc ttc acc ttc tgc ttt ttc cgt ggc 1392Leu Val Cys Leu Ala Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly 450 455 460cta cag agt gac cga aat act att cac aag aac ctt tgt atc aac ctt 1440Leu Gln Ser Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu465 470 475 480ttc att gct gaa ttt att ttc cta ata ggc att gat aag aca aaa tat 1488Phe Ile Ala Glu Phe Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr 485 490 495gcg att gca tgc cca ata ttt gca gga ctt cta cac ttt ttc ttt ttg 1536Ala Ile Ala Cys Pro Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu 500 505 510gca gct ttt gct tgg atg tgc cta gaa ggt gtg cag ctc tac cta atg 1584Ala Ala Phe Ala Trp Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met 515 520 525tta gtt gaa gtt ttt gaa agt gaa tat tca agg aaa aaa tat tac tat 1632Leu Val Glu Val Phe Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr 530 535 540gtt gct ggt tac ttg ttt cct gcc aca gtg gtt gga gtt tca gct gct 1680Val Ala Gly Tyr Leu Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala545 550 555 560att gac tat aag agc tat gga aca gaa aaa gct tgc tgg ctt cat gtt 1728Ile Asp Tyr Lys Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val 565 570 575gat aac tac ttt ata tgg agc ttc att gga cct gtt acc ttc att att 1776Asp Asn Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile 580 585 590ctg cta aat att atc ttc ttg gtg atc aca ttg tgc aaa atg gtg aag 1824Leu Leu Asn Ile Ile Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys 595 600 605cat tca aac act ttg aaa cca gat tct agc agg ttg gaa aac att aag 1872His Ser Asn Thr Leu Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys 610 615 620tct tgg gtg ctt ggc gct ttc gct ctt ctg tgt ctt ctt ggc ctc acc 1920Ser Trp Val Leu Gly Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr625 630 635 640tgg tcc ttt ggg ttg ctt ttt att aat gag gag act att gtg atg gca 1968Trp Ser Phe Gly Leu Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala 645 650 655tat ctc ttc act ata ttt aat gct ttc cag gga gtg ttc att ttc atc 2016Tyr Leu Phe Thr Ile Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile 660 665 670ttt cac tgt gct ctc caa aag aaa gta cga aaa gaa tat ggc aag tgc 2064Phe His Cys Ala Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys 675 680 685ttc aga cac tca tac tgc tgt gga ggc ctc cca act gag agt ccc cac 2112Phe Arg His Ser Tyr Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His 690 695 700agt tca gtg aag gca tca acc acc aga acc agt gct cgc tat tcc tct 2160Ser Ser Val Lys Ala Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser705 710 715 720ggc aca cag agt cgt ata aga aga atg tgg aat gat act gtg aga aaa 2208Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys 725 730 735caa tca gaa tct tct ttt atc tca ggt gac atc aat agc act tca aca 2256Gln Ser Glu Ser Ser Phe Ile Ser Gly Asp Ile Asn Ser Thr Ser Thr 740 745 750ctt aat caa gga ctg aca tca cat ggt ctg aga gcc cat ctt caa gat 2304Leu Asn Gln Gly Leu Thr Ser His Gly Leu Arg Ala His Leu Gln Asp 755 760 765tta tat cat tta gag cta ctc tta ggc cag ata gcc tgagcagaca 2350Leu Tyr His Leu Glu Leu Leu Leu Gly Gln Ile Ala 770 775 780gacatgatgt gagttgtcca aagacattca ctgaacaatg ccagggatac aagtgccatg 2410gatactctac cgctaaatgg taattttaac aacagctact cgctgcacaa gggtgactat 2470aatgacagcg tgcaagttgt ggactgtgga ctaagtctga atgatactgc ttttgagaaa 2530atgatcattt cagaattagt gcacaacaac ttacggggca gcagcaagac tcacaacctc 2590gagctcacgc taccagtcaa acctgtgatt ggaggtagca gcagtgaaga tgatgctatt 2650gtggcagatg cttcatcttt aatgcacagc gacaacccag ggctggagct ccatcacaaa 2710gaactcgagg caccacttat tcctcagcgg actcactccc ttctgtacca accccagaag 2770aaagtgaagt ccgagggaac tgacagctat gtctcccaac tgacagcaga ggctgaagat 2830cacctacagt cccccaacag agactctctt tatacaagca tgcccaatct tagagactct 2890ccctatccgg agagcagccc tgacatggaa gaagacctct ctccctccag gaggagtgag 2950aatgaggaca tttactataa aagcatgcca aatcttggag ctggccatca gcttcagatg 3010tgctaccaga tcagcagggg caatagtgat ggttatataa tccccattaa caaagaaggg 3070tgtattccag aaggagatgt tagagaagga caaatgcagc tggttacaag tctttaatca 3130tacagctaag gaattccaag ggccacatgc gagtattaat aaataaagac accattggcc 3190tgacgcagct ccctcaaact ctgcttgaag agatgactct tgacctgtgg ttctctggtg 3250taaaaaagat gactgaacct tgcagttctg tgaattttta taaaacatac aaaaactttg 3310tatatacaca gagtatacta aagtgaatta tttgttacaa agaaaagaga tgccagccag 3370gtattttaag attctgctgc tgtttagaga aattgtgaaa caagcaaaac aaaactttcc 3430agccatttta ctgcagcagt ctgtgaacta aatttgtaaa tatggctgca ccatttttgt 3490aggcctgcat tgtattatat acaagacgta ggctttaaaa tcctgtggga caaatttact 3550gtaccttact attcctgaca agacttggaa aagcaggaga gatattctgc atcagtttgc 3610agttcactgc aaatctttta cattaaggca aagattgaaa acatgcttaa ccactagcaa 3670tcaagccaca ggccttattt catatgtttc ctcaactgta caatgaacta ttctcatgaa 3730aaatggctaa agaaattata ttttgttcta ttgctagggt aaaataaata catttgtgtc 3790caactgaaat ataattgtca ttaaaataat tttaaagagt gaagaaaata ttgtgaaaag 3850ctcttggttg cacatgttat gaaatgtttt ttcttacact ttgtcatggt aagttctact 3910cattttcact tcttttccac tgtatacagt gttctgcttt gacaaagtta gtctttatta 3970cttacattta aatttcttat tgccaaaaga acgtgtttta tggggagaaa caaactcttt 4030gaagccagtt atgtcatgcc ttgcacaaaa gtgatgaaat ctagaaaaga ttgtgtgtca 4090cccctgttta ttcttgaaca gagggcaaag agggcactgg gcacttctca caaactttct 4150agtgaacaaa aggtgcctat tcttttttaa aaaaaaaaaa 4190 10 780 PRT Homo sapiens 10Ala Gln Val Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu 1 5 10 15Phe Lys Thr Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro 20 25 30Met Ser Thr Thr Val Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys 35 40 45Pro Pro Pro Ala Val Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile 50 55 60Phe Pro Leu Pro Glu Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile 65 70 75 80Lys Trp Pro Gln Thr Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro 85 90 95Lys Gly Thr Arg Gly Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly 100 105 110Thr Trp Asn Pro Lys Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp 115 120 125Val Asn Gln Leu Ala Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser 130 135 140Leu Ala Asn Glu Leu Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly145 150 155 160Asp Val Ser Ser Ser Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu 165 170 175Asp Ala Gln Leu Gln Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly 180 185 190Arg Ser Tyr Asn Lys Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg 195 200 205Pro Glu Ala Leu Glu Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala 210 215 220His Thr Ala Thr Met Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val225 230 235 240Leu Ala Asp Asn Leu Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu 245 250 255Asn Ile Val Leu Glu Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln 260 265 270Asp Phe Lys Phe Pro Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln 275 280 285Leu Ser Ala Asn Thr Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys 290 295 300Leu Val Phe Ile Ile Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu305 310 315 320Asn Ala Thr Ile Lys Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr 325 330 335Ile Ala Val Asn Ser His Val Ile Ser Val Ser Ile Asn Lys Glu Ser 340 345 350Ser Arg Val Tyr Leu Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile 355 360 365Asp Pro Asp Asn Tyr Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser 370 375 380Glu Arg Thr Met Met Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val385 390 395 400Asp Thr Asn Lys Thr Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn 405 410 415Phe Ala Ile Leu Met Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val 420 425 430His Glu Leu Leu Leu Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser 435 440 445Leu Val Cys Leu Ala Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly 450 455 460Leu Gln Ser Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu465 470 475 480Phe Ile Ala Glu Phe Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr 485 490 495Ala Ile Ala Cys Pro Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu 500 505 510Ala Ala Phe Ala Trp Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met 515 520 525Leu Val Glu Val Phe Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr 530 535 540Val Ala Gly Tyr Leu Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala545 550 555 560Ile Asp Tyr Lys Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val 565 570 575Asp Asn Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile 580 585 590Leu Leu Asn Ile Ile Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys 595 600 605His Ser Asn Thr Leu Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys 610 615 620Ser Trp Val Leu Gly Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr625 630 635 640Trp Ser Phe Gly Leu Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala 645 650 655Tyr Leu Phe Thr Ile Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile 660 665 670Phe His Cys Ala Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys 675 680 685Phe Arg His Ser Tyr Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His 690 695 700Ser Ser Val Lys Ala Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser705 710 715 720Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys 725 730 735Gln Ser Glu Ser Ser Phe Ile Ser Gly Asp Ile Asn Ser Thr Ser Thr 740 745 750Leu Asn Gln Gly Leu Thr Ser His Gly Leu Arg Ala His Leu Gln Asp 755 760 765Leu Tyr His Leu Glu Leu Leu Leu Gly Gln Ile Ala 770 775 780 11 3156 DNA Homo sapiens CDS (49)..(2553) 11ctgtcccact cactctttcc cctgccgctc ctgccggcag ctccaacc atg gga ggc 57 Met Gly Gly 1cgc gtc ttt ctc gca ttc tgt gtc tgg ctg act ctg ccg gga gct gaa 105Arg Val Phe Leu Ala Phe Cys Val Trp Leu Thr Leu Pro Gly Ala Glu 5 10 15acc cag gac tcc agg ggc tgt gcc cgg tgg tgc cct cag aac tcc tcg 153Thr Gln Asp Ser Arg Gly Cys Ala Arg Trp Cys Pro Gln Asn Ser Ser 20 25 30 35tgt gtc aat gcc acc gcc tgt cgc tgc aat cca ggg ttc agc tct ttt 201Cys Val Asn Ala Thr Ala Cys Arg Cys Asn Pro Gly Phe Ser Ser Phe 40 45 50tct gag atc atc acc acc ccg acg gag act tgt gac gac atc aac gag 249Ser Glu Ile Ile Thr Thr Pro Thr Glu Thr Cys Asp Asp Ile Asn Glu 55 60 65tgt gca aca ccg tcg aaa gtg tca tgc gga aaa ttc tcg gac tgc tgg 297Cys Ala Thr Pro Ser Lys Val Ser Cys Gly Lys Phe Ser Asp Cys Trp 70 75 80aac aca gag ggg agc tac gac tgc gtg tgc agc ccg gga tat gag cct 345Asn Thr Glu Gly Ser Tyr Asp Cys Val Cys Ser Pro Gly Tyr Glu Pro 85 90 95gtt tct ggg aca aaa aca ttc aag aat gag agc gag aac acc tgt caa 393Val Ser Gly Thr Lys Thr Phe Lys Asn Glu Ser Glu Asn Thr Cys Gln100 105 110 115gat gtg gac gaa tgt cag cag aac cca agg ctc tgt aaa agc tac ggc 441Asp Val Asp Glu Cys Gln Gln Asn Pro Arg Leu Cys Lys Ser Tyr Gly 120 125 130acc tgc gtc aac acc ctt ggc agc tat acc tgc cag tgc ctg cct ggc 489Thr Cys Val Asn Thr Leu Gly Ser Tyr Thr Cys Gln Cys Leu Pro Gly 135 140 145ttc aag ttc ata cct gag gat ccg aag gtc tgc aca gat gtg aat gaa 537Phe Lys Phe Ile Pro Glu Asp Pro Lys Val Cys Thr Asp Val Asn Glu 150 155 160tgc acc tcc gga caa aat ccg tgc cac agc tcc acc cac tgc ctc aac 585Cys Thr Ser Gly Gln Asn Pro Cys His Ser Ser Thr His Cys Leu Asn 165 170 175aac gtg ggc agc tat cag tgt cgc tgc cga ccg ggc tgg caa ccg att 633Asn Val Gly Ser Tyr Gln Cys Arg Cys Arg Pro Gly Trp Gln Pro Ile180 185 190 195ccg ggg tcc ccc aat ggc cca aac aat acc gtc tgt gaa gat gtg gac 681Pro Gly Ser Pro Asn Gly Pro Asn Asn Thr Val Cys Glu Asp Val Asp 200 205 210gag tgc agc tcc ggg cag cat cag tgt gac agc tcc acc gtc tgc ttc 729Glu Cys Ser Ser Gly Gln His Gln Cys Asp Ser Ser Thr Val Cys Phe 215 220 225aac acc gtg ggt tca tac agc tgc cgc tgc cgc cca ggc tgg aag ccc 777Asn Thr Val Gly Ser Tyr Ser Cys Arg Cys Arg Pro Gly Trp Lys Pro 230 235 240aga cac gga atc ccg aat aac caa aag gac act gtc tgt gaa gat atg 825Arg His Gly Ile Pro Asn Asn Gln Lys Asp Thr Val Cys Glu Asp Met 245 250 255act ttc tcc acc tgg acc ccg ccc cct gga gtc cac agc cag acg ctt 873Thr Phe Ser Thr Trp Thr Pro Pro Pro Gly Val His Ser Gln Thr Leu260 265 270 275tcc cga ttc ttc gac aaa gtc cag gac ctg ggc aga gac tcc aag aca 921Ser Arg Phe Phe Asp Lys Val Gln Asp Leu Gly Arg Asp Ser Lys Thr 280 285 290agc tca gcc gag gtc acc atc cag aat gtc atc aaa ttg gtg gat gaa 969Ser Ser Ala Glu Val Thr Ile Gln Asn Val Ile Lys Leu Val Asp Glu 295 300 305ctg atg gaa gct cct gga gac gta gag gcc ctg gcg cca cct gtc cgg 1017Leu Met Glu Ala Pro Gly Asp Val Glu Ala Leu Ala Pro Pro Val Arg 310 315 320cac ctc ata gcc acc cag ctg ctc tca aac ctt gaa gat atc atg agg 1065His Leu Ile Ala Thr Gln Leu Leu Ser Asn Leu Glu Asp Ile Met Arg 325 330 335atc ctg gcc aag agc ctg cct aaa ggc ccc ttc acc tac att tcc cct 1113Ile Leu Ala Lys Ser Leu Pro Lys Gly Pro Phe Thr Tyr Ile Ser Pro340 345 350 355tcg aac aca gag ctg acc ctg atg atc cag gag cgg ggg gac aag aac 1161Ser Asn Thr Glu Leu Thr Leu Met Ile Gln Glu Arg Gly Asp Lys Asn 360 365 370gtc act atg ggt cag agc agc gca cgc atg aag ctg aat tgg gct gtg 1209Val Thr Met Gly Gln Ser Ser Ala Arg Met Lys Leu Asn Trp Ala Val 375 380 385gca gct gga gcc gag gat cca ggc ccc gcc gtg gcg ggc atc ctc tcc 1257Ala Ala Gly Ala Glu Asp Pro Gly Pro Ala Val Ala Gly Ile Leu Ser 390 395 400atc cag aac atg acg aca ttg ctg gcc aat gcc tcc ttg aac ctg cat 1305Ile Gln Asn Met Thr Thr Leu Leu Ala Asn Ala Ser Leu Asn Leu His 405 410 415tcc aag aag caa gcc gaa ctg gag gag ata tat gaa agc agc atc cgt 1353Ser Lys Lys Gln Ala Glu Leu Glu Glu Ile Tyr Glu Ser Ser Ile Arg420 425 430 435ggt gtc caa ctc aga cgc ctc tct gcc gtc aac tcc atc ttt ctg agc 1401Gly Val Gln Leu Arg Arg Leu Ser Ala Val Asn Ser Ile Phe Leu Ser 440 445 450cac aac aac acc aag gaa ctc aac tcc ccc atc ctt ttc gcc ttc tcc 1449His Asn Asn Thr Lys Glu Leu Asn Ser Pro Ile Leu Phe Ala Phe Ser 455 460 465cac ctt gag tcc tcc gat ggg gag gcg gga aga gac cct cct gcc aag 1497His Leu Glu Ser Ser Asp Gly Glu Ala Gly Arg Asp Pro Pro Ala Lys 470 475 480gac gtg atg cct ggg cca cgg cag gag ctg ctc tgt gcc ttc tgg aag 1545Asp Val Met Pro Gly Pro Arg Gln Glu Leu Leu Cys Ala Phe Trp Lys 485 490 495agt gac agc gac agg gga ggg cac tgg gcc acc gag ggc tgc cag gtg 1593Ser Asp Ser Asp Arg Gly Gly His Trp Ala Thr Glu Gly Cys Gln Val500 505 510 515ctg ggc agc aag aac ggc agc acc acc tgc caa tgc agc cac ctg agc 1641Leu Gly Ser Lys Asn Gly Ser Thr Thr Cys Gln Cys Ser His Leu Ser 520 525 530agc ttt gcg atc ctt atg gct cat tat gac gtg gag gac tgg aag ctg 1689Ser Phe Ala Ile Leu Met Ala His Tyr Asp Val Glu Asp Trp Lys Leu 535 540 545acc ctg atc acc agg gtg gga ctg gcg ctg tca ctc ttc tgc ctg ctg 1737Thr Leu Ile Thr Arg Val Gly Leu Ala Leu Ser Leu Phe Cys Leu Leu 550 555 560ctg tgc atc ctc act ttc ctg ctg gtg cgg ccc atc cag ggc tcg cgc 1785Leu Cys Ile Leu Thr Phe Leu Leu Val Arg Pro Ile Gln Gly Ser Arg 565 570 575acc acc ata cac ctg cac ctc tgc atc tgc ctc ttc gtg ggc tcc acc 1833Thr Thr Ile His Leu His Leu Cys Ile Cys Leu Phe Val Gly Ser Thr580 585 590 595atc ttc ctg gcc ggc atc gag aac gaa ggc ggc cag gtg ggg ctg cgc 1881Ile Phe Leu Ala Gly Ile Glu Asn Glu Gly Gly Gln Val Gly Leu Arg 600 605 610tgc cgc ctg gtg gcc ggg ctg ctg cac tac tgt ttc ctg gcc gcc ttc 1929Cys Arg Leu Val Ala Gly Leu Leu His Tyr Cys Phe Leu Ala Ala Phe 615 620 625tgc tgg atg agc ctc gaa ggc ctg gag ctc tac ttt ctt gtg gtg cgc 1977Cys Trp Met Ser Leu Glu Gly Leu Glu Leu Tyr Phe Leu Val Val Arg 630 635 640gtg ttc caa ggc cag ggc ctg agt acg cgc tgg ctc tgc ctg atc ggc 2025Val Phe Gln Gly Gln Gly Leu Ser Thr Arg Trp Leu Cys Leu Ile Gly 645 650 655tat ggc gtg ccc ctg ctc atc gtg ggc gtc tcg gct gcc atc tac agc 2073Tyr Gly Val Pro Leu Leu Ile Val Gly Val Ser Ala Ala Ile Tyr Ser660 665 670 675aag ggc tac ggc cgc ccc aga tac tgc tgg ttg gac ttt gag cag ggc 2121Lys Gly Tyr Gly Arg Pro Arg Tyr Cys Trp Leu Asp Phe Glu Gln Gly 680 685 690ttc ctc tgg agc ttc ttg gga cct gtg acc ttc atc att ttg tgc aat 2169Phe Leu Trp Ser Phe Leu Gly Pro Val Thr Phe Ile Ile Leu Cys Asn 695 700 705gct gtc att ttc gtg act acc gtc tgg aag ctc act cag aag ttt tct 2217Ala Val Ile Phe Val Thr Thr Val Trp Lys Leu Thr Gln Lys Phe Ser 710 715 720gaa atc aat cca gac atg aag aaa tta aag aag gcg agg gcg ctg acc 2265Glu Ile Asn Pro Asp Met Lys Lys Leu Lys Lys Ala Arg Ala Leu Thr 725 730 735atc acg gcc atc gcg cag ctc ttc ctg ttg ggc tgc acc tgg gtc ttt 2313Ile Thr Ala Ile Ala Gln Leu Phe Leu Leu Gly Cys Thr Trp Val Phe740 745 750 755ggc ctg ttc atc ttc gac gat cgg agc ttg gtg ctg acc tat gtg ttt 2361Gly Leu Phe Ile Phe Asp Asp Arg Ser Leu Val Leu Thr Tyr Val Phe 760 765 770acc atc ctc aac tgc ctg cag ggc gcc ttc ctc tac ctg ctg cac tgc 2409Thr Ile Leu Asn Cys Leu Gln Gly Ala Phe Leu Tyr Leu Leu His Cys 775 780 785ctg ctc aac aag aag gtt cgg gaa gaa tac cgg aag tgg gcc tgc cta 2457Leu Leu Asn Lys Lys Val Arg Glu Glu Tyr Arg Lys Trp Ala Cys Leu 790 795 800gtt gct ggg ggg agc aag tac tca gaa ttc acc tcc acc acg tct ggc 2505Val Ala Gly Gly Ser Lys Tyr Ser Glu Phe Thr Ser Thr Thr Ser Gly 805 810 815act ggc cac aat cag acc cgg gcc ctc agg gca tca gag tcc ggc ata 2553Thr Gly His Asn Gln Thr Arg Ala Leu Arg Ala Ser Glu Ser Gly Ile820 825 830 835tgaaggcgca tggttctgga cggcccagca gctcctgtgg ccacagcagc tttgtacacg 2613aagaccatcc atcctccctt cgtccaccac tctactccct ccaccctccc tccctgatcc 2673cgtgtgccac caggagggag tggcagctat agtctggcac caaagtccag gacacccagt 2733ggggtggagt cggagccact ggtcctgctg ctggctgcct ctctgctcca ccttgtgacc 2793cagggtgggg acaggggctg gcccagggct gcaatgcagc atgttgccct ggcacctgtg 2853gccagtactc gggacagact aagggcgctt gtcccatcct ggacttttcc tctcatgtct 2913ttgctgcaga actgaagaga ctaggcgctg gggctcagct tccctcttaa gctaagactg 2973atgtcagagg ccccatggcg aggccccttg gggccactgc ctgaggctca cggtacagag 3033gcctgccctg cctggccggg caggaggttc tcactgttgt gaaggttgta gacgttgtgt 3093aatgtgtttt tatctgttaa aatttttcag tgttgacact taaaattaaa cacatgcata 3153cag 3156 12 835 PRT Homo sapiens 12Met Gly Gly Arg Val Phe Leu Ala Phe Cys Val Trp Leu Thr Leu Pro 1 5 10 15Gly Ala Glu Thr Gln Asp Ser Arg Gly Cys Ala Arg Trp Cys Pro Gln 20 25 30Asn Ser Ser Cys Val Asn Ala Thr Ala Cys Arg Cys Asn Pro Gly Phe 35 40 45Ser Ser Phe Ser Glu Ile Ile Thr Thr Pro Thr Glu Thr Cys Asp Asp 50 55 60Ile Asn Glu Cys Ala Thr Pro Ser Lys Val Ser Cys Gly Lys Phe Ser 65 70 75 80Asp Cys Trp Asn Thr Glu Gly Ser Tyr Asp Cys Val Cys Ser Pro Gly 85 90 95Tyr Glu Pro Val Ser Gly Thr Lys Thr Phe Lys Asn Glu Ser Glu Asn 100 105 110Thr Cys Gln Asp Val Asp Glu Cys Gln Gln Asn Pro Arg Leu Cys Lys 115 120 125Ser Tyr Gly Thr Cys Val Asn Thr Leu Gly Ser Tyr Thr Cys Gln Cys 130 135 140Leu Pro Gly Phe Lys Phe Ile Pro Glu Asp Pro Lys Val Cys Thr Asp145 150 155 160Val Asn Glu Cys Thr Ser Gly Gln Asn Pro Cys His Ser Ser Thr His 165 170 175Cys Leu Asn Asn Val Gly Ser Tyr Gln Cys Arg Cys Arg Pro Gly Trp 180 185 190Gln Pro Ile Pro Gly Ser Pro Asn Gly Pro Asn Asn Thr Val Cys Glu 195 200 205Asp Val Asp Glu Cys Ser Ser Gly Gln His Gln Cys Asp Ser Ser Thr 210 215 220Val Cys Phe Asn Thr Val Gly Ser Tyr Ser Cys Arg Cys Arg Pro Gly225 230 235 240Trp Lys Pro Arg His Gly Ile Pro Asn Asn Gln Lys Asp Thr Val Cys 245 250 255Glu Asp Met Thr Phe Ser Thr Trp Thr Pro Pro Pro Gly Val His Ser 260 265 270Gln Thr Leu Ser Arg Phe Phe Asp Lys Val Gln Asp Leu Gly Arg Asp 275 280 285Ser Lys Thr Ser Ser Ala Glu Val Thr Ile Gln Asn Val Ile Lys Leu 290 295 300Val Asp Glu Leu Met Glu Ala Pro Gly Asp Val Glu Ala Leu Ala Pro305 310 315 320Pro Val Arg His Leu Ile Ala Thr Gln Leu Leu Ser Asn Leu Glu Asp 325 330 335Ile Met Arg Ile Leu Ala Lys Ser Leu Pro Lys Gly Pro Phe Thr Tyr 340 345 350Ile Ser Pro Ser Asn Thr Glu Leu Thr Leu Met Ile Gln Glu Arg Gly 355 360 365Asp Lys Asn Val Thr Met Gly Gln Ser Ser Ala Arg Met Lys Leu Asn 370 375 380Trp Ala Val Ala Ala Gly Ala Glu Asp Pro Gly Pro Ala Val Ala Gly385 390 395 400Ile Leu Ser Ile Gln Asn Met Thr Thr Leu Leu Ala Asn Ala Ser Leu 405 410 415Asn Leu His Ser Lys Lys Gln Ala Glu Leu Glu Glu Ile Tyr Glu Ser 420 425 430Ser Ile Arg Gly Val Gln Leu Arg Arg Leu Ser Ala Val Asn Ser Ile 435 440 445Phe Leu Ser His Asn Asn Thr Lys Glu Leu Asn Ser Pro Ile Leu Phe 450 455 460Ala Phe Ser His Leu Glu Ser Ser Asp Gly Glu Ala Gly Arg Asp Pro465 470 475 480Pro Ala Lys Asp Val Met Pro Gly Pro Arg Gln Glu Leu Leu Cys Ala 485 490 495Phe Trp Lys Ser Asp Ser Asp Arg Gly Gly His Trp Ala Thr Glu Gly 500 505 510Cys Gln Val Leu Gly Ser Lys Asn Gly Ser Thr Thr Cys Gln Cys Ser 515 520 525His Leu Ser Ser Phe Ala Ile Leu Met Ala His Tyr Asp Val Glu Asp 530 535 540Trp Lys Leu Thr Leu Ile Thr Arg Val Gly Leu Ala Leu Ser Leu Phe545 550 555 560Cys Leu Leu Leu Cys Ile Leu Thr Phe Leu Leu Val Arg Pro Ile Gln 565 570 575Gly Ser Arg Thr Thr Ile His Leu His Leu Cys Ile Cys Leu Phe Val 580 585 590Gly Ser Thr Ile Phe Leu Ala Gly Ile Glu Asn Glu Gly Gly Gln Val 595 600 605Gly Leu Arg Cys Arg Leu Val Ala Gly Leu Leu His Tyr Cys Phe Leu 610 615 620Ala Ala Phe Cys Trp Met Ser Leu Glu Gly Leu Glu Leu Tyr Phe Leu625 630 635 640Val Val Arg Val Phe Gln Gly Gln Gly Leu Ser Thr Arg Trp Leu Cys 645 650 655Leu Ile Gly Tyr Gly Val Pro Leu Leu Ile Val Gly Val Ser Ala Ala 660 665 670Ile Tyr Ser Lys Gly Tyr Gly Arg Pro Arg Tyr Cys Trp Leu Asp Phe 675 680 685Glu Gln Gly Phe Leu Trp Ser Phe Leu Gly Pro Val Thr Phe Ile Ile 690 695 700Leu Cys Asn Ala Val Ile Phe Val Thr Thr Val Trp Lys Leu Thr Gln705 710 715 720Lys Phe Ser Glu Ile Asn Pro Asp Met Lys Lys Leu Lys Lys Ala Arg 725 730 735Ala Leu Thr Ile Thr Ala Ile Ala Gln Leu Phe Leu Leu Gly Cys Thr 740 745 750Trp Val Phe Gly Leu Phe Ile Phe Asp Asp Arg Ser Leu Val Leu Thr 755 760 765Tyr Val Phe Thr Ile Leu Asn Cys Leu Gln Gly Ala Phe Leu Tyr Leu 770 775 780Leu His Cys Leu Leu Asn Lys Lys Val Arg Glu Glu Tyr Arg Lys Trp785 790 795 800Ala Cys Leu Val Ala Gly Gly Ser Lys Tyr Ser Glu Phe Thr Ser Thr 805 810 815Thr Ser Gly Thr Gly His Asn Gln Thr Arg Ala Leu Arg Ala Ser Glu 820 825 830Ser Gly Ile 835 13 867 DNA Homo sapiens 13tttagaacct gaggccttct gtatcacgcg tgtggagttt cagctgctat tgactataag 60agctatggaa cagaaaaagc ttgctggctt catgttgata actactttat atggagcttc 120attggacctg ttaccttcat tattctgcta aatattatct tcttggtgat cacattgtgc 180aaaatggtga agcattcaaa cactttgaaa ccagattcta gcaggttgga aaacattaag 240tcttggggtg cttggcgctt tcgctcttct gtgtcttctt ggcctcacct gggtcctttg 300gggttgcttt ttattaatga gggagactat tgtggatggg catatctctt tcacttatat 360ttaattgctt tccgggggag tgttccattt tccatctttc cactgtgctc tccaaaagga 420agtaatgatc tatatcatat atcttgatct cagcttcaaa attgctactt agctaggtat 480atatatagta gaagatttat agtaatcaac tatctcttct ctcctagtaa gtactaatcg 540aattcggcac gagaatcctc gagttttttt tttttttttt tttatttagt tccataaatt 600aatattctat ttactctatc attaatacaa tgaaagttat aattaaaata taatagttat 660cggcactaaa ttctattgca ggatattcat tgcaggccta tgcaggataa tagcacctat 720gccgcctatg caaggcaagg atgtcctcaa tgaaggagac acgctcctga actcaagggc 780aatgaaggca cgctcgcgca cgctcaggat aactcaggga tagatcaatt aagggtaaat 840cggtaaatca ggctccaaaa gggaaaa 867 14 20 DNA Artificial Sequence Description of Artificial Sequence primer 14tggagtttca gctgctattg 20 15 20 DNA Artificial Sequence Description of Artificial Sequence primer 15tgcccatcca caatagtctc 20 16 3165 DNA Homo sapiens 16aagaaagagt ccagccgagt atacctgact gatcctgtgc tttttaccct gccacacatt 60gatcctgaca attatttcaa tgcaaactgc tccttctgga actactcaga gagaactatg 120atgggatatt ggtctaccca gggctgcaag ctggttgaca ctaataaaac tcgaacaacg 180tgtgcatgca gccacctaac caattttgca attctcatgg cccacaggga aattgcatat 240aaagatggcg ttcatgaatt acttcttaca gtcatcacct gggtgggaat tgtcatttcc 300cttgtttgcc tggctatctg catcttcacc ttctgctttt tccgtggcct acagagtgac 360cgaaatacta ttcacaagaa cctttgtatc aaccttttca ttgctgaatt tattttccta 420ataggcattg ataagacaaa atatgcgatt gcatgcccaa tatttgcagg acttctacac 480tttttctttt tggcagcttt tgcttggatg tgcctagaag gtgtgcagct ctacctaatg 540ttagttgaag tttttgaaag tgaatattca aggaaaaata ttactatgtt gctggttact 600tgtttcctgc cacagtggtt ggagtttcag ctgctattga ctataagagc tatggaacag 660aaaaagcttg ctggcttcat gttgataact actttatatg gagcttcatt ggacctgtta 720ccttcattat tctgctaaat attatcttct tggtgatcac attgtgcaaa atggtgaagc 780attcaaacac tttgaaacca gattctagca ggttggaaaa cattaagtct tgggtgcttg 840gcgctttcgc tcttctgtgt cttcttggcc tcacctggtc ctttgggttg ctttttatta 900atgaggagac tattgtgatg gcatatctct tcactatatt taatgctttc cagggagtgt 960tcattttcat ctttcactgt gctctccaaa agaaagtacg aaaagaatat ggcaagtgct 1020tcagacactc atactgctgt ggaggcctcc caactgagag tccccacagt tcagtgaagg 1080catcaaccac cagaaccagt gctcgctatt cctctggcac acaggacatt cactgaacaa 1140tgccagggat acaagtgcca tggatactct accgctaaat ggtaatttta acaacagcta 1200ctcgctgcac aagggtgact ataatgacag cgtgcaagtt gtggactgtg gactaagtct 1260gaatgatact gcttttgaga aaatgatcat ttcagaatta gtgcacaaca acttacgggg 1320cagcagcaag actcacaacc tcgagctcac gctaccagtc aaacctgtga ttggaggtag 1380cagcagtgaa gatgatgcta ttgtggcaga tgcttcatct ttaatgcaca gcgacaaccc 1440agggctggag ctccatcaca aagaactcga ggcaccactt attcctcagc ggactcactc 1500ccttctgtac caaccccaga agaaagtgaa gtccgaggga actgacagct atgtctccca 1560actgacagca gaggctgaag atcacctaca gtcccccaac agagactctc tttatacaag 1620catgcccaat cttagagact ctccctatcc ggagagcagc cctgacatgg aagaagacct 1680ctctccctcc aggaggagtg agaatgagga catttactat aaaagcatgc caaatcttgg 1740agctggccat cagcttcaga tgtgctacca gatcagcagg ggcaatagtg atggttatat 1800aatccccatt aacaaagaag ggtgtattcc agaaggagat gttagagaag gacaaatgca 1860gctggttaca agtctttaat catacagcta aggaattcca agggccacat gcgagtatta 1920ataaataaag acaccattgg cctgacgcag ctccctcaaa ctctgcttga agagatgact 1980cttgacctgt ggttctctgg tgtaaaaaag atgactgaac cttgcagttc tgtgaatttt 2040tataaaacat acaaaaactt tgtatataca cagagtatac taaagtgaat tatttgttac 2100aaagaaaaga gatgccagcc aggtatttta agattctgct gctgtttaga gaaattgtga 2160aacaagcaaa acaaaacttt ccagccattt tactgcagca gtctgtgaac taaatttgta 2220aatatggctg caccattttt gtaggcctgc attgtattat atacaagacg taggctttaa 2280aatcctgtgg gacaaattta ctgtacctta ctattcctga caagacttgg aaaagcagga 2340gagatattct gcatcagttt gcagttcact gcaaatcttt tacattaagg caaagattga 2400aaacatgctt aaccactagc aatcaagcca caggccttat ttcatatgtt tcctcaactg 2460tacaatgaac tattctcatg aaaaatggct aaagaaatta tattttgttc tattgctagg 2520gtaaaataaa tacatttgtg tccaactgaa atataattgt cattaaaata attttaaaga 2580gtgaagaaaa tattgtgaaa agctcttggt tgcacatgtt atgaaatgtt ttttcttaca 2640ctttgtcatg gtaagttcta ctcattttca cttcttttcc actgtataca gtgttctgct 2700ttgacaaagt tagtctttat tacttacatt taaatttctt attgccaaaa gaacgtgttt 2760tatggggaga aacaaactct ttgaagccag ttatgtcatg ccttgcacaa aagtgatgaa 2820atctagaaaa gattgtgtgt cacccctgtt tattcttgaa cagagggcaa agagggcact 2880gggcacttct cacaaacttt ctagtgaaca aaaggtgcct attctttttt aaaaaaataa 2940aataaaacat aaatattact cttccatatt ccttctgcct atatttagta attaatttat 3000tttatgataa agttctaatg aaatgtaaat tgtttcagca aaattctgct tttttttcat 3060ccctttgtgt aaacctgtta ataatgagcc catcactaat atccagtgta aagtttaaca 3120cggtttgaca gtaaataaat gtgaattttt tcaaaaaaaa aaaaa 3165 17 25 DNA Artificial Sequence Description of Artificial Sequence primer 17gtgatccagc tacagttgtg ctcat 25 18 26 DNA Artificial Sequence Description of Artificial Sequence primer 18ctaatgcttc acagaatctc tctggc 26 19 5693 DNA Rattus rattus CDS (425)..(4822) 19gagctctgac gccgcccccg cccctccgcc tccacgcctc gctccccggg aggggcgcag 60acccgcgcgc ccggggccgg ggccgcctcc ggagcgccgc gatccgcctt ttctttcctt 120ttttttccct tcccttcttc ccttttaaat tttggttggt ggcggcagtg ctgggccgga 180ggaaagaagg gacacggagt cctccctcgc tcagccaccc cctccccgct tccccctggg 240ccgggctccg ggagatgtgc cgggcggggg gcccggcttc gcggagccgc gggaggagcg 300cgcacggccg accccgaagc gccgctggac aggctggtgg gccaggcctt ggtaccctgg 360tgatgcgggg caaggccccc cccacagtcc gctgagatca ccgtgcccgc ccctggcctt 420cgcc atg gcc cgc ttg gct gca gca ctc tgg agt ctc tgt gtg acg act 469 Met Ala Arg Leu Ala Ala Ala Leu Trp Ser Leu Cys Val Thr Thr 1 5 10 15gtc ctc gtc acc tct gct acc caa ggc ctg agc cgg gct gga ctc cca 517Val Leu Val Thr Ser Ala Thr Gln Gly Leu Ser Arg Ala Gly Leu Pro 20 25 30ttt gga ttg atg cgc cgg gag cta gca tgc gaa ggc tac ccc att gag 565Phe Gly Leu Met Arg Arg Glu Leu Ala Cys Glu Gly Tyr Pro Ile Glu 35 40 45ctg cgg tgc ccg ggc agt gac gtc atc atg gtg gag aat gca aac tat 613Leu Arg Cys Pro Gly Ser Asp Val Ile Met Val Glu Asn Ala Asn Tyr 50 55 60ggg cgc aca gat gac aag atc tgc gat gcc gac cct ttt cag atg gag 661Gly Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu 65 70 75aac gtg cag tgc tac ctg cct gac gcc ttc aaa atc atg tca cag aga 709Asn Val Gln Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Ser Gln Arg 80 85 90 95tgt aat aac cga acc cag tgt gtg gtg gtg gcc ggc tct gac gcc ttt 757Cys Asn Asn Arg Thr Gln Cys Val Val Val Ala Gly Ser Asp Ala Phe 100 105 110cct gac ccc tgt cct gga acc tac aag tac ctg gag gtg cag tac gac 805Pro Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Asp 115 120 125tgt gtc cct tac atc ttc gtg tgc cca ggg aca ctg cag aag gtg ctg 853Cys Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Gln Lys Val Leu 130 135 140gag ccc acc tcc aca cat gaa tcg gag cac cag tct ggc gca tgg tgc 901Glu Pro Thr Ser Thr His Glu Ser Glu His Gln Ser Gly Ala Trp Cys 145 150 155aag gac cca ctg cag gca ggt gac cgt atc tac gtt atg ccc tgg atc 949Lys Asp Pro Leu Gln Ala Gly Asp Arg Ile Tyr Val Met Pro Trp Ile160 165 170 175ccc tac cgc acg gac aca ctg acc gag tat gct tcc tgg gag gac t at 997Pro Tyr Arg Thr Asp Thr Leu Thr Glu Tyr Ala Ser Trp Glu Asp Tyr 180 185 190gtg gct gca cgc cac acc acc acg tac aga ctg ccc aac cgt gta gat 1045Val Ala Ala Arg His Thr Thr Thr Tyr Arg Leu Pro Asn Arg Val Asp 195 200 205ggc act ggc ttt gtg gta tat gat ggt gcc gtc ttc tat aac aag gaa 1093Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Tyr Asn Lys Glu 210 215 220cgt act cgc aac att gtc aaa tat gac ctg cgg acc cgc atc aag agc 1141Arg Thr Arg Asn Ile Val Lys Tyr Asp Leu Arg Thr Arg Ile Lys Ser 225 230 235gga gaa aca gtc ata aac aca gcc aac tac cac gac acc tca cct tat 1189Gly Glu Thr Val Ile Asn Thr Ala Asn Tyr His Asp Thr Ser Pro Tyr240 245 250 255cgc tgg gga ggc aaa acc gac att gac ctg gca gtg gat gag aac ggg 1237Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly 260 265 270ctg tgg gtc atc tat gcc acc gag ggg aac aac ggg cgt ctg gtg gtg 1285Leu Trp Val Ile Tyr Ala Thr Glu Gly Asn Asn Gly Arg Leu Val Val 275 280 285agc cag ctc aac ccc tac aca ctg cgt ttc gag ggc acc tgg gaa aca 1333Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Gly Thr Trp Glu Thr 290 295 300ggc tat gac aag cgc tca gcc tcc aat gcc ttc atg gtg tgt ggt gtc 1381Gly Tyr Asp Lys Arg Ser Ala Ser Asn Ala Phe Met Val Cys Gly Val 305 310 315ctc tat gtg ctg cgc tct gtt tat gtg gat gac gac agt gag gca gca 1429Leu Tyr Val Leu Arg Ser Val Tyr Val Asp Asp Asp Ser Glu Ala Ala320 325 330 335ggc aac cgc gtg gac tat gcc ttt aac acc aat gca aac cga gag gag 1477Gly Asn Arg Val Asp Tyr Ala Phe Asn Thr Asn Ala Asn Arg Glu Glu 340 345 350ccc gtc agt ctc gcc ttc ccc aac ccc tac cag ttt gta tct tct gtt 1525Pro Val Ser Leu Ala Phe Pro Asn Pro Tyr Gln Phe Val Ser Ser Val 355 360 365gac tac aat ccc cgg gac aac cag ctg tat gtg tgg aac aac tat ttc 1573Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Tyr Phe 370 375 380gtg gtg cgc tac agc ctg gag ttt gga ccc cca gat ccc agt gct ggc 1621Val Val Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ser Ala Gly 385 390 395cca gcc act tcc cca cct ctc agt acc acc acc aca gct cgg cct acg 1669Pro Ala Thr Ser Pro Pro Leu Ser Thr Thr Thr Thr Ala Arg Pro Thr400 405 410 415ccc ctc acc agc aca gcc tca cct gca gcc acc act cca ctc cgc cgg 1717Pro Leu Thr Ser Thr Ala Ser Pro Ala Ala Thr Thr Pro Leu Arg Arg 420 425 430gcg ccc ctc acc acg cac cca gta ggt gcc atc aac cag ctg gga cct 1765Ala Pro Leu Thr Thr His Pro Val Gly Ala Ile Asn Gln Leu Gly Pro 435 440 445gac ctg cct cca gcc aca gcc cca gca ccc agt acc cgg cgg cct cca 1813Asp Leu Pro Pro Ala Thr Ala Pro Ala Pro Ser Thr Arg Arg Pro Pro 450 455 460gcc ccc aat ctg cat gtg tcc cct gag ctc ttc tgt gaa ccc cga gag 1861Ala Pro Asn Leu His Val Ser Pro Glu Leu Phe Cys Glu Pro Arg Glu 465 470 475gtc cgg cgg gtc cag tgg cca gct acc cag cag ggt atg ctg gta gag 1909Val Arg Arg Val Gln Trp Pro Ala Thr Gln Gln Gly Met Leu Val Glu480 485 490 495aga cct tgc ccc aag gga act cga gga att gcc tcg ttc cag tgc ctc 1957Arg Pro Cys Pro Lys Gly Thr Arg Gly Ile Ala Ser Phe Gln Cys Leu 500 505 510cca gct ctg ggg ctc tgg aat cct cgg ggc cct gac ctc agc aac tgc 2005Pro Ala Leu Gly Leu Trp Asn Pro Arg Gly Pro Asp Leu Ser Asn Cys 515 520 525act tcc ccc tgg gtc aac caa gtc gcc cag aag atc aag agt gga gag 2053Thr Ser Pro Trp Val Asn Gln Val Ala Gln Lys Ile Lys Ser Gly Glu 530 535 540aat gca gcc aac att gct agt gag ctg gcc cgc cac acg cgg ggc tcc 2101Asn Ala Ala Asn Ile Ala Ser Glu Leu Ala Arg His Thr Arg Gly Ser 545 550 555atc tat gct ggg gac gtg tcc tca tcg gtg aag ctg atg gag caa ctg 2149Ile Tyr Ala Gly Asp Val Ser Ser Ser Val Lys Leu Met Glu Gln Leu560 565 570 575cta gat atc ctg gat gcc cag ctc cag gcc cta cgg ccc att gaa cga 2197Leu Asp Ile Leu Asp Ala Gln Leu Gln Ala Leu Arg Pro Ile Glu Arg 580 585 590gag tca gct ggc aag aac tac aat aag atg cac aag cga gag aga acc 2245Glu Ser Ala Gly Lys Asn Tyr Asn Lys Met His Lys Arg Glu Arg Thr 595 600 605tgc aag gac tat atc aag gct gtg gtg gag aca gtg gac aac ctg ctt 2293Cys Lys Asp Tyr Ile Lys Ala Val Val Glu Thr Val Asp Asn Leu Leu 610 615 620cgg cca gag gca ctt gag tca tgg aaa gac atg aat gcc acc gaa cag 2341Arg Pro Glu Ala Leu Glu Ser Trp Lys Asp Met Asn Ala Thr Glu Gln 625 630 635gtc cat acg gcc acc atg ctc cta gat gtc tta gag gag ggt gcc ttc 2389Val His Thr Ala Thr Met Leu Leu Asp Val Leu Glu Glu Gly Ala Phe640 645 650 655ctg ctg gcc gac aat gtc aga gaa cct gct cgc ttc ttg gct gcc aag 2437Leu Leu Ala Asp Asn Val Arg Glu Pro Ala Arg Phe Leu Ala Ala Lys 660 665 670cag aat gtg gtc ctg gag gtc act gtc ctg agc aca gag ggt caa gtg 2485Gln Asn Val Val Leu Glu Val Thr Val Leu Ser Thr Glu Gly Gln Val 675 680 685cag gag ttg gtg ttc ccc cag gag tat gcc agt gag agc tcc att cag 2533Gln Glu Leu Val Phe Pro Gln Glu Tyr Ala Ser Glu Ser Ser Ile Gln 690 695 700ctg tcc gcc aac acc atc aag cag aac agc cgc aat ggt gtg gtg aag 2581Leu Ser Ala Asn Thr Ile Lys Gln Asn Ser Arg Asn Gly Val Val Lys 705 710 715gtt gtc ttc att ctc tac aac aac ctg ggc ctc ttc ttg tcc acg gag 2629Val Val Phe Ile Leu Tyr Asn Asn Leu Gly Leu Phe Leu Ser Thr Glu720 725 730 735aat gcc aca gtg aag ctg gca ggt gag gca ggg acc ggt ggc cct gga 2677Asn Ala Thr Val Lys Leu Ala Gly Glu Ala Gly Thr Gly Gly Pro Gly 740 745 750ggt gcc tcc ctg gtg gtt aac tca cag gtc atc gca gca tcc atc aat 2725Gly Ala Ser Leu Val Val Asn Ser Gln Val Ile Ala Ala Ser Ile Asn 755 760 765aag gag tcc agc cgt gtc ttc ctc atg gac cct gtc atc ttt act gtg 2773Lys Glu Ser Ser Arg Val Phe Leu Met Asp Pro Val Ile Phe Thr Val 770 775 780gcc cac ttg gag gcc aag aac cac ttc aat gca aac tgc tcc ttc tgg 2821Ala His Leu Glu Ala Lys Asn His Phe Asn Ala Asn Cys Ser Phe Trp 785 790 795aac tac tca gag cgc tcc atg ctg ggc tac tgg tca acc cag ggc tgc 2869Asn Tyr Ser Glu Arg Ser Met Leu Gly Tyr Trp Ser Thr Gln Gly Cys800 805 810 815cga ctg gtg gag tcc aat aag acc cat acc aca tgt gcc tgc agc cac 2917Arg Leu Val Glu Ser Asn Lys Thr His Thr Thr Cys Ala Cys Ser His 820 825 830ctc acc aac ttc gca gtg ctc atg gct cac cga gag atc tac caa ggc 2965Leu Thr Asn Phe Ala Val Leu Met Ala His Arg Glu Ile Tyr Gln Gly 835 840 845cgt att aat gag ctg ttg ctg tca gtc atc acc tgg gtt ggc att gtc 3013Arg Ile Asn Glu Leu Leu Leu Ser Val Ile Thr Trp Val Gly Ile Val 850 855 860atc tcc ctg gtc tgt ctg gct atc tgc atc tcc acc ttc tgc ttc ctg 3061Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Ser Thr Phe Cys Phe Leu 865 870 875cgg ggc ctg cag acc gac cgc aac acc atc cac aag aac ctg tgc atc 3109Arg Gly Leu Gln Thr Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile880 885 890 895aac ctc ttc ctt gca gag ctg ctc ttc ctg gtt gga ata gac aaa act 3157Asn Leu Phe Leu Ala Glu Leu Leu Phe Leu Val Gly Ile Asp Lys Thr 900 905 910cag tat gag gtc gcc tgc cct atc ttt gcg ggc ctg ctg cac tac ttc 3205Gln Tyr Glu Val Ala Cys Pro Ile Phe Ala Gly Leu Leu His Tyr Phe 915 920 925ttc ctg gcc gcc ttc tcc tgg ctg tgc cta gag ggc gtg cac ctc tac 3253Phe Leu Ala Ala Phe Ser Trp Leu Cys Leu Glu Gly Val His Leu Tyr 930 935 940ctc ctg ctg gtc gag gtg ttc gag agc gaa tat tca cgc acc aag tac 3301Leu Leu Leu Val Glu Val Phe Glu Ser Glu Tyr Ser Arg Thr Lys Tyr 945 950 955tat tac ctg ggc ggc tac tgc ttc cca gcc ctg gtg gta ggc atc gca 3349Tyr Tyr Leu Gly Gly Tyr Cys Phe Pro Ala Leu Val Val Gly Ile Ala960 965 970 975gcc gcc att gac tac cga agc tac ggc act gag aag gcc tgc tgg ctg 3397Ala Ala Ile Asp Tyr Arg Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu 980 985 990agg gtg gat aac tat ttc atc tgg agc ttc att ggg ccc gtc tcc ttt 3445Arg Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val Ser Phe 995 1000 1005gtt att gtg gtg aac ctg gtg ttc ctc atg gtg acc ctg cac aag atg 3493Val Ile Val Val Asn Leu Val Phe Leu Met Val Thr Leu His Lys Met 1010 1015 1020atc cga agc tca tcc gtg ctc aag cct gac tcc agc cgc ctt gac aac 3541Ile Arg Ser Ser Ser Val Leu Lys Pro Asp Ser Ser Arg Leu Asp Asn 1025 1030 1035atc aag tcc tgg gcg ctg ggt gcc att gca ctg ctc ttc ctg ctg ggc 3589Ile Lys Ser Trp Ala Leu Gly Ala Ile Ala Leu Leu Phe Leu Leu Gly1040 1045 1050 1055ctc acc tgg gct ttc ggc ctc ctc ttc atc aac aag gag tca gta gta 3637Leu Thr Trp Ala Phe Gly Leu Leu Phe Ile Asn Lys Glu Ser Val Val 1060 1065 1070atg gct tac ctc ttc aca acc ttc aac gcc ttc cag ggg gtc ttc atc 3685Met Ala Tyr Leu Phe Thr Thr Phe Asn Ala Phe Gln Gly Val Phe Ile 1075 1080 1085ttt gtc ttt cac tgc gcc tta cag aaa aag gtg cac aag gag tac agc 3733Phe Val Phe His Cys Ala Leu Gln Lys Lys Val His Lys Glu Tyr Ser 1090 1095 1100aag tgc ctg cgt cac tcc tac tgc tgc att cgc tcc cca cct ggg ggg 3781Lys Cys Leu Arg His Ser Tyr Cys Cys Ile Arg Ser Pro Pro Gly Gly 1105 1110 1115gct cac ggc tcc ctt aag acc tca gcc atg cga agt aac acc cgc tac 3829Ala His Gly Ser Leu Lys Thr Ser Ala Met Arg Ser Asn Thr Arg Tyr1120 1125 1130 1135tac aca ggg acc cag agc cga atc cgg agg atg tgg aat gac acc gtg 3877Tyr Thr Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val 1140 1145 1150agg aag cag aca gag tcg tcc ttt atg gca ggg gac atc aac agc acc 3925Arg Lys Gln Thr Glu Ser Ser Phe Met Ala Gly Asp Ile Asn Ser Thr 1155 1160 1165ccc acc ctg aac cga ggt acc atg ggg aac cac cta ctg acc aac cct 3973Pro Thr Leu Asn Arg Gly Thr Met Gly Asn His Leu Leu Thr Asn Pro 1170 1175 1180gtg cta cag ccc cgt ggg ggc act agc cca tac aat aca ctc att gca 4021Val Leu Gln Pro Arg Gly Gly Thr Ser Pro Tyr Asn Thr Leu Ile Ala 1185 1190 1195gag tct gtg ggc ttc aat ccc tcc tcg ccc cca gtc ttc aac tcc cca 4069Glu Ser Val Gly Phe Asn Pro Ser Ser Pro Pro Val Phe Asn Ser Pro1200 1205 1210 1215gga agc tac agg gaa cct aag cac ccc ttg ggc ggc cgg gaa gcc tgt 4117Gly Ser Tyr Arg Glu Pro Lys His Pro Leu Gly Gly Arg Glu Ala Cys 1220 1225 1230ggc atg gac aca ctg ccc ctt aat ggc aac ttc aac aac agc tac tcc 4165Gly Met Asp Thr Leu Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser 1235 1240 1245ttg cga agt ggt gat ttc cct ccg ggg gat ggg ggt cct gag cca ccc 4213Leu Arg Ser Gly Asp Phe Pro Pro Gly Asp Gly Gly Pro Glu Pro Pro 1250 1255 1260cga ggc cga aac cta gcg gat gct gcg gcc ttt gag aag atg atc atc 4261Arg Gly Arg Asn Leu Ala Asp Ala Ala Ala Phe Glu Lys Met Ile Ile 1265 1270 1275tca gag ctg gtg cac aac aac ctt cgg ggg gcc agt ggg ggc gcc aaa 4309Ser Glu Leu Val His Asn Asn Leu Arg Gly Ala Ser Gly Gly Ala Lys1280 1285 1290 1295ggt cct cca cca gag cct cct gtg cca ccc gtg cca gga gtc agt gag 4357Gly Pro Pro Pro Glu Pro Pro Val Pro Pro Val Pro Gly Val Ser Glu 1300 1305 1310gac gag gct ggt ggg cct ggg ggt gct gac cgg gct gag att gaa ctt 4405Asp Glu Ala Gly Gly Pro Gly Gly Ala Asp Arg Ala Glu Ile Glu Leu 1315 1320 1325ctc tac aag gcc ctg gag gag cca ctg ctg ctg ccc cgg gcc cag tcg 4453Leu Tyr Lys Ala Leu Glu Glu Pro Leu Leu Leu Pro Arg Ala Gln Ser 1330 1335 1340gtg ctg tac cag agt gat ctg gat gag tcg gag agc tgt acg gca gag 4501Val Leu Tyr Gln Ser Asp Leu Asp Glu Ser Glu Ser Cys Thr Ala Glu 1345 1350 1355gat ggg gcc acc agc cgg ccc ctc tcc tcc cct ccc ggc cgg gac tcc 4549Asp Gly Ala Thr Ser Arg Pro Leu Ser Ser Pro Pro Gly Arg Asp Ser1360 1365 1370 1375ctc tat gcc agc ggg gcc aac ctg cgg gac tcg ccc tcc tac ccg gac 4597Leu Tyr Ala Ser Gly Ala Asn Leu Arg Asp Ser Pro Ser Tyr Pro Asp 1380 1385 1390agc agc ccc gaa ggg cct aat gag gcc ctg ccc cct ccc cca cct gct 4645Ser Ser Pro Glu Gly Pro Asn Glu Ala Leu Pro Pro Pro Pro Pro Ala 1395 1400 1405ccc cct ggg ccc cca gaa atc tac tac acc tct cgc ccg ccg gcc ctg 4693Pro Pro Gly Pro Pro Glu Ile Tyr Tyr Thr Ser Arg Pro Pro Ala Leu 1410 1415 1420gtg gct cgg aat ccc cta cag ggc tac tac cag gtg cgg cgg ccc agc 4741Val Ala Arg Asn Pro Leu Gln Gly Tyr Tyr Gln Val Arg Arg Pro Ser 1425 1430 1435cat gag ggc tac ctg gca gcc ccc agc ctt gag ggg cca ggg ccc gat 4789His Glu Gly Tyr Leu Ala Ala Pro Ser Leu Glu Gly Pro Gly Pro Asp1440 1445 1450 1455ggg gat ggg caa atg cag ttg gtc act agt ctc tgaggggcct catggaccag 4842Gly Asp Gly Gln Met Gln Leu Val Thr Ser Leu 1460 1465aggcctggcc agggagggaa tccaggaggg gctctggtgg gagcagagac tgatggaggc 4902agtggctggt gggccactct ctccaggtgc ccctctgcct gtgggcccca cagtcccctt 4962ggggactatg acctgggccc caggtgccag ggttagtaga cagggtttcc accagccaca 5022agccccagct tctttagggg agtgcattga ggagaagccc ccagggccct aggagtgagg 5082gagaagctgg taggtgtgac caacgtccaa agctccctcc ctttggaggg agaaagcaag 5142ggataaggct tccctaggtg tacaggggtg gccacttttg aggtggccga agccttgcag 5202gatacaccct atctgctgct catcttcttc gtccaccaga aaggagcagt gggacagatg 5262gacaggtcct tccatgctac agttccttgc ttcttggaga ctgggcctaa catcctgaga 5322gagcccaggc ccaggggatg gatggggttg tgagggctgg tggttaatgg tggaactttc 5382tctgaagctc ctttctccct tgctattggt ccctatctcc cgagcaagcc taccctaaac 5442ccccagagtg cacccaatga ccccctccct tggggtgact cctgatgaag cacaactccc 5502cgcagggccc caacccactg cagtggccat atttgggcag ttcccagtcc tgtgggctgg 5562gctatctggg gagcagatgt ggggtctggg gctccctgag gagtgggtcc tgggtttgga 5622tctttcccta gggggtcctc ttacccttct cttcctcccc tattgctgta aatatttcaa 5682caaaatggaa a 5693 20 1466 PRT Rattus rattus 20Met Ala Arg Leu Ala Ala Ala Leu Trp Ser Leu Cys Val Thr Thr Val 1 5 10 15Leu Val Thr Ser Ala Thr Gln Gly Leu Ser Arg Ala Gly Leu Pro Phe 20 25 30Gly Leu Met Arg Arg Glu Leu Ala Cys Glu Gly Tyr Pro Ile Glu Leu 35 40 45Arg Cys Pro Gly Ser Asp Val Ile Met Val Glu Asn Ala Asn Tyr Gly 50 55 60Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn 65 70 75 80Val Gln Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Ser Gln Arg Cys 85 90 95Asn Asn Arg Thr Gln Cys Val Val Val Ala Gly Ser Asp Ala Phe Pro 100 105 110Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Asp Cys 115 120 125Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Gln Lys Val Leu Glu 130 135 140Pro Thr Ser Thr His Glu Ser Glu His Gln Ser Gly Ala Trp Cys Lys145 150 155 160Asp Pro Leu Gln Ala Gly Asp Arg Ile Tyr Val Met Pro Trp Ile Pro 165 170 175Tyr Arg Thr Asp Thr Leu Thr Glu Tyr Ala Ser Trp Glu Asp Tyr Val 180 185 190Ala Ala Arg His Thr Thr Thr Tyr Arg Leu Pro Asn Arg Val Asp Gly 195 200 205Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Tyr Asn Lys Glu Arg 210 215 220Thr Arg Asn Ile Val Lys Tyr Asp Leu Arg Thr Arg Ile Lys Ser Gly225 230 235 240Glu Thr Val Ile Asn Thr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg 245 250 255Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu 260 265 270Trp Val Ile Tyr Ala Thr Glu Gly Asn Asn Gly Arg Leu Val Val Ser 275 280 285Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Gly Thr Trp Glu Thr Gly 290 295 300Tyr Asp Lys Arg Ser Ala Ser Asn Ala Phe Met Val Cys Gly Val Leu305 310 315 320Tyr Val Leu Arg Ser Val Tyr Val Asp Asp Asp Ser Glu Ala Ala Gly 325 330 335Asn Arg Val Asp Tyr Ala Phe Asn Thr Asn Ala Asn Arg Glu Glu Pro 340 345 350Val Ser Leu Ala Phe Pro Asn Pro Tyr Gln Phe Val Ser Ser Val Asp 355 360 365Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Tyr Phe Val 370 375 380Val Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ser Ala Gly Pro385 390 395 400Ala Thr Ser Pro Pro Leu Ser Thr Thr Thr Thr Ala Arg Pro Thr Pro 405 410 415Leu Thr Ser Thr Ala Ser Pro Ala Ala Thr Thr Pro Leu Arg Arg Ala 420 425 430Pro Leu Thr Thr His Pro Val Gly Ala Ile Asn Gln Leu Gly Pro Asp 435 440 445Leu Pro Pro Ala Thr Ala Pro Ala Pro Ser Thr Arg Arg Pro Pro Ala 450 455 460Pro Asn Leu His Val Ser Pro Glu Leu Phe Cys Glu Pro Arg Glu Val465 470 475 480Arg Arg Val Gln Trp Pro Ala Thr Gln Gln Gly Met Leu Val Glu Arg 485 490 495Pro Cys Pro Lys Gly Thr Arg Gly Ile Ala Ser Phe Gln Cys Leu Pro 500 505 510Ala Leu Gly Leu Trp Asn Pro Arg Gly Pro Asp Leu Ser Asn Cys Thr 515 520 525Ser Pro Trp Val Asn Gln Val Ala Gln Lys Ile Lys Ser Gly Glu Asn 530 535 540Ala Ala Asn Ile Ala Ser Glu Leu Ala Arg His Thr Arg Gly Ser Ile545 550 555 560Tyr Ala Gly Asp Val Ser Ser Ser Val Lys Leu Met Glu Gln Leu Leu 565 570 575Asp Ile Leu Asp Ala Gln Leu Gln Ala Leu Arg Pro Ile Glu Arg Glu 580 585 590Ser Ala Gly Lys Asn Tyr Asn Lys Met His Lys Arg Glu Arg Thr Cys 595 600 605Lys Asp Tyr Ile Lys Ala Val Val Glu Thr Val Asp Asn Leu Leu Arg 610 615 620Pro Glu Ala Leu Glu Ser Trp Lys Asp Met Asn Ala Thr Glu Gln Val625 630 635 640His Thr Ala Thr Met Leu Leu Asp Val Leu Glu Glu Gly Ala Phe Leu 645 650 655Leu Ala Asp Asn Val Arg Glu Pro Ala Arg Phe Leu Ala Ala Lys Gln 660 665 670Asn Val Val Leu Glu Val Thr Val Leu Ser Thr Glu Gly Gln Val Gln 675 680 685Glu Leu Val Phe Pro Gln Glu Tyr Ala Ser Glu Ser Ser Ile Gln Leu 690 695 700Ser Ala Asn Thr Ile Lys Gln Asn Ser Arg Asn Gly Val Val Lys Val705 710 715 720Val Phe Ile Leu Tyr Asn Asn Leu Gly Leu Phe Leu Ser Thr Glu Asn 725 730 735Ala Thr Val Lys Leu Ala Gly Glu Ala Gly Thr Gly Gly Pro Gly Gly 740 745 750Ala Ser Leu Val Val Asn Ser Gln Val Ile Ala Ala Ser Ile Asn Lys 755 760 765Glu Ser Ser Arg Val Phe Leu Met Asp Pro Val Ile Phe Thr Val Ala 770 775 780His Leu Glu Ala Lys Asn His Phe Asn Ala Asn Cys Ser Phe Trp Asn785 790 795 800Tyr Ser Glu Arg Ser Met Leu Gly Tyr Trp Ser Thr Gln Gly Cys Arg 805 810 815Leu Val Glu Ser Asn Lys Thr His Thr Thr Cys Ala Cys Ser His Leu 820 825 830Thr Asn Phe Ala Val Leu Met Ala His Arg Glu Ile Tyr Gln Gly Arg 835 840 845Ile Asn Glu Leu Leu Leu Ser Val Ile Thr Trp Val Gly Ile Val Ile 850 855 860Ser Leu Val Cys Leu Ala Ile Cys Ile Ser Thr Phe Cys Phe Leu Arg865 870 875 880Gly Leu Gln Thr Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn 885 890 895Leu Phe Leu Ala Glu Leu Leu Phe Leu Val Gly Ile Asp Lys Thr Gln 900 905 910Tyr Glu Val Ala Cys Pro Ile Phe Ala Gly Leu Leu His Tyr Phe Phe 915 920 925Leu Ala Ala Phe Ser Trp Leu Cys Leu Glu Gly Val His Leu Tyr Leu 930 935 940Leu Leu Val Glu Val Phe Glu Ser Glu Tyr Ser Arg Thr Lys Tyr Tyr945 950 955 960Tyr Leu Gly Gly Tyr Cys Phe Pro Ala Leu Val Val Gly Ile Ala Ala 965 970 975Ala Ile Asp Tyr Arg Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu Arg 980 985 990Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val Ser Phe Val 995 1000 1005Ile Val Val Asn Leu Val Phe Leu Met Val Thr Leu His Lys Met Ile 1010 1015 1020Arg Ser Ser Ser Val Leu Lys Pro Asp Ser Ser Arg Leu Asp Asn Ile1025 1030 1035 1104Lys Ser Trp Ala Leu Gly Ala Ile Ala Leu Leu Phe Leu Leu Gly Leu 1045 1050 1055Thr Trp Ala Phe Gly Leu Leu Phe Ile Asn Lys Glu Ser Val Val Met 1060 1065 1070Ala Tyr Leu Phe Thr Thr Phe Asn Ala Phe Gln Gly Val Phe Ile Phe 1075 1080 1085Val Phe His Cys Ala Leu Gln Lys Lys Val His Lys Glu Tyr Ser Lys 1090 1095 1100Cys Leu Arg His Ser Tyr Cys Cys Ile Arg Ser Pro Pro Gly Gly Ala1105 1110 1115 1112His Gly Ser Leu Lys Thr Ser Ala Met Arg Ser Asn Thr Arg Tyr Tyr 1125 1130 1135Thr Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg 1140 1145 1150Lys Gln Thr Glu Ser Ser Phe Met Ala Gly Asp Ile Asn Ser Thr Pro 1155 1160 1165Thr Leu Asn Arg Gly Thr Met Gly Asn His Leu Leu Thr Asn Pro Val 1170 1175 1180Leu Gln Pro Arg Gly Gly Thr Ser Pro Tyr Asn Thr Leu Ile Ala Glu1185 1190 1195 1120Ser Val Gly Phe Asn Pro Ser Ser Pro Pro Val Phe Asn Ser Pro Gly 1205 1210 1215Ser Tyr Arg Glu Pro Lys His Pro Leu Gly Gly Arg Glu Ala Cys Gly 1220 1225 1230Met Asp Thr Leu Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser Leu 1235 1240 1245Arg Ser Gly Asp Phe Pro Pro Gly Asp Gly Gly Pro Glu Pro Pro Arg 1250 1255 1260Gly Arg Asn Leu Ala Asp Ala Ala Ala Phe Glu Lys Met Ile Ile Ser1265 1270 1275 1128Glu Leu Val His Asn Asn Leu Arg Gly Ala Ser Gly Gly Ala Lys Gly 1285 1290 1295Pro Pro Pro Glu Pro Pro Val Pro Pro Val Pro Gly Val Ser Glu Asp 1300 1305 1310Glu Ala Gly Gly Pro Gly Gly Ala Asp Arg Ala Glu Ile Glu Leu Leu 1315 1320 1325Tyr Lys Ala Leu Glu Glu Pro Leu Leu Leu Pro Arg Ala Gln Ser Val 1330 1335 1340Leu Tyr Gln Ser Asp Leu Asp Glu Ser Glu Ser Cys Thr Ala Glu Asp1345 1350 1355 1136Gly Ala Thr Ser Arg Pro Leu Ser Ser Pro Pro Gly Arg Asp Ser Leu 1365 1370 1375Tyr Ala Ser Gly Ala Asn Leu Arg Asp Ser Pro Ser Tyr Pro Asp Ser 1380 1385 1390Ser Pro Glu Gly Pro Asn Glu Ala Leu Pro Pro Pro Pro Pro Ala Pro 1395 1400 1405Pro Gly Pro Pro Glu Ile Tyr Tyr Thr Ser Arg Pro Pro Ala Leu Val 1410 1415 1420Ala Arg Asn Pro Leu Gln Gly Tyr Tyr Gln Val Arg Arg Pro Ser His1425 1430 1435 1144Glu Gly Tyr Leu Ala Ala Pro Ser Leu Glu Gly Pro Gly Pro Asp Gly 1445 1450 1455Asp Gly Gln Met Gln Leu Val Thr Ser Leu 1460 1465 21 829 DNA Homo sapiens 21agtggttgga gtttcagctg ctattgacta taagagctat ggaacagaaa aagcttgctg 60gcttcatgtt gataactact ttatatggag cttcattgga cctgttacct tcattattct 120gctaaatatt atcttcttgg tgatcacatt gtgcaaaatg gtgaagcatt caaacacttt 180gaaaccagat tctagcaggt tggaaaacat taagtcttgg gtgcttggcg ctttcgctct 240tctgtgtctt cttggcctca cctggtcctt tgggttgctt tttattaatg aggagactat 300tgtgatggca tatctcttca ctatatttaa tgctttccag ggagtgttca ttttcatctt 360tcactgtgct ctccaaaaga aagtacgaaa agaatatggc aagtgcttca gacactcata 420ctgctgtgga ggcctcccaa ctgagagtcc ccacagttca gtgaaggcat caaccaccag 480aaccagtgct cgctattcct ctggcacaca gagtcgtata agaagaatgt ggaatgatac 540tgtgagaaaa caatcagaat cttcttttat ctcaggtgac atcaatagca cttcaacact 600taatcaagga cattcactga acaatgccag ggatacaagt gccatggata ctctaccgct 660aaatggtaat tttaacaaca gctactcgct gcacaagggt gactataatg acagcgtgca 720agttgtggac tgtggactaa gtctgaatga tactgctttt gagaaaatga tcatttcaga 780attagtgcac aacaacttac ggggcagcag caagactcac aacctcgag 829 22 429 DNA Homo sapiens 22ggggactggt gcccccacgc gtgtcagcac ggggttggtc agcaggtggt tccccatggt 60acctcggttc agggtggggg tgctgttgat gtcacccgcc atgaaggagg actccgtctg 120tttcctcaca gtgtcattcc acatcctccg aattcggctc tgggtccctg tgtagtagcg 180ggtgttgctt cgcatggctg aggtcttgag ggatccgtga gtgcccccgg gtgggatgcg 240gatgcagcag taggagtgac gcaggcactt gctgtactcc ttgtgcacct tcttctgtaa 300ggcgcagtga aagacgaaga tgaagacccc ctggaaggcg ttgaaggtgg tgaagagata 360ggccatgacc accgactcct tgttgatgaa gaggaggccg aaagcccagg tgaggcccag 420caggaacag 429 23 280 DNA Homo sapiens 23ctgagtcttg tcgatcccga ccaggaagag cagctcagcc aggaagaggt tgatgcacag 60gttcttgtgg atggtgttgc ggtcggtctg cagcccccgc agaagcagaa ggtggagatg 120cagatggcca agcagaccag ggagatcaca atgcccaccc aggtgatgac cgacagcagc 180agctcgttga tgcggccctg gtagatctca cggtgagcca tgagcacagc gaagttggtg 240aggtggctgc aggcacacgt ggtatgggtc ttgttggact 280 24 24 DNA Artificial Sequence Description of Artificial Sequence primer 24tcttcagctg agctcttcaa aacc 24 25 24 DNA Artificial Sequence Description of Artificial Sequence primer 25ggttttgaag agctcagctg aaga 24 26 51 DNA Artificial Sequence Description of Artificial Sequence primer 26cagcagggat ccaccatggt gtcttctggt tgcagaatgc gaagtctgtg g 51 27 55 DNA Artificial Sequence Description of Artificial Sequence primer 27gacgatgacg cggccgccta ttaaagactt gtaaccagct gcatttgtcc ttctc 55 28 27 DNA Artificial Sequence Description of Artificial Sequence primer 28tacaaccatg ggcacaactg tagctgg 27 29 34 DNA Artificial Sequence Description of Artificial Sequence primer 29tacaagatct agcagatagc caggcaaaca aggg 34 30 439 DNA Homo sapiens 30aaaagcagta tcattcagac ttagtccaca gtccacaact tgcacgctgt cattatagtc 60acccttgtgc agcgagtagt gtntgttaaa attaccattt agcggtagag tatccatggc 120acttgtatcc ctgggcattg ttcagtgaat gtccttgatt aagtgttgaa gtgctattga 180tgtcacctga gataaaagaa gattctgatt gttttctcac agtatcattc cacattcttc 240ttatacggac tctgtgtgcc agagggaata gcgagcactg ggttctgggt gggttgatgc 300cttcactgaa ctgtgggggg actctcaggt tggggagggc ctncacaggc agtatggagg 360tgtcttgaag gcactttgcc ataattcttt ttcgtacctt tccttttggg agagcacagt 420gaaagntgga aaattgacc 439 31 27 DNA Artificial Sequence Description of Artificial Sequence primer 31tacaaccatg ggcacaactg tagctgg 27 32 34 DNA Artificial Sequence Description of Artificial Sequence primer 32tacaagatct agcagatagc caggcaaaca aggg 34 33 5598 DNA Homo sapiens CDS (407)..(3748) 33cggcgaacag acgttctttc tcctccatgc agttacacaa aaggagggct acggaaacta 60aaagtttcgg ggcctctggc tcggtgtgtg gagaaaagag aaaacctgga gacgggatat 120gaagatcaat gatgcagact gatggtcttg atgaagctgg gcatttataa ctagattcat 180taaggaatac aaagaaaata cttaaaggga tcaataatgg tgtcttctgg ttgcagaatg 240cgaagtctgt ggtttatcat tgtaatcagc ttcttaccaa atacagaagg tttcagcaga 300gcagctttac catttgggct ggtgaggcga gaattatcct gtgaaggtta ttctatagat 360ctgcgatgcc cgggcagtga tgtcatcatg attgagagcg ctaact atg gtc gga 415 Met Val Gly 1cgg atg aca aga ttt gtg atg ctg acc cat ttc aga tgg gag aat aca 463Arg Met Thr Arg Phe Val Met Leu Thr His Phe Arg Trp Glu Asn Thr 5 10 15gac tgc tac ctc ccc gat gcc ttc aaa att atg act caa agg tgc aac 511Asp Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Thr Gln Arg Cys Asn 20 25 30 35aat cga aca cag tgt ata gta gtt act ggg tca gat gtg ttt cct gat 559Asn Arg Thr Gln Cys Ile Val Val Thr Gly Ser Asp Val Phe Pro Asp 40 45 50cca tgt cct gga aca tac aaa tac ctt gaa gtc caa tat gaa tgt gtc 607Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Glu Cys Val 55 60 65cct tac att ttt gtg tgt cct ggg acc ttg aaa gca att gtg gac tca 655Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Lys Ala Ile Val Asp Ser 70 75 80cca tgt ata tat gaa gct gaa caa aag gcg ggt gct tgg tgc aag gac 703Pro Cys Ile Tyr Glu Ala Glu Gln Lys Ala Gly Ala Trp Cys Lys Asp 85 90 95cct ctt cag gct gca gat aaa att tat ttc atg ccc tgg act ccc tat 751Pro Leu Gln Ala Ala Asp Lys Ile Tyr Phe Met Pro Trp Thr Pro Tyr100 105 110 115cgt acc gat act tta ata gaa tat gct tct tta gaa gat ttc caa aat 799Arg Thr Asp Thr Leu Ile Glu Tyr Ala Ser Leu Glu Asp Phe Gln Asn 120 125 130agt cgc caa aca aca aca tat aaa ctt cca aat cga gta gat ggt act 847Ser Arg Gln Thr Thr Thr Tyr Lys Leu Pro Asn Arg Val Asp Gly Thr 135 140 145gga ttt gtg gtg tat gat ggt gct gtc ttc ttt aac aaa gaa aga acg 895Gly Phe Val Val Tyr Asp Gly Ala Val Phe Phe Asn Lys Glu Arg Thr 150 155 160agg aat att gtg aaa ttt gac ttg agg act aga att aag agt ggc gag 943Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu 165 170 175gcc ata att aac tat gcc aac tac cat gat acc tca cca tac aga tgg 991Ala Ile Ile Asn Tyr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp180 185 190 195gga gga aag act gat atc gac cta gca gtt gat gaa aat ggt tta tgg 1039Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu Trp 200 205 210gtc att tac gcc act gaa cag aac aat gga atg ata gtt att agc cag 1087Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Met Ile Val Ile Ser Gln 215 220 225ctg aat cca tac act ctt cga ttt gaa gca acg tgg gag act gta tac 1135Leu Asn Pro Tyr Thr Leu Arg Phe Glu Ala Thr Trp Glu Thr Val Tyr 230 235 240gac aaa cgt gcc gca tca aat gct ttt atg ata tgc gga gtc ctc tat 1183Asp Lys Arg Ala Ala Ser Asn Ala Phe Met Ile Cys Gly Val Leu Tyr 245 250 255gtg gtt agg tca gtt tat caa gac aat gaa agt gaa aca ggc aag aac 1231Val Val Arg Ser Val Tyr Gln Asp Asn Glu Ser Glu Thr Gly Lys Asn260 265 270 275tca att gat tac att tat aat acc cga tta aac cga gga gaa tat gta 1279Ser Ile Asp Tyr Ile Tyr Asn Thr Arg Leu Asn Arg Gly Glu Tyr Val 280 285 290gac gtt ccc ttc ccc aac cag tat cag tat att gct gca gtg gat tac 1327Asp Val Pro Phe Pro Asn Gln Tyr Gln Tyr Ile Ala Ala Val Asp Tyr 295 300 305aat cca aga gat aac caa ctt tac gtg tgg aac aat aac ttc att tta 1375Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Asn Phe Ile Leu 310 315 320cga tat tct ctg gag ttt ggt cca cct gat cct gcc caa gtg cct acc 1423Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ala Gln Val Pro Thr 325 330 335aca gct gtg aca ata act tct tca gct gag ctg ttc aaa acc ata ata 1471Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu Phe Lys Thr Ile Ile340 345 350 355tca acc aca agc act act tca cag aaa ggc ccc atg agc aca act gta 1519Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro Met Ser Thr Thr Val 360 365 370gct gga tca cag gaa gga agc aaa ggg aca aaa cca cct cca gca gtt 1567Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro Ala Val 375 380 385tct aca acc aaa att cca cct ata aca aat att ttt ccc ctg cca gag 1615Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu Pro Glu 390 395 400aga ttc tgt gaa gca tta gac tcc aag ggg ata aag tgg cct cag aca 1663Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro Gln Thr 405 410 415caa agg gga atg atg gtt gaa cga cca tgc cct aag gga aca aga gga 1711Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro Lys Gly Thr Arg Gly420 425 430 435act gcc tca tat ctc tgc atg att tcc act gga aca tgg aac cct aag 1759Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly Thr Trp Asn Pro Lys 440 445 450ggc ccc gat ctt agc aac tgt acc tca cac tgg gtg aat cag ctg gct 1807Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp Val Asn Gln Leu Ala 455 460 465cag aag atc aga agc gga gaa aat gct gct agt ctt gcc aat gaa ctg 1855Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn Glu Leu 470 475 480gct aaa cat acc aaa ggg cca gtg ttt gct ggg gat gta agt tct tca 1903Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly Asp Val Ser Ser Ser 485 490 495gtg aga ttg atg gag cag ttg gtg gac atc ctt gat gca cag ctg cag 1951Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu Asp Ala Gln Leu Gln500 505 510 515gaa ctg aaa cct agt gaa aaa gat tca gct gga cgg agt tat aac aag 1999Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr Asn Lys 520 525 530gca att gtt gac aca gtg gac aac ctt ctg aga cct gaa gct ttg gaa 2047Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu 535 540 545tca tgg aaa cat atg aat tct tct gaa caa gca cat act gca aca atg 2095Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala His Thr Ala Thr Met 550 555 560tta ctc gat aca ttg gaa gaa gga gct ttt gtc cta gct gac aat ctt 2143Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val Leu Ala Asp Asn Leu 565 570 575tta gaa cca aca agg gtc tca atg ccc aca gaa aat att gtc ctg gaa 2191Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu Asn Ile Val Leu Glu580 585 590 595gtt gcc gta ctc agt aca gaa gga cag atc caa gac ttt aaa ttt cct 2239Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln Asp Phe Lys Phe Pro 600 605 610ctg ggc atc aaa gga gca ggc agc tca atc caa ctg tcc gca aat acc 2287Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln Leu Ser Ala Asn Thr 615 620 625gtc aaa cag aac agc agg aat ggg ctt gca aag ttg gtg ttc atc att 2335Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys Leu Val Phe Ile Ile 630 635 640tac cgg agc ctg gga cag ttc ctt agt aca gaa aat gca acc att aaa 2383Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu Asn Ala Thr Ile Lys 645 650 655ctg ggt gct gat ttt att ggt cgt aat agc acc att gca gtg aac tct 2431Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr Ile Ala Val Asn Ser660 665 670 675cac gtc att tca gtt tca atc aat aaa gag tcc agc cga gta tac ctg 2479His Val Ile Ser Val Ser Ile Asn Lys Glu Ser Ser Arg Val Tyr Leu 680 685 690act gat cct gtg ctt ttt acc ctg cca cac att gat cct gac aat tat 2527Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile Asp Pro Asp Asn Tyr 695 700 705ttc aat gca aac tgc tcc ttc tgg aac tac tca gag aga act atg atg 2575Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg Thr Met Met 710 715 720gga tat tgg tct acc cag ggc tgc aag ctg gtt gac act aat aaa act 2623Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val Asp Thr Asn Lys Thr 725 730 735cga aca acg tgt gca tgc agc cac cta acc aat ttt gca att ctc atg 2671Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn Phe Ala Ile Leu Met740 745 750 755gcc cac agg gaa att gca tat aaa gat ggc gtt cat gaa tta ctt ctt 2719Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val His Glu Leu Leu Leu 760 765 770aca gtc atc acc tgg gtg gga att gtc att tcc ctt gtt tgc ctg gct 2767Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser Leu Val Cys Leu Ala 775 780 785atc tgc atc ttc acc ttc tgc ttt ttc cgt ggc cta cag agt gac cga 2815Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp Arg 790 795 800aat act att cac aag aac ctt tgt atc aac ctt ttc att gct gaa ttt 2863Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu Phe Ile Ala Glu Phe 805 810 815att ttc cta ata ggc att gat aag aca aaa tat gcg att gca tgc cca 2911Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr Ala Ile Ala Cys Pro820 825 830 835ata ttt gca gga ctt cta cac ttt ttc ttt ttg gca gct ttt gct tgg 2959Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu Ala Ala Phe Ala Trp 840 845 850atg tgc cta gaa ggt gtg cag ctc tac cta atg tta gtt gaa gtt ttt 3007Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met Leu Val Glu Val Phe 855 860 865gaa agt gaa tat tca agg aaa aaa tat tac tat gtt gct ggt tac ttg 3055Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr Val Ala Gly Tyr Leu 870 875 880ttt cct gcc aca gtg gtt gga gtt tca gct gct att gac tat aag agc 3103Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala Ile Asp Tyr Lys Ser 885 890 895tat gga aca gaa aaa gct tgc tgg ctt cat gtt gat aac tac ttt ata 3151Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val Asp Asn Tyr Phe Ile900 905 910 915tgg agc ttc att gga cct gtt acc ttc att att ctg cta aat att atc 3199Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile Leu Leu Asn Ile Ile 920 925 930ttc ttg gtg atc aca ttg tgc aaa atg gtg aag cat tca aac act ttg 3247Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys His Ser Asn Thr Leu 935 940 945aaa cca gat tct agc agg ttg gaa aac att aag tct tgg gtg ctt ggc 3295Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys Ser Trp Val Leu Gly 950 955 960gct ttc gct ctt ctg tgt ctt ctt ggc ctc acc tgg tcc ttt ggg ttg 3343Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ser Phe Gly Leu 965 970 975ctt ttt att aat gag gag act att gtg atg gca tat ctc ttc act ata 3391Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala Tyr Leu Phe Thr Ile980 985 990 995ttt aat gct ttc cag gga gtg ttc att ttc atc ttt cac tgt gct ctc 3439Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile Phe His Cys Ala Leu 1000 1005 1010caa aag aaa gta cga aaa gaa tat ggc aag tgc ttc aga cac tca tac 3487Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Phe Arg His Ser Tyr 1015 1020 1025tgc tgt gga ggc ctc cca act gag agt ccc cac agt tca gtg aag gca 3535Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His Ser Ser Val Lys Ala 1030 1035 1040tca acc acc aga acc agt gct cgc tat tcc tct ggc aca cag agt cgt 3583Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser Gly Thr Gln Ser Arg 1045 1050 1055ata aga aga atg tgg aat gat act gtg aga aaa caa tca gaa tct tct 3631Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser Glu Ser Ser1060 1065 1070 1075ttt atc tca ggt gac atc aat agc act tca aca ctt aat caa gga ctg 3679Phe Ile Ser Gly Asp Ile Asn Ser Thr Ser Thr Leu Asn Gln Gly Leu 1080 1085 1090aca tca cat ggt ctg aga gcc cat ctt caa gat tta tat cat tta gag 3727Thr Ser His Gly Leu Arg Ala His Leu Gln Asp Leu Tyr His Leu Glu 1095 1100 1105cta ctc tta ggc cag ata gcc tgagcagaca gacatgatgt gagttgtcca 3778Leu Leu Leu Gly Gln Ile Ala 1110aagacattca ctgaacaatg ccagggatac aagtgccatg gatactctac cgctaaatgg 3838taattttaac aacagctact cgctgcacaa gggtgactat aatgacagcg tgcaagttgt 3898ggactgtgga ctaagtctga atgatactgc ttttgagaaa atgatcattt cagaattagt 3958gcacaacaac ttacggggca gcagcaagac tcacaacctc gagctcacgc taccagtcaa 4018acctgtgatt ggaggtagca gcagtgaaga tgatgctatt gtggcagatg cttcatcttt 4078aatgcacagc gacaacccag ggctggagct ccatcacaaa gaactcgagg caccacttat 4138tcctcagcgg actcactccc ttctgtacca accccagaag aaagtgaagt ccgagggaac 4198tgacagctat gtctcccaac tgacagcaga ggctgaagat cacctacagt cccccaacag 4258agactctctt tatacaagca tgcccaatct tagagactct ccctatccgg agagcagccc 4318tgacatggaa gaagacctct ctccctccag gaggagtgag aatgaggaca tttactataa 4378aagcatgcca aatcttggag ctggccatca gcttcagatg tgctaccaga tcagcagggg 4438caatagtgat ggttatataa tccccattaa caaagaaggg tgtattccag aaggagatgt 4498tagagaagga caaatgcagc tggttacaag tctttaatca tacagctaag gaattccaag 4558ggccacatgc gagtattaat aaataaagac accattggcc tgacgcagct ccctcaaact 4618ctgcttgaag agatgactct tgacctgtgg ttctctggtg taaaaaagat gactgaacct 4678tgcagttctg tgaattttta taaaacatac aaaaactttg tatatacaca gagtatacta 4738aagtgaatta tttgttacaa agaaaagaga tgccagccag gtattttaag attctgctgc 4798tgtttagaga aattgtgaaa caagcaaaac aaaactttcc agccatttta ctgcagcagt 4858ctgtgaacta aatttgtaaa tatggctgca ccatttttgt aggcctgcat tgtattatat 4918acaagacgta ggctttaaaa tcctgtggga caaatttact gtaccttact attcctgaca 4978agacttggaa aagcaggaga gatattctgc atcagtttgc agttcactgc aaatctttta 5038cattaaggca aagattgaaa acatgcttaa ccactagcaa tcaagccaca ggccttattt 5098catatgtttc ctcaactgta caatgaacta ttctcatgaa aaatggctaa agaaattata 5158ttttgttcta ttgctagggt aaaataaata catttgtgtc caactgaaat ataattgtca 5218ttaaaataat tttaaagagt gaagaaaata ttgtgaaaag ctcttggttg cacatgttat 5278gaaatgtttt ttcttacact ttgtcatggt aagttctact cattttcact tcttttccac 5338tgtatacagt gttctgcttt gacaaagtta gtctttatta cttacattta aatttcttat 5398tgccaaaaga acgtgtttta tggggagaaa caaactcttt gaagccagtt atgtcatgcc 5458ttgcacaaaa gtgatgaaat ctagaaaaga ttgtgtgtca cccctgttta ttcttgaaca 5518gagggcaaag agggcactgg gcacttctca caaactttct agtgaacaaa aggtgcctat 5578tcttttttaa aaaaaaaaaa 5598 34 1114 PRT Homo sapiens 34Met Val Gly Arg Met Thr Arg Phe Val Met Leu Thr His Phe Arg Trp 1 5 10 15Glu Asn Thr Asp Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Thr Gln 20 25 30Arg Cys Asn Asn Arg Thr Gln Cys Ile Val Val Thr Gly Ser Asp Val 35 40 45Phe Pro Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr 50 55 60Glu Cys Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Lys Ala Ile 65 70 75 80Val Asp Ser Pro Cys Ile Tyr Glu Ala Glu Gln Lys Ala Gly Ala Trp 85 90 95Cys Lys Asp Pro Leu Gln Ala Ala Asp Lys Ile Tyr Phe Met Pro Trp 100 105 110Thr Pro Tyr Arg Thr Asp Thr Leu Ile Glu Tyr Ala Ser Leu Glu Asp 115 120 125Phe Gln Asn Ser Arg Gln Thr Thr Thr Tyr Lys Leu Pro Asn Arg Val 130 135 140Asp Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe Phe Asn Lys145 150 155 160Glu Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys 165 170 175Ser Gly Glu Ala Ile Ile Asn Tyr Ala Asn Tyr His Asp Thr Ser Pro 180 185 190Tyr Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn 195 200 205Gly Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Met Ile Val 210 215 220Ile Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Ala Thr Trp Glu225 230 235 240Thr Val Tyr Asp Lys Arg Ala Ala Ser Asn Ala Phe Met Ile Cys Gly 245 250 255Val Leu Tyr Val Val Arg Ser Val Tyr Gln Asp Asn Glu Ser Glu Thr 260 265 270Gly Lys Asn Ser Ile Asp Tyr Ile Tyr Asn Thr Arg Leu Asn Arg Gly 275 280 285Glu Tyr Val Asp Val Pro Phe Pro Asn Gln Tyr Gln Tyr Ile Ala Ala 290 295 300Val Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Asn305 310 315 320Phe Ile Leu Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ala Gln 325 330 335Val Pro Thr Thr Ala Val Thr Ile Thr Ser Ser Ala Glu Leu Phe Lys 340 345 350Thr Ile Ile Ser Thr Thr Ser Thr Thr Ser Gln Lys Gly Pro Met Ser 355 360 365Thr Thr Val Ala Gly Ser Gln Glu Gly Ser Lys Gly Thr Lys Pro Pro 370 375 380Pro Ala Val Ser Thr Thr Lys Ile Pro Pro Ile Thr Asn Ile Phe Pro385 390 395 400Leu Pro Glu Arg Phe Cys Glu Ala Leu Asp Ser Lys Gly Ile Lys Trp 405 410 415Pro Gln Thr Gln Arg Gly Met Met Val Glu Arg Pro Cys Pro Lys Gly 420 425 430Thr Arg Gly Thr Ala Ser Tyr Leu Cys Met Ile Ser Thr Gly Thr Trp 435 440 445Asn Pro Lys Gly Pro Asp Leu Ser Asn Cys Thr Ser His Trp Val Asn 450 455 460Gln Leu Ala Gln Lys Ile Arg Ser Gly Glu Asn Ala Ala Ser Leu Ala465 470 475 480Asn Glu Leu Ala Lys His Thr Lys Gly Pro Val Phe Ala Gly Asp Val 485 490 495Ser Ser Ser Val Arg Leu Met Glu Gln Leu Val Asp Ile Leu Asp Ala 500 505 510Gln Leu Gln Glu Leu Lys Pro Ser Glu Lys Asp Ser Ala Gly Arg Ser 515 520 525Tyr Asn Lys Ala Ile Val Asp Thr Val Asp Asn Leu Leu Arg Pro Glu 530 535 540Ala Leu Glu Ser Trp Lys His Met Asn Ser Ser Glu Gln Ala His Thr545 550 555 560Ala Thr Met Leu Leu Asp Thr Leu Glu Glu Gly Ala Phe Val Leu Ala 565 570 575Asp Asn Leu Leu Glu Pro Thr Arg Val Ser Met Pro Thr Glu Asn Ile 580 585 590Val Leu Glu Val Ala Val Leu Ser Thr Glu Gly Gln Ile Gln Asp Phe 595 600 605Lys Phe Pro Leu Gly Ile Lys Gly Ala Gly Ser Ser Ile Gln Leu Ser 610 615 620Ala Asn Thr Val Lys Gln Asn Ser Arg Asn Gly Leu Ala Lys Leu Val625 630 635 640Phe Ile Ile Tyr Arg Ser Leu Gly Gln Phe Leu Ser Thr Glu Asn Ala 645 650 655Thr Ile Lys Leu Gly Ala Asp Phe Ile Gly Arg Asn Ser Thr Ile Ala 660 665 670Val Asn Ser His Val Ile Ser Val Ser Ile Asn Lys Glu Ser Ser Arg 675 680 685Val Tyr Leu Thr Asp Pro Val Leu Phe Thr Leu Pro His Ile Asp Pro 690 695 700Asp Asn Tyr Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg705 710 715 720Thr Met Met Gly Tyr Trp Ser Thr Gln Gly Cys Lys Leu Val Asp Thr 725 730 735Asn Lys Thr Arg Thr Thr Cys Ala Cys Ser His Leu Thr Asn Phe Ala 740 745 750Ile Leu Met Ala His Arg Glu Ile Ala Tyr Lys Asp Gly Val His Glu 755 760 765Leu Leu Leu Thr Val Ile Thr Trp Val Gly Ile Val Ile Ser Leu Val 770 775 780Cys Leu Ala Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln785 790 795 800Ser Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu Phe Ile 805 810 815Ala Glu Phe Ile Phe Leu Ile Gly Ile Asp Lys Thr Lys Tyr Ala Ile 820 825 830Ala Cys Pro Ile Phe Ala Gly Leu Leu His Phe Phe Phe Leu Ala Ala 835 840 845Phe Ala Trp Met Cys Leu Glu Gly Val Gln Leu Tyr Leu Met Leu Val 850 855 860Glu Val Phe Glu Ser Glu Tyr Ser Arg Lys Lys Tyr Tyr Tyr Val Ala865 870 875 880Gly Tyr Leu Phe Pro Ala Thr Val Val Gly Val Ser Ala Ala Ile Asp 885 890 895Tyr Lys Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu His Val Asp Asn 900 905 910Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val Thr Phe Ile Ile Leu Leu 915 920 925Asn Ile Ile Phe Leu Val Ile Thr Leu Cys Lys Met Val Lys His Ser 930 935 940Asn Thr Leu Lys Pro Asp Ser Ser Arg Leu Glu Asn Ile Lys Ser Trp945 950 955 960Val Leu Gly Ala Phe Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ser 965 970 975Phe Gly Leu Leu Phe Ile Asn Glu Glu Thr Ile Val Met Ala Tyr Leu 980 985 990Phe Thr Ile Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Ile Phe His 995 1000 1005Cys Ala Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Phe Arg 1010 1015 1020His Ser Tyr Cys Cys Gly Gly Leu Pro Thr Glu Ser Pro His Ser Ser1025 1030 1035 1040Val Lys Ala Ser Thr Thr Arg Thr Ser Ala Arg Tyr Ser Ser Gly Thr 1045 1050 1055Gln Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser 1060 1065 1070Glu Ser Ser Phe Ile Ser Gly Asp Ile Asn Ser Thr Ser Thr Leu Asn 1075 1080 1085Gln Gly Leu Thr Ser His Gly Leu Arg Ala His Leu Gln Asp Leu Tyr 1090 1095 1100His Leu Glu Leu Leu Leu Gly Gln Ile Ala1105 1110 35 28 DNA Artificial Sequence Description of Artificial Sequence primer 35gggcctcacc tgggctttcg gcctcctc 28 36 28 DNA Artificial Sequence Description of Artificial Sequence primer 36ggactggtgc ccccacgcgt gtcagcac 28 37 24 DNA Artificial Sequence Description of Artificial Sequence primer 37ccaacaagac ccataccagc tgtg 24 38 22 DNA Artificial Sequence Description of Artificial Sequence primer 38ctgagtcttg tcgatcccga cc 22 39 349 DNA Homo sapiens 39aagcttggca cgagggtcta tgtgcatttt ggaattactc acctgatacc atgaatggca 60gctggtcttc agagggctgt gagctgacat actcaaatga gacccacacc tcatgccgct 120gtaatcacct gacacatttt gcaattttga tgtcctctgg tccttccatt ggtattaaag 180attataatat tcttacaagg gatcactcaa ctaggaataa ttatttcact gatttgtctt 240gccatatgca tttttacctt ctggttcttc agtgaaattc aaagcaccag gacaacaatt 300cacaaaaatc tttgctggta gcctatttct tgctgaactt ggtttttct 349 40 359 DNA Homo sapiens 40cagggaatgt ttatatttat tttccattgt gtcctacaga agaaggtacg aaaagagtat 60gggaaatgcc tgcgaacaca ttgctgtagt ggcaaaagta cagagagttc cattggttca 120gggaaaacat ctggttctcg aactcctgga cgctactcca caggctcaca gagcganatt 180ccgtagaatg tggaatgaca cggttcgaaa gcagtcagag tcttccttta ttactggaga 240cataaacagt tcagcgtcac tcaacagaga ggggcttctg aacaatgcca ggggatacaa 300gtgtcatgga tactctacca ctgaatgggt aaccatgggc aatagttaca gcattgcca 359 41 480 DNA Homo sapiens 41tttttttttc tactacatta acaggactca aattctggag gaacagaaag cagactatat 60gtgcaatgct agtatctgta cattacatag aaattgctca acttcttttt ctgccattag 120ttttatcatc agttaataca gcaaatcata aaatatgcat ttagcatata attctagaat 180tcccctccat ttcattatta attttgttgt tttattttgt tttccacagc tattccagct 240gtgggtgaaa ttcaggttgt gagtgaccaa aaaccctatg tgatacagtt ttgctttgct 300cttatgtttg tttgtgcagg cactccaatc taggatgcag cattgttact aatttcagac 360aattgttctg ggccttttna aaaggcgggt ccntgttaat tttaggtaac acggcatcgg 420ggtggtttaa agcntacaca acctattnca caggggccca tggggggcct ttttcttcaa 480 42 466 DNA Homo sapiens 42ngcgaaacga annngtnctt ctagnaactt caggcttgca acaacacang ggggtgggac 60agcagtgggt gctatgttga agaaggtgat ggggacaatg tcacctgtat ctgtgaccac 120ctaacatcat tctccatcct catgtcccct gactccccag atcctagttc tctcctggga 180atactcctgg atattatttc ttatgttggg gtgggctttt ccatcttgag cttggcagcc 240tgtctagttg tggaagctgt ggtgtggaaa tcggtgacca agaatcggac ttcttatatg 300cgccacacct gcatagtgaa tatcgctgcc tcccttctgg tccgccaaca cctggttcat 360tgtnggtcgc tggccatcca ggacaatccg ctacatactc tgcaagacag cctgtgtggc 420tgccaccttc ttcaatccac ttcttctanc tcagcgtctt cttctn 466 43 403 DNA Homo sapiens 43tttttttttc ctgggaatat atttttttaa ttggttgatt tgcttcgttc aaagcgctta 60gaatggaaga tttagtttga ggaggggcag gtttgggggt aggctcagcg ggcatagtgg 120ccacaagaag atgcccatct cacacctgga gacgtccatg agcacctcga agctggccgt 180ntggctgcac tggcgtacga catgggtccg gttcctggac aggagcttga agccccgggc 240aggaccaccc tcccgtccca ctgacactgc gtagagaagg gagaagaggc aggggtgaga 300cggttccctc cgcccatgtc tnttgggggc antctttncc cgggccctgg ggacttccca 360ggccattcct gggccaaaac caaacagcag gtattagttg agt 403 44 358 DNA Homo sapiens 44ttttgagagg tttggctttt tttaatctgc ttccaaaaca aagcctcgat gatcaggcat 60aaaatgagac ttccaatgga gatacccagt cccacatagg tgatccattt tacaacgggg 120aagattgtag aggggacaaa aggtgacatc aatatggaga aggaggtcaa gtgagtacat 180tggcacgtca cgatgtcttg agtttcattc actaggtggc agcctgcatc gttccactgc 240aaatgactga aatcccaaaa cacacaatga ggctggctca ggtttgactc tatcttggaa 300aaaaatagga aaacttcatt tatggaatag ttttgaataa ccgtggatat cacaggtc 358 45 556 DNA Homo sapiens 45gctggctgcc gagccagtgc catcttcctg cacttctccc tgctcacctg cctttcctgg 60atgggcctcg aggggtacaa cctctaccga ctcgtggtgg aggtctttgg cacctatgtc 120cctggctacc tactcaagct gagcgccatg ggctggggct tccccatctt tctggtgacg 180ctggtggccc tggtggatgt ggacaactat ggccccatca tcttggctgt gcataggact 240ccagagggcg tcatctaccc ttccatgtgc tggatccggg actccctggt cagctacatc 300accaacctgg gcctcttcag cctggtgttt ctgttcaaca tggccatgct agccaccatg 360gtggtgcaga tcctgcggct gcgcccccac acccaaaagt ggtcacatgt gctgacactg 420ctgggcctca gcctggtcct tggcctgccc tgggccttga ccttcttctc ctttgcttct 480ggcaccttcc agcttgtcgt cctctacctt ttcagcatca tcacctcctt ccaaggcttc 540ctcatcttca tctggt 556 46 324 DNA Homo sapiens 46gatccccatt gcgccantgn ggactactcc agagcagatg ccagctcagg agtctgggnc 60actgaaaatt gccagaccct ggagacccag gcagctcaca cccgctgcca gtgccagcac 120ctgtccacct ttgctgtact agcccagccg cccaaggacc tgaccctgga gctggcgggc 180tccccctcgg tccccctggt gatcggctgt gcagtgtcgt gcatggcgct gctcaccctg 240ctcgccatct atgccgcctt ttggaggttc ataaaatctg aacgctccat catcttgctg 300aacttntgcc tgtccatctt ggca 324 47 391 DNA Homo sapiens 47ttaaagcata actgtatttt tnnttttagg gccttattga tgttttgccg ttccaatgta 60tgcatttttt nactcaataa acttgtctta attttaaata tggggcttcc ttggacctgt 120ctgcgccatc ttctctgtga atttagttct ctttctggtg actctctgga ttttnaaaaa 180cagactctcc tccctcaata gtgaagtgtc caccctccgg aacacaaggt ccgggagcaa 240tatgggaaat ggtccaaagg gatcaggaaa ttgaaaactg agtctgagat gcacacactc 300tccagcagtg ctaaggctga caactccaaa cccagcacgg gtaactagaa aaatcttctg 360aataagatct tcccctttgc ccgtgggaaa t 391 48 5749 DNA Homo sapiens 48ggaaagcgga aagaggaaaa agcataagct tgagccttcc gatccgacca cgaatactcc 60tgtaataaac ccaccgcccc aacaaatctg ccatagcagc cgccgccgcc gccggtcact 120tctcgtctca gcgctttctt tgcttcttgg tttgttgggg gtagctttta tgaaacaaat 180ctttgctatt aagccactta cattttgggg ggttccttag agtctccctt gggggggctt 240ctccctccct ttagcccccc tcggtttgga ggttggattc agttggatac ggcgcaaggt 300tctgggctcc tgctggcttt tttttcctct ctctcatcga cccccctttg gttcccaccc 360cccacctttt gcttttcgta tgtatgcatt tttaaaaata aatcctgatt ttggaagctg 420agccggggaa aatgggcaac ggtgattggg accgaagggg agtctctccg tcactgttgc 480tgggacgcgt gcctgtgctg gtgtcttaga gcaagagcct ccctgagctt tcggagtgga 540agaacagtgg aagagactgc agcctaaaga cttttaaaat taacttggca tcacttttat 600cagctcaaag gctaaacaaa caaacaaaag cagtgtcatt tattctaaga aataacttct 660taaaggttaa agctgaaaaa tattcaagtt atttttggat aacaacttac agaggccaaa 720tgacatagga tgaaggctgt tcgtaacctg ctgatttata tattttccac ctatctcctg 780gttatgtttg gatttaatgc tgcccaagac ttctggtgtt caactttggt gaagggagtc 840atttatggat cgtattctgt aagtgaaatg tttcctaaaa actttacaaa ctgcacttgg 900acgctggaaa atccagatcc aaccaaatat agcatttacc tgaaattttc caaaaaggac 960cttagctgct ctaacttttc actcctggct tatcagtttg atcatttttc ccatgaaaaa 1020ataaaggatc ttttaagaaa gaatcattct ataatgcaac tctgcaattc caagaatgct 1080ttcgtttttc tacagtatga taaaaatttt attcaaatac gtcgagtatt tccaactaat 1140ttcccaggat tacagaaaaa aggggaagaa gatcagaaat ctttttttga gtttttggta 1200ttgaacaagg tcagcccaag ccagtttggt tgccatgtat tatgtacttg gttggagagc 1260tgcttaaaat cagaaaatgg gagaacagaa tcatgtggga tcatgtatac aaaatgcacc 1320tgccctcagc atttgggaga gtgggggatc gacgaccagt cgctgatttt gttaaataac 1380gtggtgttac ccctgaatga gcagacagag ggctgcctga cccaggagct gcaaaccacc 1440caagtctgca atcttaccag ggaggccaag cgaccaccca aagaagaatt tggaatgatg 1500ggagatcata caattaaaag tcagcgacct cgatctgttc atgaaaaaag ggtccctcag 1560gaacaagctg atgctgctaa atttatggca caaactggtg aatctggtgt ggaagagtgg 1620tcccagtgga gcacatgttc ggttacttgt ggtcaagggt cgcaggtgcg aaccagaact 1680tgtgtatcac cttacgggac acactgcagc ggcccattaa gagaatcaag ggtttgcaat 1740aacactgccc tctgtccagt acacggagta tgggaggaat ggtcaccatg gagtttatgt 1800tcatttacat gtggtcgagg ccaaagaaca agaacaaggt catgcacacc tcctcagtat 1860ggaggaaggc cgtgtgaagg acctgaaaca catcataagc cttgtaatat tgctctttgc 1920ccagttgatg gacagtggca agagtggagt tcgtggagcc agtgctcagt aacgtgctcg 1980aatgggactc agcagagaag ccggcagtgc actgcagctg cccatggagg ctccgaatgc 2040agagggccat gggcagaaag cagagagtgc tataaccctg aatgtacagc caatggtcaa 2100tggaatcagt ggggtcattg gagtggttgt tccaagtcct gtgatggcgg ctgggaaagg 2160cgaataagga cctgtcaggg tgcagtgata acagggcagc aatgtgaagg aacgggcgaa 2220gaagtgagaa gatgcagtga gcagcgatgc cctgcacctt atgaaatatg ccctgaggat 2280tatctgatgt cgatggtgtg gaaaagaact ccagcaggcg acttggcatt caatcaatgt 2340cccctgaatg ccacaggcac cactagcaga cgctgctctc tcagtcttca tggagtggcc 2400ttctgggaac agccgagctt tgcaagatgc atatcaaatg agtacagaca cttgcagcat 2460tcaattaaag agcaccttgc taaggggcag cgaatgctgg caggtgatgg aatgtcccag 2520gtgaccaaga cactgttgga tttaactcag agaaaaaatt tctatgcagg cgatcttctg 2580atgtctgtgg agatcctgag aaatgtgaca gacacattta aaagggcaag ttacatccct 2640gcatctgatg gtgtccagat ttatccaggg tcaatagagt taatgcaggt gattgaagat 2700tttatacaca ttgttggaat ggggatgatg gactttcaga attcatactt aatgactgga 2760aatgtagtgg ctagtattca gaagcttcct gcagcctctg ttctaacaga catcaacttt 2820ccaatgaaag gacggaaggg aatggttgac tgggcaagaa actcagaaga tagggtagta 2880attccaaaaa gcattttcac tccggtgtca tcaaaagaat tagatgaatc atctgtattt 2940gttcttggcg cagtcctata caaaaactta gatctaattt tgcccacttt gagaaattat 3000actgtcatta attccaaaat catcgtggtc acaataaggc ctgaacccaa aacaaccgat 3060tcgtttctgg agatagaact agctcatttg gctaatggta ctttgaatcc ctattgtgta 3120ttgtgggatg actccaaaac gaacgagtct ttgggaacgt ggtccaccca gggatgtaaa 3180actgtgctta ccgatgcatc ccatacgaaa tgcttatgtg atcgtctctc taccttcgcc 3240attttggctc agcaacctag agaaataatc atggaatcct ctggcacacc ttcagttacc 3300ctaatagtag gcagtggtct ttcttgcttg gccttgatta ccctagcagt tgtctatgca 3360gcattatgga ggtacatacg ctctgagaga tccataatac taattaactt ctgcctgtct 3420atcatctcat ccaatatcct catactggtt ggacagactc agacacataa taagagtatc 3480tgcacaacca ccactgcatt tttgcacttt ttcttcctgg cttcattctg ttgggttttg 3540actgaggcgt ggcaatcata tatggctgta actggaaaaa ttaggacacg gcttataaga 3600aaacgctttt tgtgccttgg atggggtaag catattgata taccgtttca tgctcttctc 3660aaaatgacgt tgaacacaca ttagaaagca gtcatgagtg attagacaca ggctactttg 3720tgtctaattt aatctatgga agtgaaaata catgagctgg tcagttttga acattcattg 3780gtcatttgga actttaaaag gaagtaagta ttgaatgctc atttagctag tcagttaaca 3840ttcaacagtg tctagatagt atgaaatgag accccgagat gcctacacac agaaaaacag 3900tgctctctgt taatattttc tgaaagtgca aaatacctta aaattttcaa ggcctaatgt 3960gtgatggttc actaggcatg tactcccacc aagaaaactt agaagatttc atttcaagaa 4020atctcaaagc aattaaagaa taaaagcgat tcatttcata gggagaacac catctagaga 4080attaatgaaa cctcacagct tgttgacctg gtcctcaaaa gcagaaacag aattgctgac 4140agactgagaa ctaattcttt acttgtgttt attaagaagt ttctctcaaa ttgcctcatg 4200acatggacat ctcaaagatc tatattatag ggccaattct aatgatagcc tagttaattt 4260aagaagctac ttttagaaaa agcccaaata tacaataata tctactgtat tagaagactg 4320gcatatggga tgctaggagg aacctgggaa attacaaata agtgtgctta taacaattcc 4380agaattattt aggctggaaa aatatgatca agaacacgta aatattattc attaggtttc 4440agcaaggtct attatgtcta gctaataaat taggacttta tccacagaca aatggaaaag 4500caattaataa gaagttgaag agtaggccag acatggtggc tcacgcctgt aatcctagca 4560ctttgggaaa ccaaggcggg tggactacct gagcgtgggt ggactacctg agcgcgggtg 4620gactacctga gcacgggagt tcgagattag cctgagcaat atggcaaaac cccatctcta 4680ccaaaaatgc aaaaaattag ccgggagtga tggcacatac ctgtagtccc agctactcgg 4740gaggctaagg tgggaggatt gcatgagcct gggaagtgga ggttgcagtg agccaagatc 4800acaccacgac actccaactt gtgtcacaga gtaagaccct atctcacacc aacacaaaag 4860ttgaagactt tgttctactt agaatttcat caaatttttg tctaaatttc ctgacaaagg 4920ccttctaaag ttgagatagt atttaaatca agggacactt ttgccatgaa ttagtaccat 4980tctaagaaat acagaataca ggtaaaagaa cacatttttt gatgaagaac aaaacatggt 5040gattttcaag attagtgact accttgttta aaattattac taaagatttt gaggagaggg 5100ttcacagaca gtctccgtat ttacagctaa tattaaacta ctctaggtag caaaaacctg 5160aactgatggt gctaaagtat cagaaagttt atgggttggc agaatagtgg tgtgtgtgtt 5220tcattatgaa caagtacaat aaaatgaatc tagaaaaaat ttaatctaaa ttgtatgaaa 5280taaatactat taattcttca gttataaccc atgaggaatt tttttttcct aatgaacttg 5340gtccagtcaa tcaaaaaaaa tcaacaaatg acatgtgtgg aggaagagga gaaggaggga 5400caagaagagg agaaacagaa ggaggaaagg gaagaggagg aaagggagga taaggatgag 5460gaggggacta tatatttata attttatata catatatgta tagtcaccag tgtttgttta 5520acactatggt gtgtccttct gagatgtttt ccatagttct tgtcattaaa tctcatgaag 5580gaatgtgatg ccactagaga aggctcacag aagagaatag caggaggtat gtgaaatgat 5640agtaagaaag aagacagaca gaggacatac aataaaatga ttagatgacg gatttttcaa 5700ccggaaaagg caaacatgat cttcctgaaa agaaggcata accaaaact 5749 49 21 DNA Artificial Sequence Description of Artificial Sequence primer 49tcagacactc atactgctgt g 21 50 19 DNA Artificial Sequence Description of Artificial Sequence primer 50cacagtccac aacttgcac 19 51 40 DNA Artificial Sequence Description of Artificial Sequence primer 51gacgctggtc gactaggtgg ctgcatgcac acgttgttcg 40 52 37 DNA Artificial Sequence Description of Artificial Sequence primer 52cctaccacag ctgtgacaat aacttcttca gctgagc 37 53 16 PRT Homo sapiens 53Cys Leu Gln Asp Leu Tyr His Leu Glu Leu Leu Leu Gly Gln Ile Ala 1 5 10 15 54 15 PRT Homo sapiens 54Cys Thr Arg Thr Ser Ala Arg Tyr Ser Ser Thr Gln Asp Ile His 1 5 10 15 55 16 PRT Homo sapiens 55Cys Glu Gly Asp Val Arg Glu Gly Gln Met Gln Leu Val Thr Ser Leu 1 5 10 15 56 16 PRT Homo sapiens 56Cys Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser 1 5 10 15 57 5610 DNA Homo sapiens CDS (281)..(4687) 57ctaatttttg gtcggcggcg gtgctgggcc aggggaagga agggacacgg aggccgccct 60cgtcccgcca cctcctaccc gcttcccccc agccccggct ccgggagatg tgccgggcgg 120ggggcccggg ttcgccgagc cgcaggagag acacgctggg ccgaccccag agaggcgctg 180gacaggctgg tggtccaggc cgtggtgcct gccaggtgat gtggggcaaa gccccccgca 240caggccactg agagctccgg acacgcaccc ggctgccacc atg gcc cgc cta gcc 295 Met Ala Arg Leu Ala 1 5gca gtg ctc tgg aat ctg tgt gtc acc gcc gtc ctg gtc acc tcg gcc 343Ala Val Leu Trp Asn Leu Cys Val Thr Ala Val Leu Val Thr Ser Ala 10 15 20acc caa ggc ctg agc cgg gcc ggg ctc ccg ttc ggg ctg atg cgc cgg 391Thr Gln Gly Leu Ser Arg Ala Gly Leu Pro Phe Gly Leu Met Arg Arg 25 30 35gag ctg gcg tgt gaa ggc tac ccc atc gag ctg cgg tgc ccc ggc agc 439Glu Leu Ala Cys Glu Gly Tyr Pro Ile Glu Leu Arg Cys Pro Gly Ser 40 45 50gac gtc atc atg gtg gag aat gcc aac tac ggg cgc acg gac gac aag 487Asp Val Ile Met Val Glu Asn Ala Asn Tyr Gly Arg Thr Asp Asp Lys 55 60 65att tgc gat gct gac cct ttc cag atg gag aat gtg cag tgc tac ctg 535Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn Val Gln Cys Tyr Leu 70 75 80 85ccg gac gcc ttc aag atc atg tca cag agg tgt aac aac cgc acc cag 583Pro Asp Ala Phe Lys Ile Met Ser Gln Arg Cys Asn Asn Arg Thr Gln 90 95 100tgc gtg gtg gtc gcc ggc tcg gat gcc ttt cct gac ccc tgt cct ggg 631Cys Val Val Val Ala Gly Ser Asp Ala Phe Pro Asp Pro Cys Pro Gly 105 110 115acc tac aag tac ctg gag gtg cag tac gac tgt gtc ccc tac atc ttc 679Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Asp Cys Val Pro Tyr Ile Phe 120 125 130gtg tgc cca ggg acc ctg cag aag gtg ctg gag ccc acc tcg aca cac 727Val Cys Pro Gly Thr Leu Gln Lys Val Leu Glu Pro Thr Ser Thr His 135 140 145gag tca gag cac cag tct ggc gca tgg tgc aag gac ccg ctg cag gcg 775Glu Ser Glu His Gln Ser Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala150 155 160 165ggt gac cgc atc tac gtg atg ccc tgg atc ccc tac cgc acg gac aca 823Gly Asp Arg Ile Tyr Val Met Pro Trp Ile Pro Tyr Arg Thr Asp Thr 170 175 180ctg act gag tat gcc tcg tgg gag gac tac gtg gcc gcc cgc cac acc 871Leu Thr Glu Tyr Ala Ser Trp Glu Asp Tyr Val Ala Ala Arg His Thr 185 190 195acc acc tac cgc ctg ccc aac cgc gtg gat ggc aca ggc ttt gtg gtc 919Thr Thr Tyr Arg Leu Pro Asn Arg Val Asp Gly Thr Gly Phe Val Val 200 205 210tac gat ggt gcc gtc ttg tac aac aag gag cgc acg cgc aac atc gtc 967Tyr Asp Gly Ala Val Leu Tyr Asn Lys Glu Arg Thr Arg Asn Ile Val 215 220 225aag tat gac cta cgg acg cgc atc aag agc ggg gag acg gtc atc aat 1015Lys Tyr Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Thr Val Ile Asn230 235 240 245acc gcc aac tac cat gac acc tcg ccc tac cgc tgg ggc gga aag acc 1063Thr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp Gly Gly Lys Thr 250 255 260gac att gac ctg gcg gtg gac gag aac ggg ctg tgg gtc atc tac gcc 1111Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala 265 270 275act gag ggc aac aac ggg cgg ctg gtg gtg agc cag ctg aac ccc tac 1159Thr Glu Gly Asn Asn Gly Arg Leu Val Val Ser Gln Leu Asn Pro Tyr 280 285 290aca ctg cgc ttt gag ggc acg tgg gag acg ggt tac gac aag cgc tcg 1207Thr Leu Arg Phe Glu Gly Thr Trp Glu Thr Gly Tyr Asp Lys Arg Ser 295 300 305gca tcc aac gcc ttc atg gtg tgt ggg gtc ctg tac gtc ctg cgt tcc 1255Ala Ser Asn Ala Phe Met Val Cys Gly Val Leu Tyr Val Leu Arg Ser310 315 320 325gtg tac gtg gat gat gac agc gag gcg gct ggc aac cgc gtg gac tat 1303Val Tyr Val Asp Asp Asp Ser Glu Ala Ala Gly Asn Arg Val Asp Tyr 330 335 340gcc ttc aac acc aat gcc aac cgc gag gag cct gtc agc ctc acc ttc 1351Ala Phe Asn Thr Asn Ala Asn Arg Glu Glu Pro Val Ser Leu Thr Phe 345 350 355ccc aac ccc tac cag ttc atc tcc tcc gtt gac tac aac cct cgc gac 1399Pro Asn Pro Tyr Gln Phe Ile Ser Ser Val Asp Tyr Asn Pro Arg Asp 360 365 370aac cag ctg tac gtc tgg aac aac tat ttc gtg gtg cgc tac agc ctg 1447Asn Gln Leu Tyr Val Trp Asn Asn Tyr Phe Val Val Arg Tyr Ser Leu 375 380 385gag ttc ggg ccg ccc gac ccc agt gct ggc cca gcc act tcc cca ccc 1495Glu Phe Gly Pro Pro Asp Pro Ser Ala Gly Pro Ala Thr Ser Pro Pro390 395 400 405ctc agc acg acc acc aca gcc agg ccc acg ccc ctc acc agc aca gcc 1543Leu Ser Thr Thr Thr Thr Ala Arg Pro Thr Pro Leu Thr Ser Thr Ala 410 415 420tcg ccc gca gcc acc acc ccg ctc cgc cgg gca ccc ctc acc acg cac 1591Ser Pro Ala Ala Thr Thr Pro Leu Arg Arg Ala Pro Leu Thr Thr His 425 430 435cca gtg ggt gcc atc aac cag ctg gga cct gat ctg cct cca gcc aca 1639Pro Val Gly Ala Ile Asn Gln Leu Gly Pro Asp Leu Pro Pro Ala Thr 440 445 450gcc cca gtc ccc agc acc cgg cgg ccc cca gcc ccg aat cta cac gtg 1687Ala Pro Val Pro Ser Thr Arg Arg Pro Pro Ala Pro Asn Leu His Val 455 460 465tcc cct gag ctc ttc tgc gag ccc cga gag gta cgg cgg gtc cag tgg 1735Ser Pro Glu Leu Phe Cys Glu Pro Arg Glu Val Arg Arg Val Gln Trp470 475 480 485ccg gcc acc cag cag ggc atg ctg gtg gag agg ccc tgc ccc aag ggg 1783Pro Ala Thr Gln Gln Gly Met Leu Val Glu Arg Pro Cys Pro Lys Gly 490 495 500act cga gga att gcc tcc ttc cag tgt cta cca gcc ttg ggg ctc tgg 1831Thr Arg Gly Ile Ala Ser Phe Gln Cys Leu Pro Ala Leu Gly Leu Trp 505 510 515aac ccc cgg ggc cct gac ctc agc aac tgc acc tcc ccc tgg gtc aac 1879Asn Pro Arg Gly Pro Asp Leu Ser Asn Cys Thr Ser Pro Trp Val Asn 520 525 530cag gtg gcc cag aag atc aag agt ggg gag aac gcg gcc aac atc gcc 1927Gln Val Ala Gln Lys Ile Lys Ser Gly Glu Asn Ala Ala Asn Ile Ala 535 540 545agc gag ctg gcc cga cac acc cgg ggc tcc atc tac gcg ggg gac gtc 1975Ser Glu Leu Ala Arg His Thr Arg Gly Ser Ile Tyr Ala Gly Asp Val550 555 560 565tcc tcc tct gtg aag ctg atg gag cag ctg ctg gac atc ctg gat gcc 2023Ser Ser Ser Val Lys Leu Met Glu Gln Leu Leu Asp Ile Leu Asp Ala 570 575 580cag ctg cag gcc ctg cgg ccc atc gag cgc gag tca gcc ggc aag aac 2071Gln Leu Gln Ala Leu Arg Pro Ile Glu Arg Glu Ser Ala Gly Lys Asn 585 590 595tac aac aag atg cac aag cga gag aga act tgt aag gat tat atc aag 2119Tyr Asn Lys Met His Lys Arg Glu Arg Thr Cys Lys Asp Tyr Ile Lys 600 605 610gcc gtg gtg gag aca gtg gac aat ctg ctc cgg cca gaa gct ctg gag 2167Ala Val Val Glu Thr Val Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu 615 620 625tcc tgg aag gac atg aat gcc acg gag cag gtg cac acg gcc acc atg 2215Ser Trp Lys Asp Met Asn Ala Thr Glu Gln Val His Thr Ala Thr Met630 635 640 645ctc ctc gac gtc ctg gag gag ggc gcc ttc ctg ctg gcc gac aat gtc 2263Leu Leu Asp Val Leu Glu Glu Gly Ala Phe Leu Leu Ala Asp Asn Val 650 655 660agg gag cct gcc cgc ttc ctg gct gcc aag gag aac gtg gtc ctg gag 2311Arg Glu Pro Ala Arg Phe Leu Ala Ala Lys Glu Asn Val Val Leu Glu 665 670 675gtc aca gtc ctg aac aca gag ggc cag gtg cag gag ctg gtg ttc ccc 2359Val Thr Val Leu Asn Thr Glu Gly Gln Val Gln Glu Leu Val Phe Pro 680 685 690cag gag gag tac ccg aga aag aac tcc atc cag ctg tct gcc aaa acc 2407Gln Glu Glu Tyr Pro Arg Lys Asn Ser Ile Gln Leu Ser Ala Lys Thr 695 700 705atc aag cag aac agc cgc aat ggg gtg gtc aaa gtt gtc ttc atc ctc 2455Ile Lys Gln Asn Ser Arg Asn Gly Val Val Lys Val Val Phe Ile Leu710 715 720 725tac aac aac ctg ggc ctc ttc ctg tcc acg gag aat gcc aca gtg aag 2503Tyr Asn Asn Leu Gly Leu Phe Leu Ser Thr Glu Asn Ala Thr Val Lys 730 735 740ctg gcc ggc gaa gca ggc ccg ggt ggc cct ggg ggc gcc tct cta gtg 2551Leu Ala Gly Glu Ala Gly Pro Gly Gly Pro Gly Gly Ala Ser Leu Val 745 750 755gtg aac tca cag gtc atc gca gca tcc atc aac aag gag tcc agc cgc 2599Val Asn Ser Gln Val Ile Ala Ala Ser Ile Asn Lys Glu Ser Ser Arg 760 765 770gtc ttc ctc atg gac cct gtc atc ttc acc gtg gcc cac ctg gag gac 2647Val Phe Leu Met Asp Pro Val Ile Phe Thr Val Ala His Leu Glu Asp 775 780 785aag aac cac ttc aat gct aac tgc tcc ttc tgg aac tac tcg gag cgt 2695Lys Asn His Phe Asn Ala Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg790 795 800 805tcc atg ctg ggc tac tgg tcg acc caa ggc tgc cgc ctg gtg gag tcc 2743Ser Met Leu Gly Tyr Trp Ser Thr Gln Gly Cys Arg Leu Val Glu Ser 810 815 820aac aag acc cat acc acg tgt gcc tgc agc cac ctc acc aac ttc gct 2791Asn Lys Thr His Thr Thr Cys Ala Cys Ser His Leu Thr Asn Phe Ala 825 830 835gtg ctc atg gct cac cgt gag atc tac cag ggc cgc atc aac gag ctg 2839Val Leu Met Ala His Arg Glu Ile Tyr Gln Gly Arg Ile Asn Glu Leu 840 845 850ctg ctg tcg gtc atc acc tgg gtg ggc att gtg atc tcc ctg gtc tgc 2887Leu Leu Ser Val Ile Thr Trp Val Gly Ile Val Ile Ser Leu Val Cys 855 860 865ttg gcc atc tgc atc tcc acc ttc tgc ttc ctg cgg ggg ctg cag acc 2935Leu Ala Ile Cys Ile Ser Thr Phe Cys Phe Leu Arg Gly Leu Gln Thr870 875 880 885gac cgc aac acc atc cac aag aac ctg tgc atc aac ctc ttc ctg gct 2983Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Asn Leu Phe Leu Ala 890 895 900gag ctg ctc ttc ctg gtc ggg atc gac aag act cag tat gag att gcc 3031Glu Leu Leu Phe Leu Val Gly Ile Asp Lys Thr Gln Tyr Glu Ile Ala 905 910 915tgc ccc atc ttc gcc ggc ctg ctg cac tat ttc ttc ctg gct gcc ttc 3079Cys Pro Ile Phe Ala Gly Leu Leu His Tyr Phe Phe Leu Ala Ala Phe 920 925 930tcc tgg ctg tgc ctg gag ggc gtg cac ctc tac ctg cta cta gtg gag 3127Ser Trp Leu Cys Leu Glu Gly Val His Leu Tyr Leu Leu Leu Val Glu 935 940 945gtg ttt gag agc gag tat tcc cgc acc aag tac tac tac ctg ggt ggc 3175Val Phe Glu Ser Glu Tyr Ser Arg Thr Lys Tyr Tyr Tyr Leu Gly Gly950 955 960 965tac tgc ttc ccg gcc ctg gtg gtg ggc atc gcg gct gcc att gac tac 3223Tyr Cys Phe Pro Ala Leu Val Val Gly Ile Ala Ala Ala Ile Asp Tyr 970 975 980cgc agc tac ggc acc gag aag gcc tgc tgg ctc cga gtg gac aat tac 3271Arg Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu Arg Val Asp Asn Tyr 985 990 995ttc atc tgg agt ttc atc ggg cca gtc tcc ttc gtt atc gtg gtc aac 3319Phe Ile Trp Ser Phe Ile Gly Pro Val Ser Phe Val Ile Val Val Asn 1000 1005 1010ctg gtg ttc ctc atg gtg acc ctg cac aag atg atc cga agc tca tct 3367Leu Val Phe Leu Met Val Thr Leu His Lys Met Ile Arg Ser Ser Ser 1015 1020 1025gtg ctc aag ccc gac tcc agc cgc ctg gac aac att aaa tcc tgg gcg 3415Val Leu Lys Pro Asp Ser Ser Arg Leu Asp Asn Ile Lys Ser Trp Ala1030 1035 1040 1045ctg ggg gcc atc gcg ctg ctg ttc ctg ctg ggc ctc acc tgg gct ttc 3463Leu Gly Ala Ile Ala Leu Leu Phe Leu Leu Gly Leu Thr Trp Ala Phe 1050 1055 1060ggc ctc ctc ttc atc aac aag gag tcg gtg gtc atg gcc tat ctc ttc 3511Gly Leu Leu Phe Ile Asn Lys Glu Ser Val Val Met Ala Tyr Leu Phe 1065 1070 1075acc acc ttc aac gcc ttc cag ggg gtc ttc atc ttc gtc ttt cac tgc 3559Thr Thr Phe Asn Ala Phe Gln Gly Val Phe Ile Phe Val Phe His Cys 1080 1085 1090gcc tta cag aag aag gtg cac aag gag tac agc aag tgc ctg cgt cac 3607Ala Leu Gln Lys Lys Val His Lys Glu Tyr Ser Lys Cys Leu Arg His 1095 1100 1105tcc tac tgc tgc atc cgc tcc cca ccc ggg ggc act cac gga tcc ctc 3655Ser Tyr Cys Cys Ile Arg Ser Pro Pro Gly Gly Thr His Gly Ser Leu1110 1115 1120 1125aag acc tca gcc atg cga agc aac acc cgc tac tac aca ggg acc cag 3703Lys Thr Ser Ala Met Arg Ser Asn Thr Arg Tyr Tyr Thr Gly Thr Gln 1130 1135 1140agc cga att cgg agg atg tgg aat gac act gtg agg aaa cag acg gag 3751Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Thr Glu 1145 1150 1155tcc tcc ttc atg gcg ggt gac atc aac agc acc ccc acc ctg aac cga 3799Ser Ser Phe Met Ala Gly Asp Ile Asn Ser Thr Pro Thr Leu Asn Arg 1160 1165 1170ggt acc atg ggg aac cac ctg ctg acc aac ccc gtg ctg cag ccc cgt 3847Gly Thr Met Gly Asn His Leu Leu Thr Asn Pro Val Leu Gln Pro Arg 1175 1180 1185ggg ggc acc agt ccc tac aac acc ctc atc gcc gag tca gtg ggc ttc 3895Gly Gly Thr Ser Pro Tyr Asn Thr Leu Ile Ala Glu Ser Val Gly Phe1190 1195 1200 1205aat ccc tcc tcg ccc cct gtc ttc aac tcc cca ggg agc tac cgg gaa 3943Asn Pro Ser Ser Pro Pro Val Phe Asn Ser Pro Gly Ser Tyr Arg Glu 1210 1215 1220ccc aag cac ccc ttg gga ggc cgg gaa gcc tgt ggc atg gac acc ctg 3991Pro Lys His Pro Leu Gly Gly Arg Glu Ala Cys Gly Met Asp Thr Leu 1225 1230 1235ccc ctg aac ggc aac ttc aat aac agt tac tcc ttg cga agt ggg gat 4039Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser Leu Arg Ser Gly Asp 1240 1245 1250ttc cct ccc ggg gat ggg ggc cct gag ccg ccc cga ggc cgg aac cta 4087Phe Pro Pro Gly Asp Gly Gly Pro Glu Pro Pro Arg Gly Arg Asn Leu 1255 1260 1265gcc gat gcg gcg gcc ttt gag aag atg atc atc tca gag ctg gtg cac 4135Ala Asp Ala Ala Ala Phe Glu Lys Met Ile Ile Ser Glu Leu Val His1270 1275 1280 1285aac aac ctg cgg ggg agc agc agc gcg gcc aag ggc cct cca ccg cct 4183Asn Asn Leu Arg Gly Ser Ser Ser Ala Ala Lys Gly Pro Pro Pro Pro 1290 1295 1300gag ccc cct gtg cca cct gtg cca ggg ggc ggg ggc gag gaa gag gcg 4231Glu Pro Pro Val Pro Pro Val Pro Gly Gly Gly Gly Glu Glu Glu Ala 1305 1310 1315ggc ggg ccc ggg ggt gct gac cgg gcc gag att gaa ctt ctc tat aag 4279Gly Gly Pro Gly Gly Ala Asp Arg Ala Glu Ile Glu Leu Leu Tyr Lys 1320 1325 1330gcc ctg gag gag cct ctg ctg ctg ccc cgg gcc cag tcg gtg ctg tac 4327Ala Leu Glu Glu Pro Leu Leu Leu Pro Arg Ala Gln Ser Val Leu Tyr 1335 1340 1345cag agc gat ctg gac gag tcg gag agc tgc acg gcc gag gac ggc gcc 4375Gln Ser Asp Leu Asp Glu Ser Glu Ser Cys Thr Ala Glu Asp Gly Ala1350 1355 1360 1365acc agc cgg ccc ctc tcc tcc cct cct ggc cgg gac tcc ctc tat gcc 4423Thr Ser Arg Pro Leu Ser Ser Pro Pro Gly Arg Asp Ser Leu Tyr Ala 1370 1375 1380agc ggg gcc aac ctg cgg gac tca ccc tcc tac ccg gac agc agc cct 4471Ser Gly Ala Asn Leu Arg Asp Ser Pro Ser Tyr Pro Asp Ser Ser Pro 1385 1390 1395gag ggg ccc agt gag gcc ctg ccc cca ccc cct ccc gca ccc ccc ggc 4519Glu Gly Pro Ser Glu Ala Leu Pro Pro Pro Pro Pro Ala Pro Pro Gly 1400 1405 1410ccc ccc gaa atc tac tac acc tcg cgc ccg cca gcc ctg gtg gcc cgg 4567Pro Pro Glu Ile Tyr Tyr Thr Ser Arg Pro Pro Ala Leu Val Ala Arg 1415 1420 1425aat ccc ctg cag ggc tac tac cag gtg cgg cgt cct agc cac gag ggc 4615Asn Pro Leu Gln Gly Tyr Tyr Gln Val Arg Arg Pro Ser His Glu Gly1430 1435 1440 1445tac ctg gca gcc cca ggc ctt gag ggg cca ggg ccc gat ggg gac ggg 4663Tyr Leu Ala Ala Pro Gly Leu Glu Gly Pro Gly Pro Asp Gly Asp Gly 1450 1455 1460cag atg cag ctg gtc acc agt ctc tgagggcacc tcatggacca ggggctggtg 4717Gln Met Gln Leu Val Thr Ser Leu 1465gcccaggcca gggagggaac cctgggcagg gctctggtgg gagagggaga cagatggagg 4777cagtggctgg tgggccactc tctccaggtg cccctcagcc atgggcccta cagtcccctc 4837aggggactct aacctggggg cctgaggtgc cagggttcac agacagggtt tcccaccagc 4897cacacgcacc agctctattt gggggaagtg tagtgaggag gagcccagag gaccccaggg 4957gagtgaggag ggagaacttg gaagggtgca gcccacttcc agactctccc ctctcccacc 5017cttctaccct gtgaagggaa atgagggctt tagtttcctg ggcagggagg ggcagcttct 5077gaggttgcca aaggccccca ctggatggaa cctgttagct gctcctctcc gcagccagaa 5137atgctgccgg ctgcacccag agggagcagt gaggcaggac agatggacag gttcctcctg 5197cgctgtaatt ccctgctccc tggagactgg gaaaaggccg cagggcaggg ggactgggcg 5257gtggtggctg gtggtttaaa ggttgaactt tctctgaagc tcctttcccc ttgctcttgg 5317tccctgcccc gcaagcaaac ctgccccctc tgcctcccag tgcacccaat gaccccctcc 5377cttggggcga ctcctgatga agcacaactc cccgcagggc ccccagccca caggggtggc 5437catatttggg cagttcccag tcctgtgggc tcggctatct ggggagcaga ttttgggtct 5497ggatctccct ggggagtggg tcctgggctt ggatctttcc ctagggggcc ctcttactcc 5557ttcctctctc ctcctccttc cccattgctg taaatatttc aacgaaatgg aaa 5610 58 1469 PRT Homo sapiens 58Met Ala Arg Leu Ala Ala Val Leu Trp Asn Leu Cys Val Thr Ala Val 1 5 10 15Leu Val Thr Ser Ala Thr Gln Gly Leu Ser Arg Ala Gly Leu Pro Phe 20 25 30Gly Leu Met Arg Arg Glu Leu Ala Cys Glu Gly Tyr Pro Ile Glu Leu 35 40 45Arg Cys Pro Gly Ser Asp Val Ile Met Val Glu Asn Ala Asn Tyr Gly 50 55 60Arg Thr Asp Asp Lys Ile Cys Asp Ala Asp Pro Phe Gln Met Glu Asn 65 70 75 80Val Gln Cys Tyr Leu Pro Asp Ala Phe Lys Ile Met Ser Gln Arg Cys 85 90 95Asn Asn Arg Thr Gln Cys Val Val Val Ala Gly Ser Asp Ala Phe Pro 100 105 110Asp Pro Cys Pro Gly Thr Tyr Lys Tyr Leu Glu Val Gln Tyr Asp Cys 115 120 125Val Pro Tyr Ile Phe Val Cys Pro Gly Thr Leu Gln Lys Val Leu Glu 130 135 140Pro Thr Ser Thr His Glu Ser Glu His Gln Ser Gly Ala Trp Cys Lys145 150 155 160Asp Pro Leu Gln Ala Gly Asp Arg Ile Tyr Val Met Pro Trp Ile Pro 165 170 175Tyr Arg Thr Asp Thr Leu Thr Glu Tyr Ala Ser Trp Glu Asp Tyr Val 180 185 190Ala Ala Arg His Thr Thr Thr Tyr Arg Leu Pro Asn Arg Val Asp Gly 195 200 205Thr Gly Phe Val Val Tyr Asp Gly Ala Val Leu Tyr Asn Lys Glu Arg 210 215 220Thr Arg Asn Ile Val Lys Tyr Asp Leu Arg Thr Arg Ile Lys Ser Gly225 230 235 240Glu Thr Val Ile Asn Thr Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg 245 250 255Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val Asp Glu Asn Gly Leu 260 265 270Trp Val Ile Tyr Ala Thr Glu Gly Asn Asn Gly Arg Leu Val Val Ser 275 280 285Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Gly Thr Trp Glu Thr Gly 290 295 300Tyr Asp Lys Arg Ser Ala Ser Asn Ala Phe Met Val Cys Gly Val Leu305 310 315 320Tyr Val Leu Arg Ser Val Tyr Val Asp Asp Asp Ser Glu Ala Ala Gly 325 330 335Asn Arg Val Asp Tyr Ala Phe Asn Thr Asn Ala Asn Arg Glu Glu Pro 340 345 350Val Ser Leu Thr Phe Pro Asn Pro Tyr Gln Phe Ile Ser Ser Val Asp 355 360 365Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp Asn Asn Tyr Phe Val 370 375 380Val Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp Pro Ser Ala Gly Pro385 390 395 400Ala Thr Ser Pro Pro Leu Ser Thr Thr Thr Thr Ala Arg Pro Thr Pro 405 410 415Leu Thr Ser Thr Ala Ser Pro Ala Ala Thr Thr Pro Leu Arg Arg Ala 420 425 430Pro Leu Thr Thr His Pro Val Gly Ala Ile Asn Gln Leu Gly Pro Asp 435 440 445Leu Pro Pro Ala Thr Ala Pro Val Pro Ser Thr Arg Arg Pro Pro Ala 450 455 460Pro Asn Leu His Val Ser Pro Glu Leu Phe Cys Glu Pro Arg Glu Val465 470 475 480Arg Arg Val Gln Trp Pro Ala Thr Gln Gln Gly Met Leu Val Glu Arg 485 490 495Pro Cys Pro Lys Gly Thr Arg Gly Ile Ala Ser Phe Gln Cys Leu Pro 500 505 510Ala Leu Gly Leu Trp Asn Pro Arg Gly Pro Asp Leu Ser Asn Cys Thr 515 520 525Ser Pro Trp Val Asn Gln Val Ala Gln Lys Ile Lys Ser Gly Glu Asn 530 535 540Ala Ala Asn Ile Ala Ser Glu Leu Ala Arg His Thr Arg Gly Ser Ile545 550 555 560Tyr Ala Gly Asp Val Ser Ser Ser Val Lys Leu Met Glu Gln Leu Leu 565 570 575Asp Ile Leu Asp Ala Gln Leu Gln Ala Leu Arg Pro Ile Glu Arg Glu 580 585 590Ser Ala Gly Lys Asn Tyr Asn Lys Met His Lys Arg Glu Arg Thr Cys 595 600 605Lys Asp Tyr Ile Lys Ala Val Val Glu Thr Val Asp Asn Leu Leu Arg 610 615 620Pro Glu Ala Leu Glu Ser Trp Lys Asp Met Asn Ala Thr Glu Gln Val625 630 635 640His Thr Ala Thr Met Leu Leu Asp Val Leu Glu Glu Gly Ala Phe Leu 645 650 655Leu Ala Asp Asn Val Arg Glu Pro Ala Arg Phe Leu Ala Ala Lys Glu 660 665 670Asn Val Val Leu Glu Val Thr Val Leu Asn Thr Glu Gly Gln Val Gln 675 680 685Glu Leu Val Phe Pro Gln Glu Glu Tyr Pro Arg Lys Asn Ser Ile Gln 690 695 700Leu Ser Ala Lys Thr Ile Lys Gln Asn Ser Arg Asn Gly Val Val Lys705 710 715 720Val Val Phe Ile Leu Tyr Asn Asn Leu Gly Leu Phe Leu Ser Thr Glu 725 730 735Asn Ala Thr Val Lys Leu Ala Gly Glu Ala Gly Pro Gly Gly Pro Gly 740 745 750Gly Ala Ser Leu Val Val Asn Ser Gln Val Ile Ala Ala Ser Ile Asn 755 760 765Lys Glu Ser Ser Arg Val Phe Leu Met Asp Pro Val Ile Phe Thr Val 770 775 780Ala His Leu Glu Asp Lys Asn His Phe Asn Ala Asn Cys Ser Phe Trp785 790 795 800Asn Tyr Ser Glu Arg Ser Met Leu Gly Tyr Trp Ser Thr Gln Gly Cys 805 810 815Arg Leu Val Glu Ser Asn Lys Thr His Thr Thr Cys Ala Cys Ser His 820 825 830Leu Thr Asn Phe Ala Val Leu Met Ala His Arg Glu Ile Tyr Gln Gly 835 840 845Arg Ile Asn Glu Leu Leu Leu Ser Val Ile Thr Trp Val Gly Ile Val 850 855 860Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Ser Thr Phe Cys Phe Leu865 870 875 880Arg Gly Leu Gln Thr Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile 885 890 895Asn Leu Phe Leu Ala Glu Leu Leu Phe Leu Val Gly Ile Asp Lys Thr 900 905 910Gln Tyr Glu Ile Ala Cys Pro Ile Phe Ala Gly Leu Leu His Tyr Phe 915 920 925Phe Leu Ala Ala Phe Ser Trp Leu Cys Leu Glu Gly Val His Leu Tyr 930 935 940Leu Leu Leu Val Glu Val Phe Glu Ser Glu Tyr Ser Arg Thr Lys Tyr945 950 955 960Tyr Tyr Leu Gly Gly Tyr Cys Phe Pro Ala Leu Val Val Gly Ile Ala 965 970 975Ala Ala Ile Asp Tyr Arg Ser Tyr Gly Thr Glu Lys Ala Cys Trp Leu 980 985 990Arg Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val Ser Phe 995 1000 1005Val Ile Val Val Asn Leu Val Phe Leu Met Val Thr Leu His Lys Met 1010 1015 1020Ile Arg Ser Ser Ser Val Leu Lys Pro Asp Ser Ser Arg Leu Asp Asn1025 1030 1035 1040Ile Lys Ser Trp Ala Leu Gly Ala Ile Ala Leu Leu Phe Leu Leu Gly 1045 1050 1055Leu Thr Trp Ala Phe Gly Leu Leu Phe Ile Asn Lys Glu Ser Val Val 1060 1065 1070Met Ala Tyr Leu Phe Thr Thr Phe Asn Ala Phe Gln Gly Val Phe Ile 1075 1080 1085Phe Val Phe His Cys Ala Leu Gln Lys Lys Val His Lys Glu Tyr Ser 1090 1095 1100Lys Cys Leu Arg His Ser Tyr Cys Cys Ile Arg Ser Pro Pro Gly Gly1105 1110 1115 1120Thr His Gly Ser Leu Lys Thr Ser Ala Met Arg Ser Asn Thr Arg Tyr 1125 1130 1135Tyr Thr Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val 1140 1145 1150Arg Lys Gln Thr Glu Ser Ser Phe Met Ala Gly Asp Ile Asn Ser Thr 1155 1160 1165Pro Thr Leu Asn Arg Gly Thr Met Gly Asn His Leu Leu Thr Asn Pro 1170 1175 1180Val Leu Gln Pro Arg Gly Gly Thr Ser Pro Tyr Asn Thr Leu Ile Ala1185 1190 1195 1200Glu Ser Val Gly Phe Asn Pro Ser Ser Pro Pro Val Phe Asn Ser Pro 1205 1210 1215Gly Ser Tyr Arg Glu Pro Lys His Pro Leu Gly Gly Arg Glu Ala Cys 1220 1225 1230Gly Met Asp Thr Leu Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser 1235 1240 1245Leu Arg Ser Gly Asp Phe Pro Pro Gly Asp Gly Gly Pro Glu Pro Pro 1250 1255 1260Arg Gly Arg Asn Leu Ala Asp Ala Ala Ala Phe Glu Lys Met Ile Ile1265 1270 1275 1280Ser Glu Leu Val His Asn Asn Leu Arg Gly Ser Ser Ser Ala Ala Lys 1285 1290 1295Gly Pro Pro Pro Pro Glu Pro Pro Val Pro Pro Val Pro Gly Gly Gly 1300 1305 1310Gly Glu Glu Glu Ala Gly Gly Pro Gly Gly Ala Asp Arg Ala Glu Ile 1315 1320 1325Glu Leu Leu Tyr Lys Ala Leu Glu Glu Pro Leu Leu Leu Pro Arg Ala 1330 1335 1340Gln Ser Val Leu Tyr Gln Ser Asp Leu Asp Glu Ser Glu Ser Cys Thr1345 1350 1355 1360Ala Glu Asp Gly Ala Thr Ser Arg Pro Leu Ser Ser Pro Pro Gly Arg 1365 1370 1375Asp Ser Leu Tyr Ala Ser Gly Ala Asn Leu Arg Asp Ser Pro Ser Tyr 1380 1385 1390Pro Asp Ser Ser Pro Glu Gly Pro Ser Glu Ala Leu Pro Pro Pro Pro 1395 1400 1405Pro Ala Pro Pro Gly Pro Pro Glu Ile Tyr Tyr Thr Ser Arg Pro Pro 1410 1415 1420Ala Leu Val Ala Arg Asn Pro Leu Gln Gly Tyr Tyr Gln Val Arg Arg1425 1430 1435 1440Pro Ser His Glu Gly Tyr Leu Ala Ala Pro Gly Leu Glu Gly Pro Gly 1445 1450 1455Pro Asp Gly Asp Gly Gln Met Gln Leu Val Thr Ser Leu 1460 1465 59 1548 DNA Homo sapiens CDS (1)..(798) 59gag ggg ctt ctg aac aat gcc agg gat aca agt gtc atg gat act cta 48Glu Gly Leu Leu Asn Asn Ala Arg Asp Thr Ser Val Met Asp Thr Leu 1 5 10 15cca ctg aat ggt aac cat ggc aat agt tac agc att gcc agc ggc gaa 96Pro Leu Asn Gly Asn His Gly Asn Ser Tyr Ser Ile Ala Ser Gly Glu 20 25 30tac ctg agc aac tgt gtg caa atc ata gac cgt ggc tat aac cat aac 144Tyr Leu Ser Asn Cys Val Gln Ile Ile Asp Arg Gly Tyr Asn His Asn 35 40 45gag acc gcc cta gag aaa aag att ctg aag gaa ctc act tcc aac tat 192Glu Thr Ala Leu Glu Lys Lys Ile Leu Lys Glu Leu Thr Ser Asn Tyr 50 55 60atc cct tct tac ctg aac aac cat gag cgc tcc agt gaa cag aac agg 240Ile Pro Ser Tyr Leu Asn Asn His Glu Arg Ser Ser Glu Gln Asn Arg 65 70 75 80aat ctg atg aac aag ctg gtg aat aac ctt ggc agt gga agg gaa gat 288Asn Leu Met Asn Lys Leu Val Asn Asn Leu Gly Ser Gly Arg Glu Asp 85 90 95gat gcc att gtc ctg gat gat gcc acc tcg ttt aac cac gag gag agt 336Asp Ala Ile Val Leu Asp Asp Ala Thr Ser Phe Asn His Glu Glu Ser 100 105 110ttg ggc ctg gaa ctc att cat gag gaa tct gat gct cct ttg ctg ccc 384Leu Gly Leu Glu Leu Ile His Glu Glu Ser Asp Ala Pro Leu Leu Pro 115 120 125cca aga gta tac tcc acc gag aac cac cag cca cac cat tat acc aga 432Pro Arg Val Tyr Ser Thr Glu Asn His Gln Pro His His Tyr Thr Arg 130 135 140agg cgg atc ccc caa gac cac agt gag agc ttt ttc cct ttg cta acc 480Arg Arg Ile Pro Gln Asp His Ser Glu Ser Phe Phe Pro Leu Leu Thr145 150 155 160aac gag cag aca gaa gat ctc cag tca ccc cat aga gac tct ctc tat 528Asn Glu Gln Thr Glu Asp Leu Gln Ser Pro His Arg Asp Ser Leu Tyr 165 170 175acc agc atg ccg aca ctg gct ggt gtg gcc gcc aca gag agt gtt acc 576Thr Ser Met Pro Thr Leu Ala Gly Val Ala Ala Thr Glu Ser Val Thr 180 185 190acc agc acc cag acc gaa ccc cca ccg gcc aaa tgt ggt gat gcc gaa 624Thr Ser Thr Gln Thr Glu Pro Pro Pro Ala Lys Cys Gly Asp Ala Glu 195 200 205gat gtt tac tac aaa agc atg cca aac cta ggc tcc aga aac cac gtc 672Asp Val Tyr Tyr Lys Ser Met Pro Asn Leu Gly Ser Arg Asn His Val 210 215 220cat cag ctg cat act tac tac cag cta ggt cgc ggc agc agt gat gga 720His Gln Leu His Thr Tyr Tyr Gln Leu Gly Arg Gly Ser Ser Asp Gly225 230 235 240ttt ata gtt cct cca aac aaa gat ggg acc cct ccc gag gga agt tca 768Phe Ile Val Pro Pro Asn Lys Asp Gly Thr Pro Pro Glu Gly Ser Ser 245 250 255aaa gga ccg gct cat ttg gtc act agt cta tagaagatga cacagaaatt 818Lys Gly Pro Ala His Leu Val Thr Ser Leu 260 265ggaaccaaca aaactgctaa caccttgttg actgttctga gttgatataa gcagtggtaa 878taatgtgtgt actcctaaat ctttatgctg tcctctaaag acaaacacaa actctcagac 938tttttttttt ttaatgggat ttttaggtca gcccagggga gaaagataac tgctaaaatt 998cccctgtacc ccatcctttc ttgtcctttc cccttcagat ggagacttca ttatgttaat 1058gaacaagata tgaagaaaat ggcactcatt gtggccttgt tgaattatgt tgtgtatgtt 1118ttaacatctc tgatgctgtg ttactaaaat tacaaggacc tgctttttaa aaggccagaa 1178caattgtctg aaattagtaa caatgctgca tctagattgg agtgctgcac aaacaaacat 1238aagagcaaag caaaactgta tcacataggg tttttggtca ctcacaacct gaattcacca 1298cagctggaat agctgtggaa aacaaaataa aacaacaaaa ttaataatga aatggagggg 1358aattctagaa ttatatgcta aatgcatatt ttatgatttg ctgtattaac tgatgataaa 1418actaatggca gaaaaagaag ttgagcaatt tctatgtaat gtacagatac tagcattgca 1478catatagtct gctttctgtt cctccagaat ttgagtcctg ttaatgtagt agaaaaaaaa 1538aaaaaaaaaa 1548 60 266 PRT Homo sapiens 60Glu Gly Leu Leu Asn Asn Ala Arg Asp Thr Ser Val Met Asp Thr Leu 1 5 10 15Pro Leu Asn Gly Asn His Gly Asn Ser Tyr Ser Ile Ala Ser Gly Glu 20 25 30Tyr Leu Ser Asn Cys Val Gln Ile Ile Asp Arg Gly Tyr Asn His Asn 35 40 45Glu Thr Ala Leu Glu Lys Lys Ile Leu Lys Glu Leu Thr Ser Asn Tyr 50 55 60Ile Pro Ser Tyr Leu Asn Asn His Glu Arg Ser Ser Glu Gln Asn Arg 65 70 75 80Asn Leu Met Asn Lys Leu Val Asn Asn Leu Gly Ser Gly Arg Glu Asp 85 90 95Asp Ala Ile Val Leu Asp Asp Ala Thr Ser Phe Asn His Glu Glu Ser 100 105 110Leu Gly Leu Glu Leu Ile His Glu Glu Ser Asp Ala Pro Leu Leu Pro 115 120 125Pro Arg Val Tyr Ser Thr Glu Asn His Gln Pro His His Tyr Thr Arg 130 135 140Arg Arg Ile Pro Gln Asp His Ser Glu Ser Phe Phe Pro Leu Leu Thr145 150 155 160Asn Glu Gln Thr Glu Asp Leu Gln Ser Pro His Arg Asp Ser Leu Tyr 165 170 175Thr Ser Met Pro Thr Leu Ala Gly Val Ala Ala Thr Glu Ser Val Thr 180 185 190Thr Ser Thr Gln Thr Glu Pro Pro Pro Ala Lys Cys Gly Asp Ala Glu 195 200 205Asp Val Tyr Tyr Lys Ser Met Pro Asn Leu Gly Ser Arg Asn His Val 210 215 220His Gln Leu His Thr Tyr Tyr Gln Leu Gly Arg Gly Ser Ser Asp Gly225 230 235 240Phe Ile Val Pro Pro Asn Lys Asp Gly Thr Pro Pro Glu Gly Ser Ser 245 250 255Lys Gly Pro Ala His Leu Val Thr Ser Leu 260 265 61 28 DNA Artificial Sequence Description of Artificial Sequence primer 61atataagctt gctgccacca tggcccgc 28 62 20 DNA Artificial Sequence Description of Artificial Sequence primer 62atgacccaca gcccgttctc 20 63 16 PRT Homo sapiens 63Cys Pro Gly Pro Asp Gly Asp Gly Gln Met Gln Leu Val Thr Ser Leu 1 5 10 15 64 16 PRT Homo sapiens 64Cys Pro Glu Gly Ser Ser Lys Gly Pro Ala His Leu Val Thr Ser Leu 1 5 10 15

Claims

1. A polynuclcotidc encoding a lectomedin polypeptide, said polypeptide characterized by the ability to bind one or more lectomedin ligands Mac-2 (galectin 3), fibrinogen γ A, and immunoglobulin mu chain constant region, said polypeptide selected from the group consisting of:(a) a mature lectomedin polypeptide encoded by SEQ ID NO: 1; and (b) a polypeptide comprising of the amino acid sequence set out in SEQ ID NO:2.

2. The polynucleotide according to claim 1 comprising the sequence set forth in SEQ ID NO: 1.

3. The polynucleotide according to claim 1 comprising the sequence set forth in SEQ ID NO: 3.

4. The polynucleotide according to claim 1 comprising the sequence set forth in SEQ ID NO: 5.

5. A polynucleotide encoding a human lectomedin polypeptide, comprising extracellular lectin-binding, olfactomedin-like, and mucin-like domains, said polypeptide characterized by the ability to bind one or more lectomedin ligands Mac-2 (galeclin-3), fibrinogen γA, and immunoglobulin mu chain constant region, wherein said polynucleotide is selected from the group consisting of:(a) the polynucleotide according to claim 1; and (b) a DNA which hybridizes under highly stringent conditions to the non-coding strand of the polynucleotide of (a), said conditions including a final wash in 1×SSC at 65° C. for 1 hour.

6. The polynucleotide of claim 5 which is a DNA molecule.

7. The DNA of claim 6 which is a cDNA molecule.

8. A fully complementary polynucleotide which specifically hybridizes with the polynucleotide of claim 6.

9. A expression construct comprising the polynucleotide according to claim 5.

10. A host cell transformed or transfected with the polynucleotide according to claim 9.

11. The polynucleotide according to claim 5 operably linked to a heterologous promoter.

12. A host cell comprising the polynucleotide according to claim 11.

13. A method for producing a human lectomedin polypeptide comprising the steps ofa) growing the host cell according to claim 10 or 12 under conditions appropriate for expression of the lectomedin polypeptide and b) isolating the lectomedin polypeptide from the host cell or the medium of its growth.